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Summary 
Wound healing and the management of chronic, non-healing wounds represent a 
significant burden to the NHS and results in substantial patient morbidity. New 
methods to further understanding of wound chronicity and potential therapies 
are needed. This PhD study aims to explore the importance of the SOCS family in 
the wound healing process, exploring their potential to act as prognostic factors in 
clinical cohorts and exploring the potential of SOCS-3 and -4 to influence key 
cellular traits linked to the healing process.  
Detection of SOCS family members within a clinical healing/non-healing cohort 
highlighted significant elevations of gene expression of SOCS-3 and -4 in non-
healing chronic wounds compared to healing chronic wounds, though this trend 
was no as obvious in a smaller cohort of IHC stained samples. However, the IHC 
stained samples potentially indicated that SOCS-3 protein relocalisation, from 
wound edge to distal wound area, was evident in the non-healing chronic wound. 
Subsequently, SOCS-3 expression and SOCS-4 knockdown lines were generated in 
human (HaCaT) keratinocytes and (HECV) endothelial cells to explore the 
functional significance of these molecules at a cellular level. In summary, SOCS-4 
knockdown decreased the migration of both HaCaT and HECV cells on plastic 
cultureware, whereas downregulation of SOCS-4 only reduced the adhesion and 
tubule formation of HECV cells on matrigel matrix. SOCS-3 expression attenuated 
the proliferation of HaCaT cells but had no effect on HECV cells. In addition, SOCS-
3 upregulation solely improved the adhesion and tubule formation of HECV cells 
on matrigel matrix. Moreover, the regulatory role of SOCS-3 and SOCS-4 in the 
migration and adhesion of HaCaT and HECV are likely to be substratum matrix 
dependent. 
Finally, to explore potential mechanisms of action for SOCS-4 role in HaCaT cell 
line, a protein microarray was utilised to highlight a number of potential key 
pathways. Based on the results from protein microarray and wound healing assay 
as well as evidences from literature review, four potential mechanisms 
(FAK/Src/p130cas, HBEGF/EGFR, VEGF/VEGFR-2, IGF-1/IGF-1R/PI3K) of SOCS-4 
relulating keratinocyte migration was highlighted for further validation, and the 
expression profile of FAK Y397 was varified by western blotting. 
Hence, SOCS-3 and SOCS-4 may regulate keratinocyte and endothelial cell 
behaviour, and potentially have effect on the wound healing process.. 
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General Introduction
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1.1 History and background of wound healing 
1.1.1 The emergance and development of wound healing treatments 
The history of open wound treatment probably dates back to the era when 
ancient human civilisation began on earth. According to documented evidence, 
ancient Egyptian and Greeks had their own method to remove pus and to 
encourage wound healing (Broughton et al., 2006a). However, it was not until the 
mid-nighteenth century that people began to realise the concept of infection 
following the first demonstrated use of antiseptics in surgery and the treatment of 
wounds with dressings. In 1876, the first antiseptic dressing, soaking lint and 
gauze in carbolic acid, was developed and later on was improved as a 
nonadherent dressing called ‘tulle gras’. It was commonly used in France and 
became extensively used worldwide in World War I. Silver foil dressings for 
wounds was also introduced during the mid- to late 1800s, and were extensively 
used in World War II, later being listed in the Physician’s Desk Reference in 1955. 
Additionally, the outbreak  of World War II introduced the impetus to develop 
new and more innovative surgical dressings, which became known as Kerlix 
sponges and bandages. In the 1880’s, several years after the emergance of the 
antiseptic dressing, skin cleansing was stressed to be of importance in wound care, 
and the teminology ‘debridement’ was raised by a Russian military surgeon who 
considerably reduced the mortality rate of the patients he treated. The modern 
practice of debridement emerged during World War I in order to cope with 
contamination from the battlefield (Broughton et al., 2006a). In addition, 
debridement was defined as the elimination of nonviable material, foreign bodies 
and poorly healing tissue from a wound (Steed, 2004). More recently, a 
systematic and relatively comprehensive guideline was proposed by a wound care 
consensus group in 2003 to address wound management (Schultz et al., 2003), 
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and is advocated by many medical professionals as well as being of benefit to 
wound healing management until present day (Powers et al., 2016). 
 
1.1.2 The neccessity and importance of study on wound healing  
The basic funcion of skin is to provide a protective barrier against the 
environment. Wound healing is a dynamic and interactive process which is 
immediately activated by the damage of skin upon injury. It is one of the 
important biological process which helps restore the barrier function of skin and 
regain skin homeostasis after injury. The primary aims of wound treatment are to 
minimise the healing time and to regenerate scar free tissue without 
compromising normal skin function.  
The process of wound healing is highly complex and requires substantial 
interaction and co-ordination between different cell types to heal the wound in an 
orderly and timely manner. Regarding the normal healing process, haemostasis 
initiates immediately after injury. Inflammatory phase occurs at the same time 
and normally last for 4 to 6 days (Schreml et al., 2010). Hours following injury, 
proliferation and re-epithelialisation consisting of epithelialisation, granulation 
tissue formation and angiogenesis overlaps with inflammation and gradually 
becomes predominant. This stage normally lasts for approximately a month. 
Finally, the maturation and remodelling phase begins around day 21 after 
wounding and continues more than a year (Bryant and Nix, 2015). Issues arising in 
the co-ordination or regulation of the wound healing process can have severe 
consequences, in some cases impairing the capacity to complete the process, 
resulting in wound chronicity.  
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1.1.2.1 Chronic wounds 
Chronic wounds are defined as wounds that fail to follow an orderly and timely 
reparative process (normal healing process) which in turn disrupts the anatomic 
and functional integrity of the wound site (Lazarus et al., 1994). Chronic wounds 
generally are casued by vascular compromise, prolonged inflammation or 
repetitive insults to the tissues (Bryant and Nix, 2015). The majority of chronic 
wounds are categorised into three subtypes: pressure ulcers, arterial and venous 
ulcers and diabetic ulcers, which, despite having diverse aetiologies (Mustoe et al., 
2006) share a similar charateristic, namely prolonged inflammation (Powers et al., 
2016). In addition, the most common type of chronic wound is lower extremity 
ulcer, of which 98% are primarily of vascular or diabetic nature (Werdin et al., 
2009). To date, general management guidelines concentrating on tissue, 
infection/inflammation, moisture balance and edge of wound (leading to the 
TIME acronym), which are critical barriers to wound healing, have been 
established by the Wound Healing Society in order to address principal elements 
for the treatment of chronic wounds regardless of the wound type (Powers et al., 
2016). Moreover, it has been hypothesised that local tissue hypoxia, bacterial 
colonisation of the wound, repetitive ischemia-reperfusion injury and an altered 
cellular and systemic stress response in the aged patient are the four major 
factors of chronic wound pathogenesis. However, the complexity of chronic 
wounds has been underestimated due to the limited success of treatment and the 
lack of successful clinical trails (Mustoe et al., 2006). It has been suggested that 
the Inflammation stage is the driving force in chronic, non-healing wounds and as 
such, pro-inflammatory regulators may possess diagnostic and/or prognostic 
value, in addition to potential as future therapeutic targets (Behm et al., 2012). 
Therefore, a comprehensive and systematic chronic wound healing model would 
be beneficial to verify this hypothesis as well as unveiling novel therapeutic 
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strategies (Menke et al., 2007). However, this requires a better understanding of 
the basic cellular and molecular traits in the wound healing process than is 
currently known. 
 
1.1.2.2 Classification of chronic wounds 
As primarily mentioned, chronic wounds are primarily categorised into venous, 
arterial, diabetic and pressure ulcers based on their distinct aetiologies (Table 1-1).  
Venous ulcers, which exhibit high recurrence rates, are considered to be 
the most common type of leg ulcer, comprising an estimated 70-90% of total 
cases (Snyder, 2005). Venous stasis ulceration is considered to be caused by 
venous hypertension. A persistently high pressure within the deep vein is 
attributed to dysfunctional and incompetent valves in the lower extremity (Moreo, 
2005). Trauma and a deep vein thrombosis may potentially result in valve damage, 
subsequently leading to secondary venous hypertension (Valencia et al., 2001). 
The precise pathophysiology behind venous ulceration still remains to be 
elucidated, however, such chronic ulcers are hypothesised to be the result of 
extravasation of red and white blood cells and other macromolecules from the 
blood vessel into the perivascular tissues caused by the elevated pressure, leading 
to epithelial cell damage and ulceration (Gohel and Poskitt, 2009). 
Arterial ulceration is caused by a reduced arterial blood supply to the 
lower limb, and is commonly seen in patients with atherosclerotic disease of the 
medium and large sized arteries (Grey et al., 2006). Inadequately supplied blood 
products and oxygen subsequently result in local ischemia in the lower extremity, 
thus, local incidental injuries are unlikely to follow the normal healing process, 
leading to chronic non-healing wound. 
Foot ulceration occurs in 15% of diabetic patients and lead to 84% of 
lower extremity amputations (Brem and Tomic-Canic, 2007). Ulceration in diabetic 
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patients generally contributes to non-healing and chronicity and are found to be 
related to almost all the key components and phases in the wound healing 
process. Dysregulation of key cell type function, altered cytokine and growth 
factor production, impaired angiogenic response, imbalanced extracellular matrix 
(ECM) reorganisation by abnormal collagen accumulation and collagenases 
activity are all potential pathophysiologic factors leading to diabetic foot 
ulceration (Galkowska et al., 2006, Goren et al., 2006b, Falanga, 2005, Galiano et 
al., 2004, Maruyama et al., 2007, Gibran et al., 2002, Lobmann et al., 2002). 
Pressure ulcers, in general, occur in patients whose movement ability is 
severely impaired, such as paralysed patients and coma patients (Moreo, 2005). 
Patients with spinal cord injuries and the elderly are the two groups at high risk of 
developing pressure ulcers. These ulcerations are normally found at the sacrum, 
heels and scapulae as well as positions which experience sustained pressure. 
Prolonged pressure consequently results in a lack of blood supply, contributing to 
ischemia and tissue necrosis as well as non-healing ulceration (Yarkony, 1994).
7 
 
Table 1-1: Four major types of chronic wounds and their potential aetiologies 
Chronic ulceration Aetiology Potential risk factors 
Venous ulcers 
Valve failure causes blood reflux, resulting in increased pressures within the deep vein 
and subsequent venous hypertension which is a direct cause of venous ulceration 
Loss of valvular competence 
Calf muscle dysfunction 
Arterial ulcers 
Critical and acute limb ischemia which cause consistent arterial insufficiency, impaired 
perfusion and consequently severe tissue ischemia may lead to arterial ulceration 
Diabetes 
Tobacco 
Atherosclerotic disease 
Thromboangiitis disease 
Sickle cell disease 
Vasculitis 
Diabetic ulcers 
Decreased sympathetic innervation results in a shunting away of blood from the capillary 
which leads to ischemia and subsequent non-healing ulceration 
Peripheral neuropathy 
Inadequate oxygenation and perfusion of tissues caused by peripheral arterial disease 
impair the healing of ulceration 
Peripheral arterial disease 
Pressure ulcers 
Persistent pressure creates tissue ischemia  and edema  through capillary damage, and 
subsequently worsen tissue hypoxia and result in pressure ulceration 
Ischemia caused by capillary occlusion 
Reperfusion injury 
Impaired lymphatic function 
Unrelieved pressure 
Key reference: (Bryant and Nix, 2015) 
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1.1.2.3 The impact of chronic wounds 
Non-healing wounds in the lower extremities represent major clinical and surgical 
challenges globally due to the significant cost on healthcare resources and 
medical professionals. Regarding medical costs, chronic, non-healing wounds are 
a significant economic burden on public healthcare. According to an investigation 
into the total (direct and indirect) costs of 22 leading skin disease categories, the 
expenditure on skin ulcers and wounds in the United States alone was 
approximately $12 billion in 2004. Furthermore, regarding direct costs only, skin 
ulcers and wounds were identified as being the most costly of the 22 skin diseases 
analysed, accounting for $9.7 billion of the $29.1 billion total annual spend 
(Bickers et al., 2006). An audit covering the population of approximately 590,000 
carried out in 2005 indicated that the estimated cost of wound care in 2005-2006 
was £15 million to £18 million, accounting for 2%-3% of local NHS healthcare 
budget (Drew et al., 2007). Moreover, according to a publication on 2008, the 
estimated annual cost of venous leg ulcers, pressure ulcers and diabetic foot 
ulcers are £168-198 million, £1.8-2.6 billion and £300 million respectively, 
suggesting a significant burden to the NHS healthcare budget caused by the 
diagnosis and treatment of chronic wounds (Posnett and Franks, 2008). Another 
report indicated that the economic costs associated with diabetic foot care are so 
considerable that it is even comparable to the expenditure on the treatment of 
breast and colorectal cancers (Barshes et al., 2013). In addition to the heavy 
burden on medical costs, due to the high recurrence rate of chronic ulcers, such 
as venous ulcers (Snyder, 2005), many recovered patients are more likely to go 
back to hospital and seek medical assistance on more than one occasion. This 
requires the continuous reoccupation of medical professional resources. 
Therefore, the establishment of a robust system of multidisciplinary care is of 
importance to the management of chronic diseases, and this requires an array of 
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healthcare specialists collaborating together to provide an appropriate primary 
prevention, and to reduce the delayed recognition as well as improving the 
management efficiency (Barshes et al., 2013). 
Regarding patient impact, chronic non-healing wounds considerably 
reduce quality of life.  A number of studies have demonstrated that chronic ulcers 
correlate with reduced overall quality of life (Goodridge et al., 2006, Jaksa and 
Mahoney, 2010, Shanmugam et al., 2010). Diabetic foot ulcers are responsible for 
the highest proportion of non-traumatic amputations in the United States 
(Barshes et al., 2013, Snyder, 2005) and compared with other complications 
associated with diabetes, amputation has been shown to have the greatest 
negative effect on a person’s quality of life (Clarke et al., 2002, Laiteerapong et al., 
2011). More than 50% of diabetic foot ulcer patients also suffer from peripheral 
arterial disease, which may further affect the ability of the ulcer to heal. It is 
noteworthy that patients with both a diabetic foot ulcer and peripheral arterial 
disease have a higher risk of cardiovascular morbidity and mortality. However, 
peripheral arterial disease is salvageable by revascularisation, with limb salvage 
rates increasing to 85% and more than 60% of ulcers healing within 1 year 
(Schaper et al., 2012). In addition to amputation, pain is another factor that 
causes chronic ulcer patients distress and restrains their lower extremity function. 
In a multinational study of over 2,000 patients, pain was chosen to be the most 
annoying symptom experienced by chronic ulcer patients rather than the other 
given choices, such as impaired mobility, difficulties in bathing, leakage, odour 
and dressing or bandage slippage (Price et al., 2008). 
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1.1.2.4 Factors leading to non-healing wound and chronic wound 
management 
It has been discovered that the wound healing process can become trapped in 
either the inflammation or proliferation and re-epithelialisation phases (Bello and 
Phillips, 2000). Although non-chronic wounds have different aetiologies, all wound 
types share similar traits to each other, including increased inflammation, 
continuous extracellular matrix (ECM) degradation, fibroblast, keratinocyte and 
endothelial cell senescence as well as epidermal arrest, which are partially 
attributed to the dysregulated production of cytokines and growth factors as well 
as the imbalanced secretion of proteolytic proteins and their inhibitors  (Harding 
et al., 2002, Telgenhoff and Shroot, 2005). Furthermore, studies examining 
components present in wound fluids demonstrated that compared to normal 
acute wounds, chronic wound fluid consists of high levels of proteases which 
could impair the proliferation of keratinocytes, fibroblasts and endothelial cells, 
all key cell types involved in the proliferation and re-epithelialisation phase 
(Bucalo et al., 1993, Trengove et al., 1999, Raffetto et al., 2001, Mendez et al., 
1999). It has been found that upregulated inflammatory cytokines contribute to 
prolonged inflammation, whereas increased proteases, especially matrix 
metalloproteinases (MMPs) and elastase, and reduced protease inhibitors result 
in excessive degradation of the ECM (Yager and Nwomeh, 1999, Harding et al., 
2002, Lobmann et al., 2002, Ladwig et al., 2002). In addition, dysregulation and 
relocalisation of growth factor expression, including platelet derived growth 
factor (PDGF), fibroblast growth factor (FGF)-2, epithelial growth factor (EGF) and 
transforming growth factor (TGF)- (Higley et al., 1995), potentially leads to 
suppressed proliferation, migration and senescence of keratinocytes, fibroblasts 
and endothelial cells. 
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Wound bed preparation, removing the barriers to healing and providing 
active measures that stimulate endogenous healing as well as analysing wound 
conditions, has been recognised as the global management method and a 
prerequisite to facilitate the effectiveness of other therapeutic measures (Schultz 
et al., 2004). Therefore, systematic protocols and treatment guidelines used for 
the preparation of an adequate wound bed and the assessment of overall health 
status of the patient are considered to be of the greatest importance (Falanga, 
2000). In 2003, a stepwise cyclical approach of ‘Wound Bed Preparation’, 
consisting of four components (TIME), was established to standardise the process 
used by clinicians to assess the status of the wound and in deciding a plan for 
further intervention (Schultz et al., 2003, Schultz et al., 2004). The establishment 
of the TIME clinical tool is not only of benefit to the management of chronic 
wounds, but to the plastic, burns injury and trauma wounds that potentially fail to 
follow the general healing process. Moreover, it provides clinicians and medical 
professionals a systematic and standard protocol to evaluate emerging 
technologies in wound management and assessment (Schultz et al., 2004). 
 
1.2 Cellular and molecular biology of wound repair 
In order to seek more cost effective and efficient therapeutic methods and to 
improve current chronic wound treatments, a better understanding of the 
molecular and cellular biology behind the chronic wound healing process is of 
great importance. The normal acute wound healing process has become clearer in 
terms of key cell types (Table 1-2), regulatory cytokines and growth factors and 
the involvement of a number of signalling pathways. The wound healing process 
consists of four highly-orchestrated overlapping stages known as 1) haemostasis, 
2) inflammation, 3) proliferation and reepithelialisation, and 4) tissue remodelling 
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(Behm et al., 2012) (Figure 1-1, Figure 1-2). Dysregulation or prolongation of one 
or more phases may lead to either delayed healing or non-closure of the wound. 
 
 
Figure 1-1: Overview of the four overlapping stages during the wound healing 
process 
A. Haemostasis and Inflammation stage; B. Proliferation and re-epithelialisation 
stage; C. Tissue remodelling stage. (Gurtner et al., 2008)  
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Figure 1-2 The phases of 
wound healing 
Neutrophils are the first cell 
type attracted to the wound 
area in the early 
inflammatory phase, whereas 
macrophages primarily exert 
function in the late 
inflammatory phase; 
fibroblasts, keratinocytes and 
endothelial cells are recruited 
into the wound site and their 
behaviours are primarily 
involved in the last two 
phases of the wound healing 
process. 
14 
 
Table 1-2 Key cell types involved in the wound healing process 
Cell type Wound healing phase Functions 
Platelet Haemostasis 
Aggregate to plug damaged blood vessel, release cytokines; chemokines and growth 
factors; initiate entire wound healing cascade 
Neutrophil Inflammation 
Removes bacteria and foreign debris by phagocytosis; release growth factors to attract 
additional leucocytes 
Monocyte/macrophage Inflammation 
Debride tissue through phagocytosis and digestion of pathogenic organisms, tissue debris 
and neutrophils; release growth factors required for angiogenesis, granulation tissue 
formation and connective tissue formation 
T lymphocyte Inflammation 
Remove viral organisms and foreign cells; produce additional cytokines and growth 
factors necessary for wound healing 
Keratinocyte Proliferation and re-epithelialisation 
Migrate and proliferate and differentiate to re-establish epidermal thickness and 
function; synthesise basement membrane; secrete growth factors required for wound 
healing 
Fibroblast 
Proliferation and re-epithelialisation, 
tissue remodelling 
Proliferate, migrate and infiltrate to provisional matrix; synthesise ECM components to 
promote new connective tissue formation; produce cytokines and growth factors benefit 
for neovascularisation; transform to myofibroblast and provide tractional forces for 
wound contraction; synthesis collagens and degrade provisional ECM components for 
tissue remodelling  
Endothelial cell 
Proliferation and re-epithelialisation, 
tissue remodelling 
Proliferate, infiltrate to the provisional matrix; establish network of new vessels to 
achieve neoangiogenesis; reconstruct and remodel newly formed vascular 
Key references: (Bryant and Nix, 2015, Clark, 1996) 
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1.2.1 Haemostasis 
Upon injury, blood vessels are damaged resulting in the extravasation of blood 
constituents. Before healing can commence, haemostasis must be achieved at the 
wound to minimise blood loss. Blood coagulation and platelet aggregation are 
immediately initialised to form as cross-linked fibrin-rich clot to plug the damaged 
blood vessels and thus to achieve haemostasis. This fibrin clot contains adequate 
molecules such as fibronectin, vitronectin, von Willebrand factor, 
thrombospondin, plasminogen, plasminogen activator, plasminogen activator 
inhibitor, thrombin and growth factors, which are required to form a reservoir and 
scaffold for cell recruitment, migration and proliferation (Clark, 1996). Following 
haemostasis, numerous mediators and chemotactic factors, such as PDGF, EGF 
and TGF-β, are secreted by platelets and by damaged cells at the wound site in 
order to recruit inflammatory cells for further debridement (Darby et al., 2014). 
The recruited monocytes and fibroblasts migrate over the matrix scaffold aided by 
the interaction between their integrin receptors and the components present in 
the provisional clot matrix, such as fibrin, fibronectin and vitronectin. Blood 
clotting also contributes to the inflammatory response through the attraction of 
neutrophils and monocytes via secreted mediators from platelets and injured 
parencheymal cells as well as by stimulating the release of vasoactive mediators 
from mast cells and granule constituents from neutrophils and macrophages 
(Clark, 1996). 
 
1.2.2 Inflammation phase 
Inflammation starts minutes after injury occurs and generally lasts between 4 and 
6 days in the physiological wound healing process (Schreml et al., 2010). The 
normal function of inflammation in an acute wound is to 1) prepare the wound 
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bed; 2) remove necrotic tissue, bacteria contaminants, dead cell debris; and 3) 
recruit and activate fibroblasts at the wound site (Menke et al., 2007). During the 
inflammatory stage, neutrophils are the first inflammatory cells infiltrating into 
the wound area, reaching peak numbers at around 24 to 48 hours following injury 
(Park and Barbul, 2004). After being activated by a variety of chemotactic factors, 
neutrophils release collagenase molecules to digest the blood vessel basement 
membrane and infiltrate from the blood vessel to the provisional matrix (Clark, 
1996). Upon arrival, neutrophils remove bacteria and foreign material through 
phagocytosis and subsequent release of enzyme and oxygen radicals. However, 
tight regulation of the quantity of neutrophils and duration of the infiltration is 
crucial as they also possess the ability to kill healthy host cells in addition to their 
major function in removing infectious agents, which may explain the persistent 
tissue-destroying nature of chronic wounds (Martin and Leibovich, 2005). 
Neutrophil infiltration ceases within a few days if no substantial contamination 
occurs and the neutrophils undergo senescence and are subsequently 
phagocytosed by tissue macropahges (Newman et al., 1982). Whether neutropil 
infiltrates resolve or persist, monocytes are subsequently attracted from the 
circulatory system, through similar mechanisms to neutrophil recruitment, into 
the wound site by selective monocyte chemoattractants. The increasing 
accumulation of monocytes differentiate into activated macrophages and then 
gradually replace the neutrophils as the prominent cell type involved in the 
removal and degredation of injured tissue debris, apoptotic neutrophils, 
microorganisms and fragments of ECM via phagocytosis. Importantly, monocytes 
also act as a source of cytokines and growth factors that subsequently benefit 
angiogenesis, fibroplasia and ECM reorganisation (Clark, 1996, Singer and Clark, 
1999).    
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1.2.3 Proliferation and re-epithelialisation phase 
The start of re-epithelialisation lags hours behind injury and initiate soon after the 
clot formation (Stenn and Depalma, 1988). Re-epithelialisation involves multiple 
processes including the migration and proliferation of epidermal keratinocytes, 
the stratification and differentiation of the neoepithelium, the reorganisation of 
provisional wound bed matrix (granulation tissue formation), angiogenesis and 
reconstruction of the basement membrane (Clark, 1996). 
 
1.2.3.1 Epithelialisation 
Upon the initiation of epithelialisation, keratinocytes at the wound periphery and 
damaged epidermal appendages throughout the wound bed alter their integrin 
and cell adhesion molecule expression profile to reduce adhesion to both 
neighbouring cells and to the basement membrane, thus enabling their migration 
to the denuded area. In addition to cell-cell junction (desmosomes) and cell-
basement membrane junctions (hemi-desmosomes) being retracted from the 
plasma membrane to a perinuclear localisation following injury, keratinocytes 
dramatically change their morphology before migrating, becoming flat and 
elongated while ‘crawling’ along the wound bed (Odland and Ross, 1968, Stenn 
and Depalma, 1988). Since the intact basement membrane is damaged by 
wounding, provisional matrix, primarily consisting of fibronectin, fibrin and 
vitronectin, acts as a scaffold and facilitates keratinocyte migration (O'Toole, 
2001). The migratory keratinocytes utilise the provisional matrix in the newly 
formed wound bed to crawl over the interface between moist viable tissue and 
the protective blood clot scab in order to restore the integrity of epithelium (Clark, 
1996). One to two days following injury, neighbouring keratinocytes at the 
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migratory leading front keratinocytes undergo proliferation to ensure sufficient 
cells are available for the formation of the epithelial barrier (Martin and Leibovich, 
2005, Pastar et al., 2014). 
It has been documented that there are various factors that can regulate 
epithelialisation. Migratory keratinocyte synthesised collagenases have been 
identified as one of the key factors. For instance, keratinocyte synthesised 
collagenases degrade types I and IV collagens and enable their migration over the 
dermal collagen (Woodley et al., 1986). In addition, the connective tissue matrix 
has also been demonstrated to be of importance to the biological behaviour of 
epithelial cells. Fibronectin and vitronectin containing an Arg-Gly-D-Asp (RGD) 
sequence have been demonstrated to facilitate the migration of keratinocyte 
through the association of 51 and v5 integrin cell receptor, whereas collagen 
facilitates keratinocyte migration via 21 (Clark, 1996). In constrast, laminin, one 
of the components in connective tissue, uniquely inhibits keratinocytes migration 
acting as a ‘brake’ for keratinocyte motility (Woodley et al., 1988). Evidence has 
shown that fibronectin is degraded into smaller molecular species in non-healing 
chronic wounds and these can be identified in wound fluid, whereas fibronectin 
remains in an intact form in normal acute healing wounds (Wysocki and Grinnell, 
1990). Therefore, the integrity of fibronectin in provisional matrix and the 
expression profile of 51 integrin in the migratory keratinocytes may potentially 
predict the healing result. Furthermore, soluble factors, such as interleukin (IL)-1, 
TGF-, TGF- and EGF were also found to promote epithelialisation in both an 
integrin dependent and independent manner (Brown et al., 1989, Mustoe et al., 
1987, Chen et al., 1993, Chen et al., 1995). 
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1.2.3.2 Granulation tissue formation 
Granulation tissue formation, also known as new stroma formation, begins 
approximately 4 days after injury to re-establish the dermal integrity. Newly 
formed stroma consists of macrophages, new blood vessels, fibroblasts and loose 
connective tissue (Clark, 1996). The macrophages recruited into the provisional 
matrix in earlier phases produce cytokines and growth factors that facilitate 
fibroplasia and ECM reorganisation by fibroblasts as well as neovascularisation by 
endothelial cells. After infiltrating into the wound space via the interaction 
between members of the cell membrane integrin superfamily and the provisional 
matrix components, dermal fibroblasts gradually move to a profibrotic phenotype 
and switch their function to collagen synthesis (Welch et al., 1990, Clark, 1996). 
TGF- has been demonstrated to be associated with collagen synthesis since it is 
found highly expressed in profibrotic fibroblasts (Clark et al., 1995). Once an 
abundant collagen deposition is achieved in the wound area, fibroblasts cease 
collagen synthesis and undergo programmed cell death, starting approximately 10 
days post injury (Williams, 1991). Although the exact mechanism or signals 
leading to the apoptosis of fibroblasts remains to be elucidated, Interferon (IFN)- 
and collagen matrix has been documented to suppress collagen synthesis by 
fibroblasts (Duncan and Berman, 1985, Granstein et al., 1987, Grinnell, 1994, Clark 
et al., 1995). 
 
1.2.3.3 Angiogenesis 
In response to a variety of chemotactic and angiogenic signals produced during 
the inflammtory phase, angiogenesis (the formation of new blood vessels) occurs 
as a result of endothelial cell migration and proliferation. Microvascular 
endothelial cells are considered to be the principal parenchymal cells involved in 
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wound angiogenesis due to their ability to respond to injury through the 
degradation of the basement membrane, proliferation, migration into the stroma, 
and the formation of new blood vessels (Marx et al., 1994, Li et al., 2003).  After 
sensing angiogenic signal, endothelial cells from the side of the venule closest to 
the angiogenic stimuli begin to synthesise and release collagenases followed by 
degradation of the basement membrane, enabling their migration and 
penetration through the fragmented basement membrane via projecting 
pseudopodia. Subsequently, the entire endothelial cell migrates into the 
perivascular area and the remaining parent vessel initiate proliferation to provide 
a continuing source of endothelial cells for angiogenesis (Clark, 1996). Being 
pushed by the proliferative behaviour and pulled by the attractive signals, the 
migrating endothelial cells start to create new blood vessel sprouts and eventually 
form new capillary networks (Tonnesen et al., 2000). Angiogenesis leads to the 
development of new capillary networks and helps restore vascular perfusion, 
subsequently facilitating the delivery of nutrients and oxygen required to sustain 
cell metabolism. Thus, the restoration of vascular perfusion by angiogenesis 
potentially relieves the hypoxic microenvironment of a lesion and hence, any 
defect capable of interfereing with angiogenesis may also lead to delayed or 
impaired wound healing. Furthermore, insuffcient vascularisation, which has been 
shown to be related to reduced re-epithelialisation and deficient granulation 
formation can potentially result in the development of chronic, non-healing 
wounds (Johnson and Wilgus, 2014). Therefore, ensuring the normal function of 
angiogenesis is essential for the wound healing process and, as such, we may be 
able to improve wound healing by regulating the behaviour of endothelial cells 
and the process of angiogenesis (Darby et al., 2014, Senger and Davis, 2011, 
Folkman and Shing, 1992, Tonnesen et al., 2000). 
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1.2.4  Tissue remodelling phase 
The final stage of wound healing, tissue remodelling, begins 2 to 3 weeks after 
injury, continuing for a period of several months to a year, potentially even 
extending to two or three years (Gurtner et al., 2008). At the initiation of tissue 
remodelling, fibroblasts switch into a myofibroblast phenotype characterised by 
rich actin-containing microfilaments along the plasma membrane. Such processes 
promote the establishment of the cell-cell and cell-matrix linkages, contributing to 
the biomechanics of ECM contraction (Welch et al., 1990). Over the lengthy 
period of the wound remodelling phase the majority of cell types participating in 
the former stages, such as endothelial cells, fibroblasts and macrophages, either 
undergo apoptosis or exit the wound site (Gurtner et al., 2008). As the matrix 
matures, the early stage components of ECM, such as hyaluronic acid (HA) and 
fibronectin, which provide a provisional substratum for the infiltrating cells, are 
gradually replaced by proteoglycans and collagens in order to increase the 
resilience and strength of the wound. Collagen remodelling also occurs during the 
transition of granulation tissue to a mature scar, and this process is tightly 
regulated by a variety of collagenases produced by granulocytes, macrophages, 
epidermal cells and fibroblasts (Clark, 1996). Normally after 6 months, the newly 
formed granulation tissue is strengthened by reorganisation of the major type III 
collagen to the predominant type I collagen (Gurtner et al., 2008). In this stage, 
granulation tissue gradually converts into mature scar tissue by collagen 
catabolism (Werner and Grose, 2003). In general, the maturation of the 
neoepithelum, fibroplasia and neovascularature as well as the reconstitution of 
the extracellular matrix at wound margin occurs in the same time as the 
granulation tissue invasion to the centre of the wound space (Kurkinen et al., 
1980). Tissue remodelling begins at the wound margin once such an area is readily 
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covered by neoepidermis and filled with granulation tissue. Meanwhile, this 
process is accompanied by the newly formed granulation tissue growing toward 
the centre of the wound site. The composition and structure of the extracellular 
matrix at the wound margin always differs from the one close to the central 
wound area (Clark, 1996). Once tissue remodelling is complete, however, unlike 
uninjured skin, the wound area will never reach a 100 percent organised collagen 
form and will never return to perfect skin. In addition, hypertrophic and keloid 
scars may form after healing (Broughton et al., 2006b). 
 
1.3 Role of cytokines / growth factors in wound healing 
1.3.1 Cytokines, growth factors and wound healing 
Cytokines and growth factors are soluble cell secreted glycoproteins released in 
response to normal biological signals or environmental stimuli. They bind with 
cognate cell transmembrane receptors and initiate intracelluar signalling cascades 
followed by regulating fundamental biological processes (Coondoo, 2011). 
Cytokines are a class of small proteins involved in both paracrine (mode 
that cell released molecules affect other cells nearby) and autocrine (mode that 
molecules affect the cell which produces them) cell signalling. Cytokines include, 
among others, chemokines (which promote chemotaxis), interferons and 
interleukins (which are both vital for the function of a healthy immune system) 
and members of the TNF family (which can induce apoptosis). The cytokines 
which are produced and released following an immune event can initially dictate 
whether an immune response is necessary and, if so, whether that response is 
cytotoxic, humoral, cellular-mediated or allergenic in nature (Borish and Steinke, 
2003). Wound healing is tightly regulated by numerous cytokines, growth factors 
and chemokines released by several cell types (Table 1-2) through various 
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sophisticated signalling pathways (Barrientos et al., 2008, Behm et al., 2012). 
Throughout the wound healing process these soluble proteins are extensively 
produced to mediate the infiltration, migration, proliferation and differentiation 
of neutrophils, monocytes, keratinocytes, fibroblasts and endothelial cells, 
contributing to the restoration of an integral skin. Therefore, a tightly spatial and 
temporal control of these mediators holds the key to a normal wound healing 
process. There have been extensive studies evaluating the functions of the large 
pool of these soluble proteins. Among them, the functions of PDGF, VEGF, FGF, 
EGF-like growth factor and TGF- families are relatively well documented 
(Barrientos et al., 2008, Clark, 1996).  
 
1.3.1.1 PDGF 
PDGF, which was originally identified as a mitogenic protein, is firstly released by 
platelets during haemostatsis and subsequently involved in mediating cell growth, 
chemotaxis and matrix production in the following healing process. After injury 
occurs, large amount of PDGF are secreted and released by platelets and 
damaged cells, thus, a influx of this chemokine in the wound area initiates the 
recruitement of fibroblasts (Seppa et al., 1982), smooth muscle cells (Grotendorst 
et al., 1981), neutrophils and macrophages (Deuel et al., 1982, Siegbahn et al., 
1990). In addition, an elevated expression of PDGF- receptor in conjunction with 
inflammation has been documented during wound healing, enhancing cell 
responsiveness to PDGF stimulation  (Reuterdahl et al., 1993, Rubin et al., 1988). 
Moreover, abundant PDGF secretion is also continuously provided by activated 
macrphages (Shimokado et al., 1985), fibroblasts (Paulsson et al., 1987), 
endothelial cells (Harlan et al., 1986) and keratinocytes (Ansel et al., 1993) in an 
autocrine and paracrine manner, contributing to the later stages of the wound 
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healing process. In addition to the chemoattractant effect, PDGF was also found 
to facilitate the production of ECM conponents, such as fibronectin and HA (Blatti 
et al., 1988, Heldin et al., 1989), suggesting the regulatory role of PDGF in early 
matrix formation. Furthermore, in vitro studies demontrated that PDGF could also 
promote the contraction of collagen matrices (Clark et al., 1989, Gullberg et al., 
1990). Such evidence potentially expands the role of PDGF as a wound 
remodelling mediator in the late stage of wound healing. Regarding angiogenesis, 
it was found that PDGF had direct and indirect influence in this event (Risau et al., 
1992, Sato et al., 1993), however, it was considered to be less effective than other 
growth factors, such as the FGF family (Folkman and Klagsbrun, 1987). 
 
1.3.1.2 VEGF 
A member of VEGF/PDGF group of the cystine-knot superfamily (Holmes and 
Zachary, 2005), VEGF exerts its function primarily on endothelial cells and plays a 
potent role in angiogenesis. An early study showed that VEGF acted as a vascular 
permeability factor  (Senger et al., 1983), which is identified that VEGF promoted 
the mitogenic activity of capillary endothelial cells (Leung et al., 1989) and 
enhanced endothelial cells survival rate (Gerber et al., 1998), which both 
contribute to angiogenesis. Additionally, the lethality brought by VEGF deficiency 
highlighted the importance of VEGF on neovascularisation (Carmeliet et al., 1996). 
Hypoxia was found to be the critical driver for VEGF upregulation (Shweiki et al., 
1992) and upregulation of its receptor, through paracrine induction (Brogi et al., 
1996). Evidence at both transcript and protein levels have shown that 
keratinocytes are an important source of VEGF, which correlates VEGF expression 
with angiogenesis in the wound healing process (Brown et al., 1992). 
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1.3.1.3 FGF 
FGF, which consists of at least 9 structrually similar but functionally distinct 
members, is known as a potent growth factor involved in wound healing. FGF was 
shown to stimulate the proliferation, differentiation, migration, invasion and 
tubule formation of endothelial cells (Montesano et al., 1986, Kanda et al., 1996), 
and has also been found to be mitogenic for endothelial cells (Schweigerer et al., 
1987). Based on the study by Folkman and colleagues (Folkman and Klagsbrun, 
1987), to date, the most extensively studied FGFs are FGF-1 and FGF-2, also 
known as acidic FGF (aFGF) and basic FGF (bFGF) respectively, regarding their 
structures and biological functions. FGF-1 and FGF-2 were found to be responsible 
for angiogenic activities. FGF has been found to be produced and released by 
several cell types including inflammatory cells, fibroblasts and vascular enothelial 
cells (Baird et al., 1985, Blotnick et al., 1994, Kandel et al., 1991, Schweigerer et al., 
1987, Ross, 1993, Vlodavsky et al., 1987), and these FGFs primarily participate in 
the proliferation and re-epithelialisation phase as they are capable of stimulating 
the proliferation and migration of fibroblasts, keratinocytes and endothelial cells, 
all the essential cell types involved in granulation tissue formation, 
epithelialisation and angiogenesis (Burgess and Maciag, 1989, Klagsbrun, 1989, 
Delli Bovi et al., 1987, Zhan et al., 1988, O'Keefe et al., 1988, Shipley et al., 1989, 
Tsuboi et al., 1993, Lobb et al., 1985). In addition to the regulatory effect on cell 
types critically involved in the healing process, FGF has also been found to be able 
to modulate ECM synthesis and collagen degradation by mediating the expression 
and localisation of proteases (Gross et al., 1983, Buckley-Sturrock et al., 1989, 
Mignatti et al., 1989, Flaumenhaft and Rifkin, 1991, Sato and Rifkin, 1988). There 
have been a large number of investigations evaluating the exogenous application 
of FGF family members in animal models of dermal wound healing utilising a wide 
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range of different types of wound healing models. Neovascularisation has always 
been identified after FGF treatment, strongly emphasising the angiogenic role of 
FGF in wound healing (Clark, 1996). Key roles of FGF in wound healing are 
summarised in Table 1-3. 
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Table 1-3 FGF family members involved in wound healing 
Isoform 
Known producing/secreting cell 
types 
Phases of wound 
healing 
Function Reference 
FGF-1 Monocyte/macrophage, 
T lymphocyte,  
endothelial cell,  
fibroblast 
Epithelialisation, 
granulation tissue 
formation, 
angiogenesis 
promote endothelial cell migration 
through stroma; stimulated chemotaxis 
of fibroblast, facilitate collagenase 
synthesis; promote the proliferation of 
keratinocyte and fibroblast 
(Mignatti et al., 1989, Buckley-Sturrock et 
al., 1989, Shipley et al., 1989, O'Keefe et al., 
1988, Baird et al., 1985, Blotnick et al., 1994, 
Vlodavsky et al., 1987, Schweigerer et al., 
1987, Kandel et al., 1991) 
FGF-2 
FGF-7 fibroblast Epithelialisation 
promote keratinocyte proliferation and 
migration, increase plasminogen 
activator activity 
(Chedid et al., 1994, Tsuboi et al., 1993) 
Table 1-4 TGF- in wound healing 
Isoform  Phases of woung healing Function Reference 
TGF-1 
Inflammation, re-
epithelialisation, 
angiogenesis, wound 
contraction 
Recruit inflammatory cells; promote the adhesion and 
migration of keratinocytes; inhibit the proliferation of 
keratinocytes; promote endothelial cell proliferation; 
increase fibronectin expression, urokinase plasminogen 
activator activity, stimulate collagen production; 
facilitate fibroblasts contraction  
(Sankar et al., 1996, Barrientos et al., 2008, Jeong and Kim, 
2004, Sellheyer et al., 1993, Border and Ruoslahti, 1992) 
TGF-2 
Inflammation, re-
epithelialisation, 
granulation formation, 
angiogenesis 
Recruit inflammatory cells and fibroblasts; induce 
angiogenesis; facilitate the granulation tissue formation; 
stimulate re-epithelialisation 
(Cordeiro et al., 1999, Roberts et al., 1986, Cox et al., 
1992) 
TGF-3 anti-scar formation Improve the architecture of the neodermis (Shah et al., 1995) 
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1.3.1.4 EGFR and TGF- 
TGF-, an EGF-like growth factor, has been suggested to be a major regulator of 
keratinocyte proliferation (Coffey et al., 1987, Pittelkow et al., 1993).  This is 
supported by the observation that overexpression of TGF- in the epidermis 
results in a hyperproliferative and hyperkeratosis phenotype, indicating the 
important regulatory role of TGF-in normal epidermis formation (Dominey et al., 
1993). Epidermal growth factor receptor (EGFR) is expressed in the basal layer and 
the first suprabasal layer of adult epidermis (Nanney et al., 1990). EGFR has been 
proposed to be a critical mediator of migration, proliferation, differentiation and 
re-establishment of barrier permeability in keratinocytes during wound healing 
(Clark, 1996). This was further supported by the evidence that membrane bound 
EGFR was reduced in chronic wounds, and that keratinocytes at the non-healing 
edge of chronic wounds were incapable of responding to EGF stimulation due to 
the cytoplasmic localisation of EGFR (Brem et al., 2007), highlighting an essential 
role of EGFR in normal keratinocyte function in the wound healing process. In 
addition, the EGFR pathway is also found to be associated with the production of 
cytokines and growth factors, reorganisation of the ECM and promotion of 
endothelial response in dermis. EGFR pathways have therefore been defined as 
one of the integral pathways affecting nearly all major events of the wound 
healing process (Clark, 1996). 
 
1.3.1.5 TGF- 
TGF- has been recognised as the cytokine with the broadest involvement in 
tissue repair since its extensive association with a variety of cell types 
participating in the wound healing process (Roberts and Sporn, 1988, Border and 
Ruoslahti, 1992) (Table 1-4). The unique feature of this cytokine is its auto-
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induction property which enables the continuous expression of TGF- once it is 
induced either by endogenous release or exogenous application to a wound. To 
date, three isoforms have been discovered in mammalian cells and exogenous 
TGF-1 and -2 seem to hold similar effects on wound healing outcomes (Ksander 
et al., 1993), whereas application of TGF-3 results in less scaring (Shah et al., 
1995). After injury, TGF- is firstly released by aggregate platelets and damaged 
parenchymal cells, acting as chemoattractant to stimulate the migration of 
inflammatory cells, keratinocytes, fibroblasts and endothelial cells to the wound 
site. Subsequently, TGF- mediates ECM reorganisation and remodelling by 
stimulating the recruited cells to produce matrix proteins, matrix-degrading 
proteases and their inhibitors as well as modulating interactions between matrix 
components and cells via integrin receptors (Clark, 1996). However, this complex 
process depends on a cell- and context-specific manner. TGF- was also identified 
as a critical mediator of angiogenesis and re-epithelialisation, although the precise 
effects of TGF- on these two events still remians unclear due to contrasting 
results being identified in different models (Sporn et al., 1983, Roberts et al., 1986, 
Phillips et al., 1992, Flaumenhaft et al., 1993, Mustoe et al., 1991, Chen et al., 
1992, Ksander et al., 1990, Jones et al., 1991). Nevertheless, TGF- has been 
documented to be involved in the modulation of all phases of the wound healing 
process. Since initial data demonstrated abnormal growth factor profiles and 
differential proteolytic balances present in chronic wound fluids (Wysocki et al., 
1993) and given that TGF- has been documented to regulate the ECM 
reorganisation, clinical trials have investigated the application of TGF- Such trails 
have demonstrated that TGF-2 improved the healing outcomes of venous stasis 
ulcer (Robson et al., 1995), although the specific mechanisms of such effects 
remain unknown. However, more than a decade later, Pastar et al. discovered 
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that exogenous TGF- may not be of benefit to non-healing venous ulcers patients 
since its impact could be minimised by phenotypes which lacked the TGF- 
receptor and downstream target genes (Pastar et al., 2010). 
 
1.3.1.6 Other cytokines and growth factors 
There are a number of other cytokines and growth factors that may influence the 
healing process. IFN- was found to strongly and specifically induce the expression 
of Keratin-17 (Jiang et al., 1994), a protein expressed in various healthy epithelia 
that are characterised as contractile tissue. Thus, IFN-was suggested to 
contribute to the contractile nature of keratinocytes in the later stage of wound 
healing (Freedberg et al., 2001).  
IL-6 derived from fibroblasts, macrophages, endothelial cells and 
keratinocytes is another essential cytokine which affects granulation tissue 
formation, reepithelialisation, angiogenesis, cell infiltration and remodelling. 
Additionally, IL-6 showed enhanced expression in chronic wounds exhibiting 
aberrant inflammation, suggesting the importance of regulatedIL-6 expression 
patterns in normal wound healing (Behm et al., 2012). The above are a short list 
of well characterised factors in association with the wound healing process. There 
exists a long list of soluble factors that are active in physiological and pathological 
conditions including IL-1, hepatocyte growth factor (HGF), insulin-like growth 
factor (IGF)-1 and insulin (Behm et al., 2012, Yu et al., 2010, Barrientos et al., 
2008), which are not covered by the current literature review.  
 
1.4 SOCS 
SOCS are a group of cytokine- and growth factor-induced proteins containing 
three common structural and functional domains. SOCS proteins negatively 
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regulate cytokine receptor and receptor tyrosine kinase (RTK) signalling 
predominantly via inhibition of the JAK/STAT signalling pathway in order to 
maintain the homeostasis of cell function. The group consists of eight family 
members; cytokine inducible Src-homology 2-containing protein (CIS) and SOCS-1 
to SOCS-7, in mammals (Krebs and Hilton, 2001). Additionally, three family 
members of SOCS homology have been found in both Drosophila and Ciona 
intestinalis (Karsten et al., 2002, Rawlings et al., 2004a, Hino et al., 2003). 
 
1.4.1 Discovery of SOCS 
SOCS proteins were discovered separately by three independent groups of 
scientists. In 1997, Starr et al discovered three homologous forms of CIS, namely 
SOCS-1, SOCS-2 and SOCS-3, and suggested that SOCS-1 plays an important role in 
the classic negative-feedback loop which regulates cytokine signal transduction 
(Starr et al., 1997). In the same year, Endo et al found that a new JAK-binding 
protein (JAB), structurally related to CIS and possessing an Src-homology 2 (SH2) 
domain, acts as a negative regulator in the JAK signalling pathway (Endo et al., 
1997). Meanwhlie, a new protein, known as STAT-induced STAT Inhibitor-1 (SSI-1), 
was identified by a third group of scientists, and this protein was also found to be 
involved in the negative-feedback regulation of cytokine stimulated JAK/STAT 
signalling (Naka et al., 1997). It was later confirmed that SOCS-1, JAB and SSI-1 all 
belong to the SOCS family of proteins (Croker et al., 2008a). 
  
1.4.2 Structure and structural related function 
There are three major domains which contribute to the function of SOCS proteins: 
a conserved central SH2 domain containing an extended SH2 sequence; an N-
terminal domain of variable length and divergent sequence and a carboxy-
32 
 
terminal 40-amino-acid module called the SOCS box (Alexander, 2002, Yasukawa 
et al., 1999) (Figure 1-3). Due to the proteasomal degradation effect, the SOCS 
proteins which regulate cytokine signalling are short-live compared to the 
signalling components such as JAK and STAT proteins (Siewert et al., 1999, Bayle 
et al., 2006). 
 
1.4.2.1 JAK/STAT signalling 
The Janus kinase/signal transducer and activator of transcription (JAK/STAT) 
pathway is an essential cellular mechanism which responds to a wide array of 
cytokines by transducing their signals to the nucleus and promoting cell functions 
such as proliferation, migration, differentiation and apoptosis. Due to the 
establishment of murine knockout models, the biological significance of the 
JAK/STAT signalling pathway is extensively recognised (Igaz et al., 2001). 
To date, four JAK family members (JAK1, JAK2, JAK3, TYK2) and seven 
members of STAT (STAT-1, STAT-2, STAT-3, STAT-4, STAT-5a, STAT-5b, STAT-6) are 
found in mammals (Liongue et al., 2012). Each JAK protein consist of four 
sturctural domains, namely N-teminal FERM (abbreviation of the first four 
proteins found in this family: Four-point-one, Ezrin, Radixin, Moesin) (Tepass, 
2009), SH2 domain, “pseudo kinase” domain and C- terminal PTK domain (Liongue 
et al., 2012); while STAT family members possess five functional domains; an 
amino-terminal domain (NH2); a coiled-coiled domain (CCD); a DNA-binding 
domain (DBD); an SH2 domain and a carboxy-terminal transcriptional activation 
domain (TAD) (Kisseleva et al., 2002).  
 Since the JAK/STAT signalling pathway is utilised by numerous cytokines 
to transduce signals to nucleus, any mutation which holds the potential to 
compromise the regular function of the JAK/STAT pathway may also impair the 
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cytokine stimulated signalling. Additionally, dysregulation of this signalling 
pathway may cause inflammatory disease, erythrocytosis, gigantism and 
leukaemia (Rawlings et al., 2004b). Therefore, mechanisms regulating JAK/STAT 
signalling that can prevent activation beyond the necessary time are of great 
importance. This is achieved by the use of negative regulators which possess a 
specific SH2 domain such as SH2-containing phosphatase (SHP), protein inhibitors 
against STATs (PIAS) and suppressor of cytokine signalling (SOCS) (Wormald and 
Hilton, 2004). However, compared to SHP and PIAS, which are constitutively 
expressed (Wormald and Hilton, 2004), SOCS proteins are the only cytokine 
inducible inhibitors that may have the potential for use as a biomarker for the 
dysregulation of cell metabolism. 
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Figure 1-3: Structure of the eight suppressor of cytokine signalling (SOCS) family members 
SOCS proteins comprise three structural and functional domains which are 1) a N-terminal domain with variable length of amino acids sequences, 2) a 
central SH2 domain with extended SH2 sequence (ESS) and 3) a SOCS box domain containing a BC box, a elongin B and C binding domain, and a Cul box, a 
cullin-5 binding sequence, at the C-terminus. Each two SOCS family members are paired due to their structural and functional similarity. SOCS-1 and SOCS-3 
both possess a unique kinase inhibitory region (KIR) which inhibits JAK protein activity. SOCS-4 and SOCS-5 both contain a highly conserved region within 
their N-terminal domain termed as N-terminal conserved region. SOCS-6 and SOCS-7 share more than 50% amino acid identity in SH2 domain and SOCS box 
domain. (Feng et al., 2016) 
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SOCS proteins can be divided into two major sub-families according to the 
depth and scope of investigation and their structural similarity.  
The first sub-family, containing CIS, SOCS-1, SOCS-2 and SOCS-3, has been 
extensively investigated, whereas scientific study on the other sub-family 
comprising SOCS-4 to SOCS-7 is still limited. Within each of the two sub-families 
SOCS proteins can be further paired based on similarities in structure and function. 
The CIS/SOCS-1 to SOCS-3 sub-family is the most highly investigated and it has 
been discovered that CIS and SOCS-2 possess similar structures, whereas SOCS-1 
and SOCS-3 have similar functions due to their homologous structure. Although 
investigations on the function of the SOCS-4 to SOCS-7 sub-family are limited and 
require further elucidation, SOCS-4 and SOCS-5 may be paired since they possess 
the most similarity with regards to structure, with both proteins containing a 
highly conserved region within their N-terminal domain, termed the N-terminal 
conserved region. Similarly, SOCS-6 and SOCS-7, the most homologous among 
SOCS family members and sharing more than 50% amino acid identity in SH2 and 
SOCS box domains (Krebs et al., 2002), were proposed to be a pair and they are 
both involved in nuclear translocation of proteins (Kremer et al., 2007, Hwang et 
al., 2007).  
SOCS family members can also be classified according to their target 
proteins. CIS/SOCS-1-3 regulate cytokine receptor signalling through the JAK/STAT 
pathway, whereas SOCS-4 to SOCS-7 are associated with regulation of growth 
factor receptor signalling (Trengove and Ward, 2013). 
The eight structurally related SOCS family members have been recognised 
as being able to attenuate cytokine and growth factor signalling by inhibition of 
JAK tyrosine kinase activity, by blocking signal transduction through competition 
for the receptor’s phosphotyrosine residue, and via the degradation of crucial 
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molecules, such as JAK and the receptor complex, through a proteasomal pathway 
(Trengove and Ward, 2013) (Figure 1-4). To date, the structures of the ternary 
complex of three SOCS family members (SOCS-2, SOCS-3, SOCS-4-elongin-C-
elongin-B) have been established for investigating SOCS function (Bergamin et al., 
2006, Babon et al., 2006, Bullock et al., 2006, Bullock et al., 2007, Babon et al., 
2008). 
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Figure 1-4: Mechanisms of SOCS 
regulation on cytokine and growth 
factor signalling 
Three mechanisms have been discovered 
accounting for the negative regulatory 
role of SOCS on cytokine and growth 
factor siganlling. 1. SOCS associates with 
activated JAK protein and inhibit JAK 
tyrosine kinase activity; 2. SOCS 
competes with STAT for the docking site 
(phosphorylated tyrosine residues) on 
the cytokine receptor; 3. SOCS associates 
with target proteins (JAK and/or cytokine 
receptors as well as receptor tyrosine 
kinases) and promote the proteasomal 
degradation of the SOCS-target protein 
complex. (JAK: Janus kinase; STAT: 
signalling transducer and activators of 
transcription; SOCS: suppressor of 
cytokine signalling; eB:elongin B; eC: 
elongin C; Cul5: Cullin-5; Rbx2: RING-box 
protein-2; P: phosphotyrosine residue) 
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1.4.2.2 N-terminal region 
Although the function of the N-terminal domain in SOCSs has not been fully 
elucidated, it has been suggested that its helical structure contributes to the 
stability of the SOCS molecule complex (Greenhalgh et al., 2005). A study showed 
that SOCS-4 and SOCS-5 both possess a highly conserved N-terminal domain (Feng 
et al., 2012) and the N-ternimal in SOCS-5 was found to be involved in recruiting 
the EGF and IL-4 receptor complex (Nicholson et al., 2005, Seki et al., 2002). 
Additionally, the N-terminal of SOCS-6 and SOC-7, containing more than 350 
amino acids, were found to be responsible for transporting proteins into the 
nucleus (Hwang et al., 2007, Kremer et al., 2007). The short region or kinase 
inhibitory region (KIR) in the N-terminal domain (amino-terminal region) of SOCS-
1 and SOCS-3 have sequence homology with the pseudosubstrate inhibitory 
region of JAK proteins and show high affinity to JAK proteins. It has been  
suggested that the interaction between the KIR region of SOCS-1 and JAK 
activation loop inhibits the catalytic activity of JAK (Yasukawa et al., 1999, 
Nicholson et al., 1999), therefore partially suppressing cytokine signalling. Further 
study on the SOCS-3-JAK-2-gp130 crystal structure showed that the KIR region is 
required for SOCS-3 to block substrate binding of JAK, which leads to the 
inhibition of JAK’s enzymatic activity. Another finding based on this structure is 
that those residues upstream of the KIR in SOCS-3 act as a JAK-2 pseudosubstrate, 
a typical characteristic of substrate-blocking inhibitors (Kershaw et al., 2013). The 
N-terminal domians found in SOCS-4 to SOCS-7, consiting of 300-400 residues, are 
greatly extended to that of in the other SOCS family members and still remain to 
be structurally and functionally investigated (Bullock et al., 2007). 
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1.4.2.3 SH2 domain 
The SH2 domain is another essential structure determining target specifity that 
enable SOCS proteins to exert their function. The SH2 domain of SOCS proteins 
binds to phosphotyrosine residues on receptor complexes and JAK proteins to 
regulate the activated JAK/STAT signalling pathway and maintain the balance of 
cell metabolism. An early study showed that compared to the typical SH2 domain, 
those present in SOCS proteins contains a extented sub-domain which is required 
for inhibition of JAK-2 signalling (Yasukawa et al., 1999). Mutation of the SH2 
domain in SOCS-1 impaired its inhibitory function on leukemia inhibitory factor 
(LIF) signal transduction (Nicholson et al., 1999). It was found that CIS utilises the 
SH2 domain to inhibit cytokine signalling through tis competitionwith STAT for the 
docking sites present on phosphorylated tyrosine residues of activated cytokine 
receptors (Matsumoto et al., 1999). Kario et al suggested that the SH2 domain in 
SOCS-5 is necessary for both its interaction with the EGFR and EGFR degradation 
(Kario et al., 2005). 
 
1.4.2.4 SOCS box domain 
The SOCS box domain is a highly conserved motif comprising two functional sub-
domains: a BC box recruiting elongin B and C and a Cul box which regulates Cullin-
5 binding to RING-box protein-2 (Zhang et al., 1999, Kamura et al., 2004). SOCS 
box attaches to elongin B/C followed by binding to Cullin-5, a scaffold protein of 
an E3 ubiquitin ligase, thereby acquiring the ability to terminate cytokine 
signalling by binding to target molecules and facilitating proteasomal degradation 
(Zhang et al., 1999). It has been previously established that SOCS proteins are 
relatively short-lived compared to the signalling components they affect, such as 
the JAK and STAT proteins, and such phenomenon was thought to be attributable 
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to proteasomal degradation through association with their SOCS box (Bayle et al., 
2006). Babon et al. (Babon et al., 2009) discovered a correlation between the 
affinity of SOCS for Cullin-5 and the importance of the SOCS box, and predicted 
that SOCS-4 and SOCS-6 are likely to be strong SOCS box-dependent molecules 
due to their high affinity for Cullin-5. Interestingly, tyrosine residues 204 and 211 
at the carboxy teminal in SOCS-3 were discovered to be able to sustain SOCS-3 
stability through the association with elongin C and phosphorylation of either 
residue resulted in loss of elongin-C binding, leading to the acceleration of SOCS-3 
turnover (Haan et al., 2003). 
The establishment of the crystal structure of SOCS-2 and SOCS-4-elong-
B/elong-C complex aided in the understanding and identification of the distinct 
functions of the SOCS box in both CIS/SOCS-1 to SOCS-3 and SOCS-4 to SOCS-7 
sub-families (Bullock et al., 2006, Bullock et al., 2007).   
It seems that not all eight SOCS members primarily take advantage of the 
SOCS box structure to exert their negative regulatory functions. Dispite higher 
effciency of cytokine signalling suppression compared to other SOCS family 
members, the SOCS box in SOCS-1 and SOCS-3 showed a distinctly lower affinity 
for Cullin-5 compared to other homologues (Babon et al., 2009), indicating 
another possible unique functional domain present in both SOCS members. So far, 
the only discovered structural domain in SOCS-1 and SOCS-3 is KIR, which 
demonstrated direct interaction with JAK protein (Sasaki et al., 1999) and 
inhibited JAK kinase activity (Yasukawa et al., 1999). Therefore, SOCS box may not 
be the only functional domain contributing to the negtive feedback regulatory 
function of SOCS-1 and SOCS-3. This hyphothesis was further supported by in vivo 
investigation in Dosophila and mouse. SOCS box depletion in SOCS36E, a SOCS 
member in Dosophila, only results in a partial reduction of SOCS36E activity 
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(Callus and Mathey-Prevot, 2002). In vivo studies on SOCS-1 and SOCS-3 using 
SOCS box knock out mice both showed similar results, demonstrating that SOCS 
box-null mice had a milder phenotye than SOCS-null mice, and SOCS box-null mice 
expressed intermediate responses between wild type and SOCS-null mice to 
cytokine stimulation (Boyle et al., 2007, Zhang et al., 2001). Therefore, SOCS box, 
along with the other two major domains in SOCS family members, mediate 
cytokine signalling complementarily and synergistically. Although most of the 
functions and structure of the SOCS-4 to SOCS-7 subfamliy still remain unclear, it 
was found that the SOCS box was required for the inhibitory function of SOCS-5 
on EGF stimulation (Kario et al., 2005, Nicholson et al., 2005). 
  
1.4.3 Biological functions of SOCS family members 
SOCS proteins have been primarily classed as negative regulator of cytokine 
signalling. However, due to the structual variance and the different expression 
profile in different tissues and cell types, they were found to play a diverse role in 
a variety of physiology and pathology conditions. 
  
1.4.3.1 CIS 
CIS is expressed in a variety of tissues and is able to associate with tyrosine 
phosphorylated molecules. CIS was found to be strongly expressed  in the kidney, 
lung and liver in mice, whereas lower expression of CIS was observed in the heart, 
stomach, testis, spleen and thymus (Yoshimura et al., 1995, Starr et al., 1997). It 
was suggested that CIS is a negative regulator of cytokine induced signalling for 
growth as well as a tumour suppressor gene (Yoshimura et al., 1995). CIS has been 
discovered to be induced by a number of cytokines and growth factors and 
primarily acts as a negatively feedback regulator to growth hormone (GH) 
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signalling via inhibition of JAK-2 and STAT-5 activation (Verdier et al., 1998, 
Matsumoto et al., 1999, Ram and Waxman, 1999, Ram and Waxman, 2000). The 
relationship between CIS and a varitety of cytokines, capable of bringing about CIS 
expression, together with the key regulatory roles played by CIS inrelated 
downstream signalling pahtways are summarised in Table 1-5. 
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Table 1-5 Summary of the association between CIS and key cytokines/growth factors together with the regulatory roles played by CIS. 
Cytokines /growth factors that induce CIS Regulatory role of CIS in signalling pathway Reference 
Erythropoietin (EPO) 
Associate with tyrosine-phosphorylated EPO receptor,  inhibit 
EPO signalling by downregulating STAT-5 activation 
(Matsumoto et al., 1997, Yoshimura et al., 
1995) 
IL-2 Impair IL-2 signalling through the association with IL-2R chain (Aman et al., 1999, Yoshimura et al., 1995) 
IL-3 Associate with IL-3R  chain 
(Yoshimura et al., 1995, Matsumoto et al., 
1997) 
Prolacin (PRL) 
Inhibit PRL signalling through the association with PRLR, thus 
suppressing the activation of STAT-5 
(Dif et al., 2001, Pezet et al., 1999, Tonko-
Geymayer et al., 2002) 
Growth hormone (GH) 
Suppress GH signal by binding to GHR phosphor-tyrosine site, 
competing with STAT-5b, faciliating proteosomal degradation of 
(GHR-JAK2)-CIS complex 
(Ram and Waxman, 1999, Ram and 
Waxman, 2000, Adams et al., 1998) 
EGF 
 
(Tonko-Geymayer et al., 2002) 
Granulocyte-macrophage colony-
stimulation factor (GM-CSF) 
(Yoshimura et al., 1995) 
Ciliary neurotrophic factor (CNTF) (Bjorbaek et al., 1999) 
IL-9 (Lejeune et al., 2001) 
Thrombopoietin (TPO) (Starr et al., 1997, Okabe et al., 1999) 
IL-6, IFN-, Tumor necrosis factor (TNF-) (Starr et al., 1997) 
Granulocyte colony-stimulating factor (G-
CSF) 
(Hunter et al., 2004) 
IL-10 (Shen et al., 2000) 
Thymic stromal lymphopoietin (TSPL) (Isaksen et al., 1999) 
IFN- (Brender et al., 2001b) 
 
Inhibit IGF-1-induced STAT-3 activation (Zong et al., 2000) 
Interact with leptin receptor on Y985 and Y1077 (Lavens et al., 2006) 
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1.4.3.1.1 In vivo role of CIS 
CIS transgenic mice have been generated and show a decreased body weight 
compared to  wild-type mice, although they developed normally. However, 
lactation failure, reduction of gamma delta T cells and natural killer cells and an 
alteration of helper T1 (Th1)/Th2 differentiation were found in this phenotype 
(Matsumoto et al., 1999). 
 
1.4.3.1.2 CIS and wound healing 
With regards to wound healing, an early study discovered that CIS could inhibit IL-
2 signalling by associating with the -chain of the IL-2 receptor and by suppressing 
the IL-2 dependent activation of STAT-5 (Aman et al., 1999). In addition, IL-2 was 
found to be able to enhance fibroblast infiltration and metabolism in vitro, and 
was suggested to be beneficial for an immunocompromised wound (Efron and 
Moldawer, 2004). Therefore, CIS may potentially act as a negative regulator in 
granulation tissue formation.  
 
1.4.3.2 SOCS-1 
SOCS-1 has been found to be highly expressed in thymus and spleen both in 
human and mouse, whereas high expression was also observed in human 
placenta (Hilton et al., 1998, Starr et al., 1997, Kato et al., 2006). Moderate 
expression of SOCS-1 was observed in lung and testis in both species, as well as in 
adipose, ovary and the uterus in humans and the colon in mice (Starr et al., 1997, 
Kato et al., 2006, Hilton et al., 1998). Studies have shown that SOCS-1 could be 
induced by a variety of cytokines and growth factors and primarily acts as a 
negative feedback regulator to proinflammatory cyotkines such as IL-6, TNF- and 
IFN- (Table 1-6). SOCS-1 is found to be able to mediate inflammation by 
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regulating the cell growth, survial, apoptosis and differentiation of innate immune 
cells as well as non-immune cells, and is essential for the balance of IFN-mediated 
Th1/Th17 cell differentiation (Tanaka et al., 2008). 
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Table 1-6 Summary of the association between SOCS-1 and key cytokines/growth factors together with the regulatory roles played by SOCS-1 
Cytokines /growth factors that induce SOCS-1 Regulatory role of SOCS-1 in signalling pathway Reference 
GH 
Inhibit the GHR-dependent tyrosine 
phosphorylation of JAK-2 directly; inhibit GH-
induced STAT-5 activation; suppress GH-induced 
transactivation effect 
(Ram and Waxman, 1999, Hansen et al., 1999, Sporri 
et al., 2001, Adams et al., 1998) 
IL-2 
Inhibit IL-2 by suppressing STAT-5 activation; 
associate with JAK-1, JAK-2 and JAK-3 to reduce 
their tyrosine-kinase activity; bind to IL-2R  
chain; reduce IL-2-induced c-fos promoter 
activation by inhibiting JAKs activity 
(Sporri et al., 2001, Endo et al., 1997) 
IL-4 
Inhibit the activation of JAK-1 and STAT-6 in 
response to IL-4 
(Sporri et al., 2001, Naka et al., 1997, Losman et al., 
1999, Hebenstreit et al., 2003, Egwuagu et al., 2002) 
IL-6 
Inhibit IL-6-induced tyrosine-phosphorylation of 
gp130 and STAT-3; associate with JAK-2 and Tyk-
2; reduce the inhibitory effect of -casein by IL-6  
(Sporri et al., 2001, Endo et al., 1997, Naka et al., 
1997, Motta et al., 2004) 
IL-10 
Potentially inhibit IL-10-induced signalling by 
suppressing the activation of STAT-3 
(Niemand et al., 2003) 
IL-13 Attenuate IL-13-induced signalling (Hebenstreit et al., 2003) 
IFN- 
Inhibit IFN--dependent STAT-1 tyrosine 
phosphorylation and nuclear translocation; 
suppress the anti-proliferative and antiviral effect 
of IFN- 
(Crespo et al., 2000, Wang et al., 2000, Song and 
Shuai, 1998) 
IFN- Attenuate IFN- chemokine-related inflammation (Crespo et al., 2000, Qin et al., 2008) 
IFN- 
Inhibit IFN--dependent STAT-1 tyrosine 
phosphorylation and nuclear translocation; 
(Sporri et al., 2001, Song and Shuai, 1998, Starr et al., 
1997, Tanaka et al., 2008, Alexander et al., 1999, 
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suppress antagonistic effect of IFN- on STAT-3 
and Smads, neutralise IFN--dependent inhibition 
of Th17 differentiation; inhibit the anti-
proliferative and antiviral effect of IFN-; 
suppress the IFN--mediated STAT1 
phosphorylation at Y701 and the association of 
STAT-1 and DNA 
Zhang et al., 2001, Park et al., 2000) 
EPO Inhibit EPO-induced EPOR activation (Sporri et al., 2001, Endo et al., 1997) 
G-CSF  (Naka et al., 1997) 
Leukemia inhibitory factor (LIF) 
Inhibit LIF-mediated cell apoptosis and 
differentiation; suppress LIF-induced STAT-3 
activation  
(Naka et al., 1997, Nicholson et al., 1999) 
PRL 
Suppress PRL-stimulated signal through the 
association with JAK-2 and inhibition of STAT-5-
mediated transcription; inhibit PRLR-mediated 
signalling 
(Sporri et al., 2001, Pezet et al., 1999, Motta et al., 
2004, Helman et al., 1998) 
Ciliary neurotrophic factor (CNTF) 
 
(Bjorbaek et al., 1999) 
leptin (Motta et al., 2004) 
Steel factor Promote steel factor-dependent cell survival (De Sepulveda et al., 1999) 
 
Suppress TNF--mediated cell apoptosis via 
sustaining the activation of p38 mitogen-
activated protein kinase (MAPK); reduce the 
inhibitory effect of -casein by TNF- 
(Morita et al., 2000, Motta et al., 2004) 
Reduce IL-3-induced c-fos promoter activation by 
inhibiting JAKs activity 
(Endo et al., 1997) 
Interfere with IL-7-stimulated-pre-TCR activation (Trop et al., 2001) 
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Negatively regulate IL-12-induced IL-12R and 
STAT-4 activation 
(Eyles et al., 2002) 
Reduce IL-15-induced STAT-5 phosphorylation (Ilangumaran et al., 2003) 
Suppress thrombopoietin(TPO)-induced signalling (Starr et al., 1997, Wang et al., 2000) 
Inhibit thymic stromal lymphopoietin (TSLP)-
mediated signalling 
(Isaksen et al., 1999) 
Surppress oncostatin M (OSM)-mediated cell 
differentiation; inhibit OSM-induced STAT-3 
activation 
(Starr et al., 1997, Song and Shuai, 1998) 
Negatively regulate insulin signalling through the 
association with IRS-1 and by the inhibition of 
JAK; associate with IRS-1 and IRS-2 for ubiquitin-
mediated degradation; inhibit insulin-dependent 
dowsteam signalling, extracellular signal-
regulated kinase (ERK), protein kinase B, 
phosphatidylinositol 3-kinase (PI3K)/Akt 
activation 
(Kawazoe et al., 2001, Rui et al., 2002, Mooney et al., 
2001, Liu et al., 2008a) 
Associate with IGF-1R to inhibit IGF-1-induced 
STAT-3 activation 
(Zong et al., 2000, Dey et al., 1998) 
Sustain ERK activated anti-inflammatory 
pathways; maintain RAS through facilitating 
degradation of RAS inhibitor, p120 RasGAP 
(Madonna et al., 2008) 
Associate with receptor tyrosine kinase KIT, FIL-3 
and suppress their mitogenic signals 
(De Sepulveda et al., 1999) 
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1.4.3.2.1 In vivo role of SOCS-1 
SOCS-1 deficient mice exhibited complex diseases in a diverse range of organs and 
could not survive beyond weaning, indicating that SOCS-1 is required for various 
cell types and is essential for normal postnatal growth and survival (Starr et al., 
1998, Naka et al., 1998, Metcalf et al., 1999, Marine et al., 1999b). Additionally, 
SOCS-1 and IFN- double knockout mice expressed other aberrant phenotypes 
including polycystic kidneys, chornic inflammatory lesions (Metcalf et al., 2002), 
pertrubed T cell development (Cornish et al., 2003, Lee et al., 2009) and enhanced 
sesitivity to lipopolysaccharide (LPS) (Kinjyo et al., 2002). In order to investigate 
the function of SOCS-1 in individual tissue, a thymocyte/T cell specific SOCS-1 
expression mouse model was established. Apart from multiple lymphoid 
abnormalities, such mice did not develop lethal multiorgan inflammatory 
pathologies seen in SOCS-1 deficient mice, indicating that thymocyte/T cell 
specific SOCS-1 deficiency alone is insufficient to cause neonatal lethality (Chong 
et al., 2003). It was suggested that SOCS-1 plays a regulatory role in the activation 
of macrophages through Toll-like receptor (TLR) signaling (Kinjyo et al., 2002, 
Nakagawa et al., 2002), indicating the potential role of SOCS-1 in regulating innate 
immunity through inhibition of macrophage activation. Investigation on a SOCS-1 
and IFN- double knockout mouse model demonstrated that dendritic cells were 
hyperactive and hyperresponsive to IFN-in SOCS-1 deficient conditions. 
Therefore, a mouse model which expressed SOCS-1 only in T and B cells was 
established to further investigate the regulatory role of SOCS-1 on dendritic cells 
in vivo. Such phenotype expressed accumulated dendrtic cells in the thymus and 
spleen as well as developing skin lesions, glomerulonephritis, and auto-antibody 
production, which are similar symptoms to systemic lupus erythematosus (SLE). 
Thus, it was suggested that SOCS-1 is essential to the normal function of dendritic 
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cells and the suppression of systemic autoimmunity. Moreover, the reduction of 
SOCS-1 expression could be a risk factor for SLE (Hanada et al., 2003).  Hepatocyte 
specific-SOCS-1 deficient mice exhibited enhanced concanavalin A (ConA)-indcued 
hepatitis. Such phenotypes expressed enhanced apopotosis signals after being 
treated with ConA, showing induced hyperactivation of STAT-1 and TNF--
mediated-Jun-terminal kinase (JNK), an proapoptotic kinase, as well as higher cell 
surface accumulation of Fas protein which meditates hepatocyte apoptosis. On 
the contrary, overexpresssion of SOCS-1 in mice prevented ConA-induced liver 
injury by repressing the induction of proinflammory cytokines. Taken together, 
SOCS-1plays a negative regulatory role in acute hepatitis (Torisu et al., 2008). 
SOCS-1 transgenic mice have also been generated using the lck proximal promoter, 
and the SOCS-1 transgene was strongly expressed in T cell lineage. This phenotype 
exhibited decreased phosphorylation of STATs induced by cytokines, and 
expressed defects in the development of T cells, which resembled the phenotype 
of mice lacking JAK-1, JAK-3 and common gamma-chain. This may indicate the 
inhibitory role of SOCS-1 in regulating downstream signalling of JAKs and common 
gamma-chain-using cytokines (Fujimoto et al., 2000). 
 
1.4.3.2.2 SOCS-1 and wound healing 
A in vitro study in human keratinocytes demonstrated that SOCS-1 exerts its 
inhibitory function against the pro-inflammatory effects of IFN- by not only 
inhibiting STAT-1 but also via maintenance of ERK-1/2-dependent anti-
inflammatory pathways (Madonna et al., 2008), indicating a direct anti-
inflammatory role of SOCS-1 on human epidermal keratinocytes. Since IFN- was 
found to contribute to the enhancement of tissue remodelling and the reduction 
of re-epithelialisation and wound contraction, regulation of IFN- is considered 
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crucial to wound healing (Efron and Moldawer, 2004). Therefore, further 
investigation of the regulatory role of SOCS-1 on IFN- during the re-
epithelialisation stage of wound healing may identify new potential therapeutic 
targets. 
Similar to CIS, SOCS-1 was also discovered to negatively regulate IL-2 
signalling through inhibition of JAK-1 and STAT-5 activity as well as associating 
with the IL-2 receptor. Additionally, SOCS-1 suppresses the signalling of IL-4, an 
anti-inflammatory cytokine, through inhibition of JAK-1 and STAT-6 (Egwuagu et 
al., 2002). Therefore, due to the fact that IL-2 and IL-4 are involved in fibrolast 
infiltration, proliferation and collagen production, SOCS-1 may hold the potential 
to mediate granulation tissue formation.  
A previous study showed that SOCS-1 inhibits TNF-induced cell 
apoptosis via regulation of p38 MAPK, indicating an important regulatory role for 
SOCS-1 in TNF- signalling (Morita et al., 2000). TNF- was found to be up-
regulated in chronic wounds and was suggested to result in prolonged 
inflammation through degradation of the ECM, growth factors and cell receptors 
by inducing MMPs production (Barrientos et al., 2008). Thus, SOCS-1 may have 
the potential to maintain homeostasis of the inflammation phase of chronic 
wounds through regulation of TNF-.  
It was discovered that SOCS-1 could inhibit HGF-induced STAT-3 activation 
(Seki et al., 2008), indicating its regulatory role in HGF-dependent signalling. HGF, 
which can be induced by TNF-, IL-1 and IL-6, was considered to promote 
granulation tissue formation and angiogenesis in wound healing. HGF exerts its 
function by binding to its receptor tyrosine kinase, HGFR. Chronic wounds were 
suggested to be attributable to HGF/HGFR pathway dysregulation, and topical 
application of HGF was recommended as a potential treatment for chronic 
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wounds (Behm et al., 2012). Therefore, the precise control of HGF signalling by 
the implementation of SOCS-1 may hold potential as another therapeutic option 
for chronic wounds.  
Upon insulin treatment, instead of direct inhibition of insulin receptor (IR) 
auto-phosphorylation SOCS-1 is more likely to inhibit insulin-dependent activation 
of ERK-1/2 (Mooney et al., 2001). During the wound healing process, ERK has 
been considered as an important regulator of wound contraction (Hirano et al., 
2002) and an in vivo study in mice showed that the inhibition of ERK activation led 
to delayed wound healing (McFarland-Mancini et al., 2010). Taken together, 
SOCS-1 may also mediate wound healing by regulating the activation of ERK. 
 
1.4.3.3 SOCS-2 
SOCS-2 has been discovered to be the most abundant in human fetal kidney as 
well as adult heart, liver, pancreas and skeletal muscle, whereas moderate 
expression was also observed in adult kidney, thymus, prostate, testis, small 
intestine and colon (Dey et al., 1998, Minamoto et al., 1997). In addition, similar 
expression profiles were found in mice which showed prominent expression of 
SOCS-2 in lung, liver, salivery gland, testis, muscle and kidney (Metcalf et al., 2000). 
SOCS-2 has been extensively studied and found to be involved in regulating a 
variety of a cytokine induced signalling pathways where the imbalance of SOCS-2 
is also considered to be related to a broad range of pathologies (Rico-Bautista et 
al., 2006) (Table 1-7).  
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Table 1-7 Summary of the association between SOCS-2 and key cytokines/growth factors together with the regulatory roles played by SOCS-2 
Cytokines /growth factors that induce SOCS-2 Regulatory role of SOCS-2 in signalling pathway Reference 
GH 
Associate with GHR on on Y487 and Y595; inhibit the GHR-
dependent tyrosine phosphorylation of JAK-2 via the 
association with GHR for GHR degradation; suppress the 
activation of STAT-5; negatively regulate GH signal through 
proteasomal degradation; interfere with the inhibitory effect of 
SOCS proteins on GH signalling; block the GH-mediated 
inhibition of neuronenin-1 expression to promote neuronal 
differentiation 
(Adams et al., 1998, Greenhalgh et al., 
2002a, Vesterlund et al., 2011, 
Dogusan et al., 2000, Piessevaux et al., 
2006, Ram and Waxman, 1999, Miller 
et al., 2004, Turnley et al., 2002, 
Uyttendaele et al., 2007, Greenhalgh 
et al., 2002b, Favre et al., 1999) 
Estrogen 
Inhibit GH signalling vis GH/JAK/STAT pathway upon estrogen 
stimulation 
(Leung et al., 2003) 
EPO  (Starr et al., 1997, Wang et al., 2004) 
PRL 
Associate with PRLR; supress the activation of STAT-5; restore 
PRL signalling through the inhibitory effect of SOCS-1  
(Pezet et al., 1999, Harris et al., 2006, 
Dogusan et al., 2000) 
IL-1-  (Dogusan et al., 2000) 
IL-2 
Enhance IL-2-induced STAT activation through the association 
with SOCS-3 for degradation 
(Minamoto et al., 1997, Tannahill et 
al., 2005, Brender et al., 2001b) 
IL-3 
Enhance IL-2-induced STAT activation through the association 
with SOCS-3 for degradation 
(Minamoto et al., 1997, Tannahill et 
al., 2005) 
IL-6 
 
(Dogusan et al., 2000) 
IL-9 (Lejeune et al., 2001) 
IL-10 (Shen et al., 2000) 
IL-15 
Regulate human NK cell effector function through the 
interaction with phosphorylated proline-rich tyrosine kinase 2 
on Y402 to facilitate its degradation in a IL-15-dependent 
(Lee et al., 2010) 
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manner 
G-CSF 
 
(Minamoto et al., 1997) 
GM-CSF (Faderl et al., 2003) 
CNTF (Bjorbaek et al., 1999) 
IFN- 
Interfere with the inhibitory effect of SOCS proteins on IFN 
signalling; inhibit IFN--induced reporter activity 
(Brender et al., 2001b, Piessevaux et 
al., 2006, Shen et al., 2000) 
IFN- 
Interfere with the inhibitory effect of SOCS proteins on IFN 
signalling 
(Dogusan et al., 2000, Piessevaux et 
al., 2006) 
LIF Suppress the apoptotic effect of LIF (Minamoto et al., 1997) 
Insulin  (Sadowski et al., 2001) 
lipoxin 
Participate in lipoxin-induced IL-12 suppression to regulate 
inflammation 
(Machado et al., 2006) 
 
Associate with EGFR and sustain phosphorylation of Y845 of 
EGFR to regulate neurite outgrowth 
(Goldshmit et al., 2004) 
Interfere with the inhibitory effect of SOCS proteins on leptin 
signalling; associate with leptin receptor on Y1077, and block 
interaction of CIS with STAT-5 at this site 
(Piessevaux et al., 2006, Lavens et al., 
2006) 
Associate with activated IGF-1R (Dey et al., 1998) 
Negatively regulate IGF-1 to inhibit cell proliferation; associate 
with IGF-1 and inhibit IGF-1-induced STAT-3 activation 
(Horvat and Medrano, 2001, Metcalf 
et al., 2000, Miller et al., 2004, Dey et 
al., 1998, Zong et al., 2000) 
Associate with Tropomyosin-related kinase A (TrkA) expression 
upon neurotrophin binding, and increase TrkA expression on 
cell surface to promote neuronal survival and neurite 
outgrowth potentially through sustained activation of pAkt and 
pERK1/2 
(Uren et al., 2014) 
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Interact with fms-like tyrosine kinase 3 (FLT-3) on Y589 and 
Y919 for degradation and negatively regulate internal tandem 
duplication mutated FLT-3 (FLT-3-ITD)-dependent STAT-5 
activation to regulate cells proliferation 
(Kazi and Ronnstrand, 2013) 
Negatively regulate the mutant JAK-2 (JAK2V617F-activating 
mutation)-induced STAT-5 activation 
(Quentmeier et al., 2008) 
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1.4.3.3.1 In vivo role of SOCS-2 
SOCS-2 deficient mice were found to display gigantism symptoms following 
weaning, although most organs were shown to be histologically normal. Such 
phenotypes resembled those shown in both GH and IGF-1 transgenic mice 
(Metcalf et al., 2000). Further investigation on the same SOCS-2 difficient mouse 
model and primary cells generated from this demonstrated that SOCS-2 could 
regulate neural progenitor cells differentiation (Turnley et al., 2002). Interestingly, 
in contrast to the hypothesis that overexpression of SOCS-2 in mice could lead to 
growth defects, SOCS-2 overexpression mice showed a hypergrowth phenotype 
which resembled that observed in SOCS-2 deficient mice, indicating the positive 
role of SOCS-2 in GH signalling. Therefore, SOCS-2 has been suggested to have a 
dual effect on GH signalling . 
 
1.4.3.3.2 SOCS-2 and wound healing 
It has been suggested that SOCS-2 is an important anti-inflammatory regulator 
and is required for immune responses in diverse pathologies (Machado et al., 
2006). Therefore, SOCS-2 holds the potential to play regulatory roles in the 
inflammatory phase in the wound healing process. It was found that SOCS-2 
increased IL-2-dependent STAT phosphorylation via the association with SOCS-3 
to facilitate its proteasomal degradation as well as blocking the interaction of CIS 
with STAT-5 (Tannahill et al., 2005, Lavens et al., 2006), a inverse function to CIS, 
SOCS-1 and SOCS-3 on IL-2 regulation. Together with that evidence that IL-2 
elevated fibroblast infiltration during wound healing (Efron and Moldawer, 2004), 
it appears that SOCS-2 may help to restore the balance of IL-2 signalling regulated 
by other SOCS family members. 
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SOCS-2 was also found to be able to associate with EGFR at the Y845 Src binding 
site and to decrease STAT-5b phosphorylation stimulated by EGF, indicating its 
negative regulatory role on EGF-induced signalling (Goldshmit et al., 2004). Upon 
EGF binding, EGFR is activated and facilitates re-epithelialisation by inducing the 
proliferation and migration of keratinocytes (Barrientos et al., 2008). Thus, SOCS-2 
may potentially suppress the re-epithelialisation via suppression of EGFR 
activation. 
 
1.4.3.4 SOCS-3 
1.4.3.4.1 SOCS-3, a diverse regulatory factor  
SOCS-3 is expressed in the spleen, thymus and lung in mice (Starr et al., 1997), 
whereas in humans, SOCS-3 is expressed in a greater number of tissues. The 
highest expression of SOCS-3 was observed in adipose, lung ovary and aortic 
tissue, and moderate expression of SOCS-3 is found in blood leucocyte, placenta, 
trachea and colon (Kato et al., 2006). The expression pattern of SOCS-3 in normal 
human tissues indicates that SOCS-3 is predominantly expressed in macrophages, 
immature myeloid DCs and endothelial cells, whereas moderately positive 
expression of SOCS-3 was found in neutrophils and some B and T-lymphocytes. 
Additionally, SOCS-3 is found to be occasionaly expressed in natural killer cells and 
many types of epithelium (White et al., 2011). SOCS-3 has been documented to be 
induced by a wide range of cytokines and growth factors, and acts as negative 
feedback inhibitor to these molecules to maintain the homeostasis of the 
activated signalling pathway, thus regulating cell behavious and metabolisms. 
(Table 1-8) SOCS-3 holds the greatest sequence homology to SOCS-1 and similarly 
but not identicaly to SOCS-1, the inhibitory mechansim of SOCS-3 on the catalytic 
activity of JAK proteins mainly depends on its binding to the activated receptors 
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rather than directly interacting with JAK proteins or competing for the docking 
site with STAT proteins (Alexander, 2002). SOCS-3 has been shown to be an 
important mediator of insulin and pro-inflammatory cytokines.  
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Table 1-8 Summary of the association between SOCS-3 and key cytokines/growth factors together with the regulatory roles played by SOCS-3 
Cytokines /growth factors that induce SOCS-3 Regulatory role of SOCS-3 in signalling pathway Reference 
IL-1 
Prevent IL-1-induced toxicity through the inhibition of  inducible 
nitric oxide synthase (iNOS) expression 
(Boisclair et al., 2000) 
IL-2 
Associate with JAK-1 and inhibit its phosphorylation through the 
interaction with IL-2R  chain; suppress the STAT-5b activation; 
inhibit IL-2-mediated lymphocyte proliferation; associate with Ras 
inhibitor, p120 RasGAP, to maintain ERK activation upon tyrosine 
phosphorylation by IL-2 on Y211 
(Cohney et al., 1999, Cacalano et 
al., 2001) 
IL-3 
Inhibit IL-3-mediated lymphocyte proliferation; block STAT-3 
activation to contribute to the inhibitory effect of IL-3 on IL-11 
signalling 
(Cohney et al., 1999, Magrangeas 
et al., 2001a) 
 Inhibit IL-4-induced STAT-6 activation and gene transcription (Losman et al., 1999) 
IL-6 
Inhibit phosphorylation of IL-6-induced STAT-1 and STAT-3; inhibit IL-
6-induced macrophage differentiation; regulate IL-6 signalling via 
the association with JAK-gp130 to block substrate binding of JAK and 
facilitate JAK ubiquitination; suppress IL-6-stimulated migration and 
proliferation of vascular smooth muscle cells by blocking STAT-3 
activation 
(Croker et al., 2003, Nicholson et 
al., 1999, Brender et al., 2007, 
Song and Shuai, 1998, Starr et al., 
1997, Xiang et al., 2013, Yasukawa 
et al., 2003, Kershaw et al., 2014, 
Niemand et al., 2003) 
IL-9 
Inhibit the IL-9-induced STAT-1, -3, -5 activation; suppress IL-9-
mediated anti-apoptotic  effect 
(Lejeune et al., 2001) 
IL-10 
Partially attenuate IL10-triggered biological response; involved in the 
attenuation of oxidized low-density lipoprotein (oxLDL)-induced 
apoptosis by IL-10 through inhibition of p38 MAPK and c-Jun N-
terminal kinase (JNK) activation 
(Shen et al., 2000, Berlato et al., 
2002, Yin et al., 2013) 
IL-11 Negatively regulate IL-11-mediated adrenocorticotropic hormone (Auernhammer and Melmed, 
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(ACTH) production 1999) 
 
Inhibit IL-12-induced STAT-4 activation through the association with 
IL-12R 2 Y800 
(Egwuagu et al., 2002, Yamamoto 
et al., 2003, Seki et al., 2003) 
IL-22  (Kotenko et al., 2001) 
 
Inhibit IL-23-mediated STAT-3 activation; inhibit generation of Th17 
cell 
(Chen et al., 2006, Li et al., 2006) 
Negatively regulate IL-27-mediated mitogenic signals to T cells (Brender et al., 2007) 
IFN- 
Inhibit IFN--dependent STAT-1 tyrosine phosphorylation and 
nuclear translocation; inhibit the anti-proliferative and antiviral 
effect of IFN-; inhibit IFN--induced reported activity 
(Song and Shuai, 1998, Shen et al., 
2000, Hong et al., 2001) 
IFN- Attenuate IFN- chemokine-related inflammation (Qin et al., 2008) 
IFN- 
Inhibit the anti-proliferative and antiviral effect of IFN-; suppress 
the IFN--mediated STAT1 phosphorylation at Y701 and the 
association of STAT-1 and DNA; suppress the IFN--stimulated 
migration and proliferation of vascular smooth muscle cells by 
blocking STAT-3 activation 
(Song and Shuai, 1998, Park et al., 
2000, Xiang et al., 2013) 
TGF- 
Negatively regulate TGF-1/Smad-3 signalling through the 
association with Smad-3 to suppress its nuclear translocation and 
transcription activity 
(Liu et al., 2008b) 
EPO 
Associate with EPOR Y401 and JAK-2 to inhibit STAT-5 activation and 
EPO-mediated proliferation; associate with Ras inhibitor, p120 
RasGAP, to maintain ERK activation upon tyrosine phosphorylation 
by EPO on Y211 
(Sasaki et al., 2000, Cacalano et 
al., 2001, Marine et al., 1999a) 
GH 
Block the GH-induced transactivation effect; inhibit GH-induced 
STAT-5 activation; inhibit JAK-2 activity in a GHR-dependent manner 
(Adams et al., 1998, Hansen et al., 
1999) 
PRL Suppress PRL-stimulated signal through the association with JAK-2 (Pezet et al., 1999, Helman et al., 
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and inhibit STAT-5-mediated transcription; inhibit PRLR-mediated 
signalling 
1998) 
Leptin Suppress leptin-mediated signal transduction (Bjorbaek et al., 1998) 
Angiotensin II (Ang II) 
Attenuate Ang II-induced JAK-2/STAT-1 activation through the 
association with JAK-2 
(Calegari et al., 2003) 
GM-CSF  (Faderl et al., 2003) 
CNTF Inhibit CNTF-induced signal transduction in astrocytes (Bjorbaek et al., 1999) 
TPO  (Wang et al., 2000) 
TNF- 
Contribute to the inhibitory effect of TNF- on IFN- signalling and 
TNF- mediated degradation of IRS-1 and IRS-2 
(Hong et al., 2001, Shi et al., 2004) 
OSM 
Inhibit OSM-induced STAT-3 activation and nuclear translocation; 
attenuate OSM-mediated ERK1/2 activation 
(Song and Shuai, 1998, 
Magrangeas et al., 2001b) 
EGF 
Associate with Ras inhibitor, p120 RasGAP, to maintain ERK 
activation upon tyrosine phosphorylation by EGF on Y211; 
contribute to the inhibitory effect of EGF on PRL-induced STAT-5 
activation 
(Cacalano et al., 2001, Tonko-
Geymayer et al., 2002) 
PDGF (induce SOCS-3 phosphorylation) 
Associate with Ras inhibitor, p120 RasGAP, to maintain ERK 
activation upon tyrosine phosphorylated by EGF on Y211 
(Cacalano et al., 2001) 
basic fibroblast growth factor (bFGF)  (Terstegen et al., 2000) 
LIF 
Inhibit LIF-induced macrophage differentiation; suppress LIF-
mediated STAT-3 tyrosine phosphorylation 
(Nicholson et al., 1999, Adams et 
al., 1998) 
TSH Associate with JAK-1 and JAK-2 upon TSH stimulation (Park et al., 2000) 
resistin Help resistin antagonise insulin signalling (Steppan et al., 2005) 
insulin 
Inhibit insulin-induced STAT-5b activation via the competition to IR 
binding motif Y960; attenuate insulin signalling through the 
association with IRS-1 and IRS-2 for proteasomal degradation; inhibit 
(Sadowski et al., 2001, Emanuelli 
et al., 2000, Rui et al., 2002, Liu et 
al., 2008a) 
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insulin-induced PI3K/Akt activation 
LPS 
Inhibit LPS-mediated IL-6 production and suppress CCAAT/enhancer-
binding protein- (C/EBP-) activity via N-terminal KIR, SH2 domain 
Y204 and SOCS box; attenuate LPS-induced STAT-1 and STAT-3 
activation 
(Yan et al., 2010, Qin et al., 2006) 
 
Inhibit C-X-C Motif chemokine Ligand-12 (CXCL-12) signalling 
through the association with C-X-C chemokine receptor- 4 (CXCR-4); 
attenuated CXCL-12 induced CXCR-4-dependent focal adhesion 
kinase (FAK) signalling by enhancing the FAK unibiquitination for 
proteasomal degradation 
(Soriano et al., 2002, Le et al., 
2007) 
G-CSF 
Suppress G-CSF-mediated STAT-3 activation; negatively regulate G-
CSF-driven signalling in myeloid cells; negatively regulate G-CSF-
induced STAT-5 activation; associate with G-CSFR on Y729 for 
ubiquitination 
(Croker et al., 2004, van de Geijn 
et al., 2004, Irandoust et al., 2007) 
 
Inhibit IGF-1-induced STAT-3 activation; interact directly with 
activated IGFIR 
(Zong et al., 2000, Dey et al., 
2000) 
Negatively regulate IL-2 production by CD28 through the association 
with phosphorylated CD28 
(Matsumoto et al., 2003) 
Associate with DP-1 on amino acids 156 and 172 to regulate cell 
cycle through the inhibition of E2F/DP-1 transcriptional activity 
(Masuhiro et al., 2008) 
Disrupt cell apoptosis by sustaining the activation of PI3K/Akt for the 
activation of nuclear factor-kappa B (NF-B) as well as inhibiting BAD  
(Madonna et al., 2012) 
Suppress TCR-mediated IL-2 production by preventing 
dephosphorylation of activated nuclear factor of activated T-cells 
(NFAT); inhibit calcineurin-mediated signalling through the 
association with its catalytic subunit 
(Banerjee et al., 2002) 
63 
 
1.4.3.4.2 In vivo role of SOCS-3 
SOCS-3 knockout mice express fatal placental defects and embryonic lethality 
(Roberts et al., 2001). Although this phenotype could be temporarily rescued by 
leukaemia inhibitory factor receptor (LIFR) deficiency (Takahashi et al., 2003), the 
dual deficient SOCS-3 and LIFR mice exhibited fatal inflammatory disease and high 
neonatal mortality (Robb et al., 2005). Additionally, absence of SOCS-3 in mice led 
to lethal inflammatory response, however, IL-6 deficiency extented the survial 
time of this phenotype, suggesting the anti-inflammatory role of SOCS-3 in IL-6-
mediated signalling (Croker et al., 2012). Mice lacking SOCS-3 in macrophages or 
hepatocytes helped to demonstrate the complementary role of SOCS-3 and SOCS-
1 on regulating cytokine signalling (Croker et al., 2003). Hematopoietic-specific 
SOCS-3 knockout mice developed a range of inflammatory pathologies after 
young adulthood (Croker et al., 2004). The progenitor cells of such mice exibited 
skewed differentiation from neutrophils toward macrophages, indicating the 
maintenance role of SOCS-3 on cell differentiation specificity in response to 
cytokine signalling (Croker et al., 2008b). T cell conditional knockout mice were 
generated and such mice displayed no significant difference in thymus or spleen 
as well as the proportions of CD4+ and CD8+ cells, except for enlarged lymph nodes. 
However, such phenotypes displayed increased responses to TCR engagement 
and was hypersentistive to gp130 cytokine stimulation (Brender et al., 2007). 
Another neural cell-specific SOCS-3 deficient mouse model displayed enhanced 
leptin reponse, resulting in body weight loss and suppression of food intake (Mori 
et al., 2004), suggesting the regulatory role of SOCS-3 in leptin signalling. Such 
evidence emphasised the importance of SOCS-3 in T cell activity and 
differentiation. Furthermore, a keratinocyte-specific SOCS-3 knockdown mouse 
model exhibited a severe skin inflammation phenotype along with epidermal 
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hyperplasia, suggesting a essicential regulatory role of SOCS-3 in proinflammatory 
responses (Uto-Konomi et al., 2012). 
The establishment of a SOCS-3 constitutive expression mouse model 
resulted in embryonic lethality due to fetal erythropoiesis blockage, which is 
similar to the phenotype seen in JAK-2 or erythropoietin receptor deficient mouse 
models and suggests a regulatory role of SOCS-3 in fetal liver hematopoiesis, 
possibly through JAK-2 or erythropoietin receptor-dependent signalling (Marine et 
al., 1999a). Another study on SOCS-3 transgenic mice and heterologous mice 
demonstrated that SOCS-3 impaired CD28-mediated IL-2 production and NF-B 
activation in primary T cells (Matsumoto et al., 2003). In addition, SOCS-3 
transgenic mice exhibited increased Th2 responses and Th2-related allergic 
disease phenotypes (Seki et al., 2003). Moreover, SOCS-3 overexpression in mice 
showed suppressed Th17 differentiation due to inhibition of STAT-3 activation 
(Tanaka et al., 2008). These evidences emphasised the important role of SOCS-3 in 
T cell activation and differentiation. Furthermore, the keratinocyte-specific SOCS-
3 overexpression mice displayed prolonged inflammation and severe impairment 
of wound closure, interfering with the proliferation and migration of keratinocytes 
in the epidermis (Linke et al., 2010b, Linke et al., 2010a).  
 
1.4.3.4.3 SOCS-3 and wound healing 
Many studies have shown that SOCS-3 is a regulator of a pool of pro-inflammatory 
cytokines, such as IL-2, IL-6, TNF-, IFN-, -, - (Table 1-8). Enhanced expression 
of IL-6, a pro-inflammatory cytokine, was observed during the inflammatory phase 
of wound healing. In addition, IL-6 is considered to be an essential initiator of the 
wound healing process due to its mitogenic and proliferative effect on 
keratinocytes and the chemoattractive function of neutrophils (Barrientos et al., 
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2008). Moreover, evidence showed that SOCS-3 inhibits IL-1 induced signalling 
(Karlsen et al., 2001) and that IL-1exhibited similar expression patterns and 
synergistic roles to TNF-in chronic wounds. Taken together, SOCS-3 may play an 
important role in regulating the homeostasis of cytokine singalling in the 
inflammation phase of wound healing. 
Another study, investigating the downstream mechanism of psoriasis, 
unveiled that the anti-apoptotic mechanism utilised by SOCS-3 in keratinocytes 
was through the sustained activation of PI3K/Akt, which in turn activates nuclear 
factor-kappa B (NF-B), an apoptosis protector, and in parallel, inhibits the pro-
apoptotic function of BAD (Madonna et al., 2012), thus, SOCS-3 may potentially 
be involved in mediating keratinocytes survival in chronic wound, another 
pathological condition in wound healing. 
A previous study has demonstrated a positive regulatory role of SOCS-3 in 
toll-like receptor-4 (TLR-4) response in macrophages, and SOCS-3 negatively 
mediates endogenous TGF-1-induced Smad-3 signalling to restore the 
production of TNF- and IL-6 (Liu et al., 2008b). One of the key functions of TGF-
β1 is the production of cytokines and inflammatory mediators during wound 
healing (Border and Ruoslahti, 1992). Therefore, SOCS-3 may indirectly modulate 
wound healing by regulating the cytokine production of TGF-1. Similar to SOCS-1, 
SOCS-3 could also suppress HGF-induced STAT-3 activation. Since SOCS-1 and 
SOCS-3 have the closest sequence homologies, they may compensate for each 
other on the regulation of HGF signalling during wound healing. 
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1.4.3.4.4 Implication of SOCS-3 in a variety of diseases and cancer 
1.4.3.4.4.1 SOCS-3 in immune diseases 
Clinical investigation of ulcerative colitis biopsies showed that the transcript 
expression level of SOCS-3 correlated with grade assessment using both 
endoscopic and histologic techniques (Miyanaka et al., 2007). An investigation of 
polytraumatised patients indicated significantly elevated expression levels of 
SOCS-3 mRNA in neutrophil granulocytes immediately after the traumatic event, 
and those who died within 90 days displayed significant higher SOCS-3 mRNA 
expression compared to those who surived (Brumann et al., 2014). This might 
suggest that the overexpression of SOCS-3 impaired normal immune function 
which then lead to fatality. An additional study on the intestinal T cells from 
patients with Crohn's disease demonstrated constitutive expression of both SOCS-
3 and STAT-3 compared to healthy volunteers. Due to the negative regulatory role 
of SOCS-3 on the stimulation of various cytokines, this constitutive expression of 
SOCS-3 may cause resistance to exogenous cytokines for Crohn's disease patients 
(Lovato et al., 2003).  
Introduction of SOCS-3, by injection of recombinant adenovirus carrying 
SOCS-3 cDNA, markedly repressed the symptoms of arthritis in an arthritic mouse 
model and the inhibitory role of SOCS-3 on STAT-3 activity was suggested asa 
potential therapeutic strategy for the treatment of rheumatoid arthritis (Shouda 
et al., 2001). Another study on using SOCS-3 deleted mouse models in 
hematopoietic and endothelial cells demonstrated severe IL-1-dependent 
inflammatory arthritis with increased neutrophil synovium infiltrate and elevated 
osteoclast generation as well as bone destruction, suggesting a negative 
regulatory role of SOCS-3 in inflammatory joint disease (Wong et al., 2006).  
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Further in vivo study demonstrated that SOCS-3 could skew T cells 
differentiation to Th2 cells (Li et al., 2006). Additionally, given that Th2 cells are 
considered to have important pathogenetic roles in immune dysfunction which 
characterises atopic dermatitis (Leung, 1995), and that the expression level of 
SOCS-3 transcript was found significantly elevated in patients with atopic 
dermatitis compared to healthy controls (Arakawa et al., 2004), it suggested that 
SOCS-3 could potentially contribute to atopic dermatitis pathogenesis by 
enhancing Th2 cells differentiation. Another study also suggested a correlation 
between SOCS-3 expression and the severity of atopic dermatitis and asthma. 
Therefore, a transgenic SOCS-3 mouse model and dominant-negative SOCS-3 
mutant mouse models were established for further investigation into the 
regulatory role of SOCS-3 in Th2 cell related pathogenesis, indicating that SOCS-3 
has an essential role in the maintenance of Th2-regulated allergic diseases (Seki et 
al., 2003). Further investigation was implemented by Moriwaki and colleagues, 
which demonstrated that suppression of SOCS-3 in CD4+ T cells helped relieve the 
development of allergic inflammation in an allergic mousce model of asthma, 
indicating a potential theraputic approach for allergic diseases (Moriwaki et al., 
2011).  
A new approch utilising intranasal treatment with SOCS-3-small 
interfering RNA (siRNA) to achieve SOCS-3 silencing in the whole lung 
environment in chronic asthmatic mouse models was examined afterwards, 
leading to an improvement in chronicity and remodelling and, demonstrating an 
alternative and easily administered potential therapeutic for asthma patients 
(Zafra et al., 2014). Another study on an allergen-induced allergic conjunctivtis (AC) 
mouse model showed that overexpression of SOCS-3 in T cells led to the 
deterioration of AC, whereas, T cell specific SOCS-3 deletion could rescue the AC 
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phenotype. This evidence further indicates that SOCS-3 could be a potential target 
for therapeutic intervention in allergic disease (Ozaki et al., 2005).  
 
1.4.3.4.4.2 SOCS-3 in vascular inflammatory diseases 
SOCS-3 is believed to be involved in atherosclerosis due to the fact that 
significantly higher expression of SOCS-3 in vascular smooth muscle cells (VSMCs) 
and macrophages was found in the inflammatory region in human plaques as well 
as in aortic lesions from atherosclerosis development mouse models. Further 
study demonstrated that SOCS-3 depeletion in mice increased the presence of 
VSMCs, CD4+ T lymphocytes and macrophages in the aortas, suggesting the 
inhibitory role of SOCS-3 in leukocyte infiltration and VSMCs proliferation in 
atherosclerosis (Ortiz-Munoz et al., 2009). Consistent results were observed in a 
study focusing on a T cell specific-SOCS-3 depletion mouse model which induced 
an anti-inflammatory effect on macropahges.  
Additionally, the correlation between the expression profile of IL-17, 
phosphorylated STAT-3 in dissected human atherosclerotic plaques and the 
stability of the plaque phenotype was consistent with the finding in SOCS-3 
deficient mice models. However, SOCS-3 overexpression models exhibited  
increased lesion size, and was found to promote atherosclerotic lesion 
development, possibly via the suppression of IL-17, leading to increased T cell 
infiltration and vascular inflammation. Given that in vivo administration of IL-17 
reduced the vascular T cell infiltration and athrosclerotic lesion development, 
SOCS-3 seems to accelerate the development of athrosclerosis (Taleb et al., 2009). 
Regardless of this controversy and diversity, SOCS-3 has been demonstrated to be 
an important regulartory factor in atherosclerosis.  
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SOCS-3 has also been linked to heart diease. The markedly decreased 
gp130 protein level and the enhanced gp130/SOCS-3 protein expression ratio in 
human heart failure myocardial tissues comparing to control donors heart 
samples suggest the inactivation of gp130 signalling pathway (Zolk et al., 2002). 
This is in agreement with the proposal that SOCS-3 could potentially be a 
pharmaceutical target to cardiac disease due to its regulatory role in gp130-
dependent pathways, a important receptor in cardiac hypertrophy and heart 
failure (Yasukawa et al., 2001).  
 
1.4.3.4.4.3 SOCS-3 in metabolic diseases 
SOCS-3 has also been linked to a number of metabolic diseases and disorders and 
has been suggested to mediate glucose homeostasis regulated by metabolic 
hormones such as lepin and insulin. This was implicated through a study on 
heterozygous SOCS-3 deficient mice which showed enhanced sensitivity to 
exogenous leptin administration and resistance to the development of diet-
induced obesity (Howard et al., 2004). Such phenotypes were also exhibited in 
neural cell-specific SOCS-3 knockout mouse models. Neural cell specific SOCS-3 
knockout mouse models were generated to elucidate the function of SOCS-3 on 
leptin signalling. These demonstrated that leptin resistance could be rescued by 
SOCS-3 deficiency in the brain, and leptin-induced STAT-3 phosphorylation was 
elevated, leading to significant body weight loss as well as a reduction of food 
intake. Such evidence indicates that SOCS-3 plays negative regulatory roles in 
lepin signalling, and highlights the concept of a potential therapeutic method of 
targeting SOCS-3 in the brain for the treatment of leptin resistance (Mori et al., 
2004).  
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Similar to the effect on leptin, insulin resistance was found in SOCS-3 
overexpression mouse models and evidence demonstrated that SOCS-3 regulated 
insulin resistance by antagonising STAT3-mediated inhibition of sterol regulatory 
element-binding protein (SREBP)-1c promoter activity (Ueki et al., 2004). It was 
later demonstrated by in vivo study that SOCS-3 could regulate leptin sensitivity in 
pro-opiomelanocortin (POMC) expressing neurons (Kievit et al., 2006), and POMC 
neurons are important to the regulatory role of SOCS-3 in metabolic abnormalities, 
however, it seems that this regulatory role of SOCS-3 could only be effective in 
specific cell types (Reed et al., 2010). Adipose tissue-specific SOCS-3 
overexpression mouse models suppressed insulin signalling in adipocyte, and 
exhibited resistance to diet-induced obesity partially by suppressing lipogenesis 
and increasing lipolysis, although this was not sufficient to systemic insulin 
resistance (Shi et al., 2006). Mouse models with SOCS-3 deficiency in liver showed 
enhanced insulin sensitivity in the liver at a young age, whereas, systemic insulin 
resistance was found in such aged mice due to the hyperactivation of STAT-3 
which produces acute-phase proteins, leading to dysregulation of lipid and 
glucose metabolism (Torisu et al., 2007). Another study exhibited that liver 
specific SOCS-3 deletion only enhanced the insulin sensitivity of chow diet mice, 
whereas, the high fat diet contributed to greater hepatic insulin resistance in this 
genotype (Sachithanandan et al., 2010).  
The phenotype of skeletal muscle-specific SOCS-3 overexpression 
exhibited the blockage of both insulin and leptin-dependent signalling, indicating 
the antagonistic role of SOCS-3 in insulin-dependent glucose disposal (Yang et al., 
2012). However, study on the skeletal muscle-specific deletion of SOCS-3 mice 
demonstrated that skeletal muscle SOCS-3 was not required for regulating whole-
body energy expenditure and the SOCS-3 knockout genotype did not protect from 
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diet-induced obesity but prevented from obesity-induced glucose intolerance and 
insulin resisitance (Jorgensen et al., 2013). Taken together,  
SOCS-3 is considered to be an important contributing factor for obesity 
associated leptin and insulin resistance as well as type 2 diabetes.  
 
1.4.3.4.4.4 SOCS-3 in cancer 
Since a variety of inflammatory mediators are of importance and utilise JAK/STAT 
signalling to exert their function in cancer associated inflammation, the role of 
SOCS-3, a negative feedback regulator of cytokine signalling, primarily mediated 
through regulation of JAK/STAT signalling, has been investigated in cancer 
initiation and progression. Lower or non-expression of SOCS-3 was found in  lung 
cancer cells and this SOCS-3 silencing results from hypermethylation in the SOCS-3 
promoter region. Furthermore, restroration of SOCS-3 expression led to 
decreased STAT-3 activation and growth suppression of lung cancer cells, 
indicating the inhibitory role of SOCS-3 in lung cancer pathogenesis (He et al., 
2003). A study on SOCS-3 overexpression in intestinal epithelial cell (IEC) and 
Caco-2 cell lines indicated an anti-proliferative role of SOCS-3 in colon cancer cells. 
Further study on IEC specific SOCS-3 knockout mice models demonstrated that 
SOCS-3 inhibits crypt proliferation and hyperplasia in the colon upon acute injury. 
Additionally, SOCS-3 was proposed to be a tumour suppressor as increased 
tumour size and number was found in IEC-selective SOCS-3 deleted mice 
compared to that of in wild-type littermates after chronic inflammatory treatment, 
SOCS-3 was proposed to be a tumour suppressor (Rigby et al., 2007).  
  It has been suggested that IL-6 trans-signalling as well as the STAT-
3/SOCS-3 pathway were involved in pancreatic intra-epithelial neoplasias 
progression and pancreatic ductal adenocarcinoma development and SOCS-
72 
 
deficient KrasG12D mice increased the progression of pancreatic cancer (Lesina et 
al., 2011), which is in agreement with the results found in lung and colon cancer. 
Gastrointestinal epithelial cell-specific SOCS-3 conditional knockout mice 
expressed enhanced lepin production and STAT-3 hyperactivation, and the 
phenotype of such SOCS-3 deficient mice resembled the pathology and molecular 
alterations found in human intestinal-type gastric tumours, although inflammtory 
responses were not required for this gastric tumorigenesis. This demonstrated the 
anti- tumorigenic role of SOCS-3 in gastric tumours (Inagaki-Ohara et al., 2014). 
However, the regulatory role of SOCS-3 in cancer seems to be more complicated 
and might be cell type specific.  
  SOCS-3 has also been suggested to be unlikely to possess tumour 
suppressive effects on breast cancer and ovarian cancer tissues (Sutherland et al., 
2004). Investigation of prostate cancer cells suggested that SOCS-3, acting as a 
tumour cell protector against growth inhibition, was induced by the cAMP 
derivative and could antagnise the inhibitory function of cyclic adenosine 
monophosphate (cAMP) on the proliferation and apoptosis of prostate cencer 
cells (Bellezza et al., 2006). Another study showed that increased expression of 
SOCS-3 correlated with the development and progression of prostate cancer (Puhr 
et al., 2009). Further in vitro study on prostate cancer cell lines exhibited that 
SOCS-3 knockdown increased IL-6 induced cell apoptosis via activation of STAT-3 
(Puhr et al., 2009). In a separate study, macrophage specific-SOCS-3 deleted mice 
exhibited increased survival rate after being challenged with melanoma cells, 
indicating a potential protective role of SOCS-3 in tumour metastasis (Hiwatashi et 
al., 2011).  
  SOCS-3 was also found to be consititutively expressed in T cell lymphoma 
cell lines, and this phenotype accounts for the prolonged IFN--induced STAT-3 
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activation (Brender et al., 2001a). Additionally, consititutive expression of SOCS-3 
was detected in the majority of chronic myelogenous leukaemia cell lines, which 
confered such cell lines with resistence to IFN- therapy (Sakai et al., 2002). 
Moreover, tumour cells generated from cutaneous T cell lymphoma patients 
exhibited constitutive expression of SOCS-3 through the constitutive activation of 
STAT-3, leading to the attenuation of IFN--dependent growth inhibition (Brender 
et al., 2005). 
 
1.4.3.5 SOCS-4 
SOCS-4 is the least investigated member of the SOCS family. Study on the 
expression profile of SOCS family members in porcine tissue demonstrated that 
the highest expression of SOCS-4 was found in the small intestine, large intenstine 
and thymus, although little variation in expression between different tissues was 
observed (Delgado-Ortega et al., 2011). To date, there are not many studies 
available to fully recognise the function of SOCS-4. Fortunately, the establishment 
of the SOCS-4-elongin-C-elong-B model has helped to aid in the elucidation of 
structural aspects of SOCS-4. SOCS 4 adapts an alternative packaging structure to 
that of earlier members of the family, CIS/SOCS1–3. This alternative packaging 
solution stabilises the SH2 region enabling SOCS-4 to be more stable and rigid 
than the alternative packaging structure seen in the CIS/SOCS-1–SOCS-3 sub-
family (Bullock et al., 2007, Bullock et al., 2006). These initial studies have 
highlighted structural differences within SOCS-4 in comparison to other family 
members, though much work remains to fully elucidate its full biological 
significance. Table 1-9 summarises known cytokine/growth factor interactions and 
regulatory roles of SOCS-4. 
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Table 1-9 Summary of the association between SOCS-4 and key cytokines/growth factors together with the regulatory roles played by SOCS-4 
Cytokines /growth factors that induce SOCS-4 Regulatory role of SOCS-4 in signalling pathway Reference 
EGF 
Negatively mediate EGFR activity; highly associate with EGFR on 
Y1092 to compete with STAT-3 
(Kario et al., 2005, Bullock et al., 2007, 
Scheitz et al., 2012) 
LIF 
Interact with cardiotrophin-like cytokine (CLC, a IL-6 cytokine), 
poly(rC) binding protein 1 (Pcbp1, affecting STAT-3 activation) 
and cytosolic malae dehydrogenase (Mdh1, influencing cell 
cycle), contributing to ovarian follicular development 
(Sutherland et al., 2012) 
 
Inhibit STAT-3 and STAT-6 phosphorylation (Hu et al., 2010) 
Potentially modulates TLR2 signalling; modulate EGFR/STAT-3 
signalling and IL-6 production 
(Arts et al., 2015) 
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1.4.3.5.1 In vivo role of SOCS-4 
SOCS-4 deficient mice, compared with control wild type littermates, exhibited 
increased susceptibility to infection with influenza A, showing delayed viral 
clearence, dysregulation of proinflammatory cytokines and chemokines, and 
impaired trafficking of virus-specific CD8 T cells to the infection site. This evidence 
suggests a regulatory role for SOCS-4 in the inflammatory response to influenza. 
Moreover, in vitro study on CD8 T cell from this mouse model has indicated the 
potential role of SOCS-4 in regulating TCR stimulation and signalling, a novel 
function of SOCS-4 (Kedzierski et al., 2014). 
 
1.4.3.5.2 SOCS-4 and wound healing 
The expression of SOCS-4 was found to be induced by Cryptosporidium parvum (a 
protozoan parasite) through the decrease of microRNA-98 and let-7 which 
normally function to target the SOCS-4 3′ untranslated region resulting in 
downregulation of SOCS-4 expression (Hu et al., 2010). In addition, an 
investigation seeking the link between genetic alteration and autoimmune 
disorder on a Turkish family highlighted that a SOCS-4 mutation which impairs the 
function of SOCS-4 protein may hold the potential to modulate EGFR/STAT-3 
signalling as well as IL-6 production (Arts et al., 2015). These data imply a possible 
mechanism of SOCS-4 in regulating autoimmunity. Moreover, convergence 
evaluation studies on animals which adapt to live in high-altitude environment 
suggested that SOCS-4 potentially acts as a regulator to hypoxia inducible factor 
(HIF)-1, a mediator required for adaptation to hypoxia, indicating the 
involvement of SOCS-4 in the regulation of hypoxia (Wang et al., 2015). Therefore, 
SOCS-4 may potentially have regulatory role in haemostasis and inflammation, the 
two early phases in the wound healing process. 
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SOCS-4 was also found to be induced by the stimulation of EGF and to be 
able to markedly reduce the expression of EGFR and EGFR-mediated signalling 
(Kario et al., 2005). It was also discovered that SOCS-4 decreased STAT-3 
activation by EGFR via enhanced EGFR degredation as well as through competing 
for the docking site with STAT-3 for the phophorylated tyrosine residue Y1092 on 
EGFR (Bullock et al., 2007). Moreover, SOCS-4 has been implicated in maintaining 
the homeostasis of keratinocyte proliferation via regulation of EGFR and STAT-3 
activation since repressed SOCS-4 expression, brought about by Runx1, exhibited 
a hypergrowth phenotype (Scheitz et al., 2012). Based on the importance of EGFR 
signalling and keratinocyte behaviour during the proliferation and re-
epithelialisation phase in wound healing, SOCS-4 may act as a modulator to keep 
the balance of EGF-like protein signal transduction as well as epidermal cell 
function. 
 
1.4.3.5.3 The involvement of SOCS-4 in cancer 
Since inflammation and angiogenesis are both critical properties in wound healing 
and cancer, investigation on the involvment of SOCS-4 in cancer may also give 
clues to potential functions of SOCS-4 in wound healing. In breast cancer biopsies,  
higher mRNA expression of SOCS-4  were found to associate with better overall 
survival, and inversely correlated with TNM classification (Sasi et al., 2010). A 
different study, investigating human gastric cancer biopsies showed attenuated 
expression of SOCS-4 compared to the control tissues, both in mRNA and protein 
level. In addition, the promoter hypermethylation of the SOCS-4 gene, which 
impaires SOCS-4 expression, correlated with poor prognosis of gastric cancer 
patients (Kobayashi et al., 2012). Another in vitro study on thyroid cancer cell lines 
indicated that the expression of SOCS-4 was attenuated by IL-23, a 
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proinflammatory cytokine, through up-regulation of the expression of microRNA-
25 which targets the 3’ untranslated region of SOCS-4 gene, leading to elevated 
cell migration and invasion (Mei et al., 2015). These envidence suggested the role 
of SOCS-4 in cancer may be tissue-dependent and may potentially hold different 
effects in distinct microenvironments.  
 
1.4.3.6 SOCS-5 
SOCS-5 is the most structurally similar member of the SOCS family to SOCS-4. It is 
expressed widely in murine tissues. The highest expression was found in the brain, 
lung, spleen and colon, whereas bladder, testis, eye and mesenteric lymph node 
(primarily in T and B cells) exhibited moderate expression (Hilton et al., 1998, 
Brender et al., 2004). Additionally, SOCS-5 was found to be constitutively 
expressed in retina cells from mouse (Takase et al., 2005). The expression profile 
in human tissues indicated a variety of expression of SOCS-5 in the spleen, lymph 
node, thymus, bone marrow, skeletal muscle, heart, brain, placenta and feotal 
liver (Magrangeas et al., 2000). Similarly to SOCS-4, SOCS-5 is one of the more 
poorly studied members of SOCS proteins, although it has been documented to be 
able to negatively regulate cytokine and growth factor signalling. (Table 1-10) 
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Table 1-10 Summary of the association between SOCS-5 and key cytokines/growth factors together with the regulatory roles played by SOCS-5 
Cytokines /growth factors that induce SOCS-5 Regulatory role of SOCS-5 in signalling pathway Reference 
EGF 
Suppresse EGF mitogenic  effect through the association 
with EGFR and use SOCS box to recruit E3 ubiquitin ligase to 
promote EGFR degradation 
(Nicholson et al., 2005, Kario et al., 2005) 
 
Associate with IL-4R  chain to inhibit IL-4-mediated 
activation of STAT-6, resulting in skewed Th cell 
differentiation from Th2 to Th1 
(Seki et al., 2002) 
Partially reduce IL-6 and LIF signalling  (Nicholson et al., 1999) 
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1.4.3.6.1 In vivo role of SOCS-5 
A SOCS-5 overexpression mouse model was found to aleviate the symptoms of 
allergic conjunctivity, a Th2 cell-mediated allergic diease (Ozaki et al., 2005). 
Moreover, enhanced bacterial clearance activity was found in a T cell specific-
SOCS-5 overexpression mouse model compared to control littermates and this 
was found to be due to the alteration of cytokine balance in such phenotypes, 
indicating the importance of SOCS-5 in T cell related innate immunity (Watanabe 
et al., 2006). In contrast, a completely SOCS-5  deficient mouse model was also 
generated to investigate the regulatory role of SOCS-5 on lymphocytes since it has 
been found that SOCS-5 is expressed in primary B and T cells in wild-type mice. 
However, unexpected results were found, indicating that SOCS-5 deficient mice 
shown normal B and T cell development and no obvious phenotype deficiency 
comparing to the control littermates, suggesting that the function and the 
development of B and T cells seemed to be SOCS-5-independent (Brender et al., 
2004). One potential explanation is due to the possible functional redundancy of 
SOCS-5 and other SOCS family members in lymphocytes modulation, since the 
expression of other SOCS members in primary T cells has been previously 
reported (Egwuagu et al., 2002). 
 
1.4.3.6.2 SOCS-5 and wound healing 
The consitutive expression of SOCS-5 and the increased SOCS-5 expression during 
experimental autoimmune uveitis suggested a negative regulatory role in the 
inflammatory response (Takase et al., 2005), raising the posibility that SOCS-5 acts 
as a mediator during wound healing. 
It has been suggested that SOCS-5 specifically interacts with the IL-4 
receptor -chain and may functionally affect IL-4-induced STAT activation 
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regardless of receptor tyrosine phosphorylation status (Seki et al., 2002). During 
the wound healing process, IL-4, secreted by T lymphocytes, basophils and mast 
cells, is able to induce fibroblast proliferation, collagen production and arginase 
activity to promote wound healing (Efron and Moldawer, 2004). Taken together, 
SOCS-5 may affect the re-epithelialisation phases of wound healing through 
modulation of IL-4 signalling. 
Similarly to SOCS-4, SOCS-5 can be induced by EGF stimulation and 
inhibited the activation of EGFR levels via proteasomal degradation (Kario et al., 
2005, Nicholson et al., 2005). Upon injury, EGF, derived from platelets, 
macrophages and fibroblasts, accelerates re-epithelialisation via the activation of 
EGFR, and subsequently promotes the proliferation and migration of 
keratinocytes (Barrientos et al., 2008). Since SOCS-5 has the ability to interact with 
EGFR, and to promote the degradation of EGFR, investigation into the interaction 
between SOCS-5 and EGFR in wound healing models may hold the potential for 
the discovery of new therapeutic targets. 
 
1.4.3.7 SOCS-6 
SOCS-6 is another ubiqutiously expressed SOCS protein whose distribution was 
found in many tissues and organs. However, relatively high expression of SOCS-6 
has been found in spleen, lung, kidney, large intestine and salivary gland in 
comparison to testis, liver, bone marrow, heart and thymus in the adult mouse 
(Krebs et al., 2002). In addition, constitutive expression of SOCS-6 was also 
observed in human, mouse and rat retinal cells (Liu et al., 2008a). SOCS-6 was 
initially documented to be an insulin signal regulator (Krebs et al., 2002, Mooney 
et al., 2001, Li et al., 2004). However, further investigation uncovered that SOCS-6 
is also involved in mediating cell proliferation signals, T cell receptor signals, 
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neuronal differentiation and potentially modulating the negative regulatory effect 
of SOCS proteins themselves (Table 1-11). 
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Table 1-11 Summary of the association between SOCS-6 and key cytokines/growth factors together with the regulatory roles played by SOCS-6 
Cytokines /growth factors that induce SOCS-6 Regulatory role of SOCS-6 in signalling pathway Reference 
Insulin 
Associate with IR in an insulin dependent manner; inhibit insulin-
mediated activation of ERK1/2 and protein kinase B as well as IRS 
phosphorylation; interact with p85 PI3K in an insulin dependent 
manner to suppress the negative effects of p85 on glucose 
metabolism; associate with IRS-2, IRS-4 and p85 PI3K; promote 
retina cell survival through the maintenance of insulin-induced 
Akt signalling 
(Mooney et al., 2001, Li et al., 2004, 
Krebs et al., 2002, Liu et al., 2008a) 
IGF-1 
Inhibit IGF-1 signalling through the association with IGFR and JAK-
2 to inhibit STAT-5 activation  
(Gupta et al., 2011) 
Stem cell factor (SCF) 
Associate with KIT substrate peptide residues 564-574, 
particularly Y567 and Y568, to reduce SCF-induced activation of 
ERK1/2 and p38 to reduce cell proliferation 
(Bayle et al., 2004, Zadjali et al., 
2011) 
 
Associate with FLT-3 Y591 and Y919 for internalisation and 
degradation of FLT-3 to inhibit FLT-3 activation as well as 
downstream ERK signalling pathway 
(Kazi et al., 2012) 
Associate with activated p56(lck) F505 for subsequent 
degradation to repress T cell receptor (TCR) signalling 
(Choi et al., 2010) 
Interact with the SOCS box of all members of SOCS to 
compromise their negative regulatory role 
(Piessevaux et al., 2006) 
Localise in the nucleus via N-terminal region, and degrade 
nuclear STAT-3 through C-terminal region 
(Hwang et al., 2007) 
Interact with Pim3 and inhibit ERK1/2 activity in response to 
glucose stimulation 
(Vlacich et al., 2010) 
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1.4.3.7.1  In vivo role of SOCS-6 
Transgenic mice overexpressing SOCS-6 developed normally despite increased 
glucose metabolism and insulin tolerance (Li et al., 2004). However, SOCS-6 
deficient mice did not show significant differences in blood glucose and plasma 
insulin levels compared to the wild-type littermates.No glucose and insulin 
tolerance was found in such phenotype (Krebs et al., 2002). The fact that no 
abnormalities were seen in SOCS-6 deficient mice compared to wild-type 
littermates may be due to the functional redundancy of SOCS-6 and SOCS-7 since 
they share more than 50% similarity in their functional domains at the protein 
level (Banks et al., 2005). It has also been proposed that the redundancy of the 
other SOCS family members may compensate for the defects caused by lack of 
SOCS-6 (Trengove and Ward, 2013). 
 
1.4.3.7.2 SOCS-6 and wound healing 
It has been suggested that SOCS-6 facilitates proteasomal degradation of target 
proteins to which the SH2 domain of SOCS-6 binds (Krebs et al., 2002). As with 
SOCS-2, SOCS-6 also has the ability to interact with other SOCS family members in 
a SOCS box dependent manner and acts as a negative regulator of SOCS protein 
activity (Piessevaux et al., 2006). Based on the above mentioned possible link 
between SOCS proteins and critical wound healing molecules, SOCS-6 may have a 
dual effect on modulating different stages of the wound healing process either via, 
similar to other SOCS members, its regulatory role on cytokine and growth factor 
signalling or through the unique ability to associate with their own family 
members, resulting in proteasome-dependent degradation. 
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1.4.3.8 SOCS-7 
Studies on two mouse strains both demonstrated that SOCS-7 expression is 
distributed across a variety of tissues including brian, muscle, liver, pancreas, fat, 
skin and spleen (Krebs et al., 2002, Banks et al., 2005). It was previously 
discovered that Nck-, Ash- and phospholipase C gamma-binding protein (NAP)-4, 
also known as SOCS-7, contains a putative nuclear localisation signal and a motif 
specific to nuclear proteins (Matuoka et al., 1997, Martens et al., 2004). SOCS-7 
has been documented to be induced by a number of cytokines and growth factors 
and primarily acts as a mediator to insulin, prolactin and growth hormone 
signalling (Table 1-12). 
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Table 1-12 Summary of the association between SOCS-7 and key cytokines/growth factors together with the regulatory roles played by SOCS-7 
Cytokines /growth factors that induce SOCS-7 Regulatory role of SOCS-7 in signalling pathway Reference 
GH Inhibit GH signalling through STAT-5 (Dogusan et al., 2000) 
PRL 
Interact with activated STAT-3 and STAT-5 to attenuate 
their DNA binding ability; inhibit PRL signalling through 
STAT-5 
(Dogusan et al., 2000, Martens et al., 2005) 
Insulin 
Associate with INSR; bind to IRS-1 for proteasomal 
degradation to negatively regulate insulin signalling 
(Banks et al., 2005) 
IL-6 
 
(Dogusan et al., 2000) 
IL-1 (Dogusan et al., 2000) 
 
Inhibit leptin-induced STAT-3 translocation (Martens et al., 2005) 
associate with IRS-4 and p85 PI3K in response to IGF-I 
stimulation 
(Krebs et al., 2002) 
Associate with phosphorylated EGFR; contains nucleus-
connection sequence for protein transportation  
(Matuoka et al., 1997) 
Negatively regulate thymic stromal lymphopoietin (TSLP) (Knisz et al., 2009) 
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1.4.3.8.1 In vivo role of SOCS-7 
A SOCS-7 deficient mouse model, using C57BL/6 mice, was established to examine 
the regulatory role of SOCS-7 in cytokine and growth factor signalling. No 
abnormalities in blood glucose and serum insulin levels were observed between 
SOCS-7 deficient mice and wild-type littermates when they were born, however, 
mild retardation and reduced body weight and organ size was shown in SOCS-7 
deficient mice. Thus, it was proposed that other SOCS family members, such as 
SOCS-6, may compensate for SOCS-7 function due to their structural similarity and 
the resemblance of in phenotypes of their deficient mouse models (Krebs et al., 
2004). However, fatal hydrocephalus developed in half of the SOCS-7 deficient 
mice between 3-15 weeks of age. This phenotype was suggested to be related to 
the disorganisation of subcommissural organ, which is the only specific 
abnormality detected in the brain of all SOCS-7 deficient mice. Additionally, in 
agreement with the SOCS-7 deficient mouse phenotype, the expression profile of 
SOCS-7 gene, prominently expressed in brain, also  indicated its important 
functional role in brain tissue (Krebs et al., 2004). Interestingly, mixed 
129S6xC57BL genetic background SOCS-7-/- mice did not show abnormalities in 
length, weight, and body composition compared to wild-type littermates within 6 
month of age. This indicated that the genectic background plays an important role 
in the establishment of SOCS-7 deficient mouse models (Banks et al., 2005). 
Another study on the mixed 129S6xC57BL genetic background SOCS-7-/- mice 
showed that approximately half of such phenotypes exhibited severe cutaneous 
inflammation, showing degranulated mast cells and elevated inflammatory 
infiltrate by 16 months of age. In addition, the significantly increased IgG1 and the 
elevated trend of IgE in such mixed 129S6xC57BL genetic background SOCS-7-/- 
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mice resembled the phenotype of the thymic stromal lymphopoietin (TSLP) 
overexpression mouse moudel (Knisz et al., 2009). 
 
1.4.3.8.2 SOCS-7 and wound healing 
Study using a SOCS-7 deficient mouse model demonstrated severe cutaneous 
inflammation phenotype and elevated production of pro-inflammatory cytokines, 
such as IL-6, IL-13 and TNF- by mast cells (Knisz et al., 2009). Therefore, SOCS-7 
may potentially negatively regulate the inflammatory phase of wound healing. 
An early study demonstrated that SOCS-7 is able to bind to activated EGFR 
via SH2 domain, therefore, it may exert similar function to SOCS-2, -4 and -5 to 
negatively regulate EGF-like signalling during the wound healing process (Matuoka 
et al., 1997). 
 
1.4.3.9 A summary of SOCS proteins and key molecules in wound healing 
Previous sections have highlighted the involvment of SOCS family members in 
wound healing. However, to date, studies focusing deeper roles of SOCS proteins 
in wound healing are limited. It is known that there are many cytokines and 
growth factors which are mediated by SOCS proteins and these themselves have 
key roles in the wound healing process (Table 1-13). Further investigation of the 
regulatory roles of SOCS on such cytokines/growth factors and their receptors 
may provide novel routes for further establishment of SOCS in wound healing and 
their potential therapeutic applications. 
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Table 1-13: SOCS and essential cytokines/growth factors and receptors involved in wound healing (Feng et al., 2016) 
Cytokine/
growth 
factor/ 
receptor 
Target components in 
wound healing  
Functions in wound healing 
SOCS 
member 
induced by 
cytokine/ 
growth 
factor 
SOCS member 
known 
tonegatively/positive
ly regulates 
downstream 
signalling 
Downstream 
pathway/molecule by 
which cytokine/receptor 
are negatively/positively 
regulated by SOCS 
IL-1 
Endothelial cells, 
macrophages, 
leukocytes, 
keratinocytes, 
fibroblasts 
Inflammation, angiogenesis, re-epithelialisation, 
tissue remodelling, induces keratinocyte, 
neutrophil and fibroblast chemotaxis, induce 
neutrophil activation 
SOCS-2 
SOCS-3/negative  
SOCS-3 
IL-2 Fibroblast 
Increase fibroblast infiltration and enhance 
fibroblast metabolism 
CIS CIS/negative IL-2R via STAT-5 
SOCS-1 SOCS-1/negative  
SOCS-2 SOCS-2/positive 
Through association with 
SOCS-3 and degradation 
SOCS-3 SOCS-3/negative 
Association with JAK-1 
and IL-2R/ Binding to 
Calcineurin 
IL-4 Macrophages, 
fibroblasts 
Enhance collagen synthesis, induces fibroblast 
proliferation 
SOCS-1 
SOCS-1/negative 
Inhibition of activated 
JAK-1 and STAT-6 SOCS-2 
IL-4R SOCS-5 SOCS-5/negative Inhibition of STAT-6 
IL-6 
Endothelial cells, 
macrophages, 
keratinocytes, 
Inflammation, angiogenesis, re-epithelialisation, 
collagen 
deposition, tissue remodelling, induce fibroblast 
CIS 
SOCS-3/negative 
 SOCS-1 
SOCS-3 SOCS-5/negative 
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leukocytes, fibroblasts proliferation  SOCS-5 
IL-10 Macrophages 
Inhibits macrophage activation and infiltration, 
inhibits TNF-, IL-1 and IL-6 expression 
CIS 
  
SOCS-3 
IFN- 
Macrophages, 
keratinocytes 
Induces collagenase activity, preventing collagen 
synthesis and crosslinking 
CIS SOCS-1/negative 
 
 
SOCS-1 
SOCS-2 
SOCS-3/negative 
SOCS-3 
TNF-  
Regulates collagen synthesis and degradation, 
increases vascular permeability and homeostasis, 
provides metabolic substrates 
CIS 
SOCS-1/negative  SOCS-1 
SOCS-3 
EGF 
Keratinocytes, 
fibroblast 
Re-epithelialisation, increases fibroblast 
collagenase secretion, inhibits fetal wound 
contraction 
CIS 
SOCS-2/negative 
Association with 
activated EGFR 
SOCS-2 
SOCS-3 
SOCS-4 
SOCS-4/negative 
Competing for docking 
site with STAT-3 SOCS-5 
EGFR 
SOCS-4 SOCS-4/negative 
Association  with 
activated EGFR and 
degradation 
SOCS-5 SOCS-5/negative 
Association with 
activated EGFR and 
degradation 
SOCS-7 SOCS-7/negative 
Association and 
degradation 
PDGF 
Leukocytes, 
macrophages, 
Inflammation, re-epithelialisation, collagen 
deposition, tissue remodelling, recruits fibroblasts 
SOCS-3   
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fibroblasts and macrophages, induces dollagen synthesis 
HGF 
Endothelial cells, 
keratinocytes 
Suppression of inflammation, granulation tissue 
formation, angiogenesis, re-epithelialisation 
SOCS-1 SOCS-1/negative Inhibition of STAT-3 
activation SOCS-3 SOCS-3/negative 
TGF- 
Fibroblasts, 
keratinocytes, 
macrophages, 
leukocytes, 
endothelial cells, ECM 
Inflammation, angiogenesis, granulation tissue 
formation, collagen synthesis, tissue remodelling, 
leukocyte chemotactic function 
SOCS-3 SOCS-3/negative  
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1.5 Aims of the thesis 
Studies have  emerged on the investigation of SOCS protein in diverse pathologies, 
especially in cancer related disease, since the discovery of such proteins in 1997 
and it has been recognised that SOCS are a cytokine inducible negative feedback 
inhibitor to cytokine and growth factor signalling. In addition, many downstream 
molecules have been discovered to be modulated by SOCS and the mechanisms of 
SOCS regulating certain cytokine and growth factor signalling are under 
investigation for further verification. 
However, there are few studies focusing on the impact of SOCS on wound 
healing, and the role of SOCS in the wound healing process remains unclear. Our 
hypothesis are 1) SOCS may hold the potential to predict healing results and; 2) 
may potentially play regulatory roles in functions of key cell types involved in 
wound healing process. 
The aim of the thesis is therefore to investigate the importance of the 
SOCS family in the wound healing process.  
Specific aims of the thesis are  
i. to investigate and define the expression profile of SOCS members in 
clinical chronic wound samples to explore their potential to differentiate 
between those chronic wounds that show healing potential and those 
which do not. Two chronic wound cohorts were collected and grouped 
based on the same criteira; 
ii. to identify the cellular impact of SOCS-3 and SOCS-4, which showed a 
significant difference in gene expression between two chronic wound 
subgroups, in both keratinocyte and endothelial in vitro cell models;  
iii. to investigate the potential role of SOCS-3 and SOCS-4 in the key 
wound healing cellular function; 
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iv. to explore potential pathway(s) that connect SOCS-3 and SOCS-4 with 
keratinocyte and endothelial cell functions that are involved in the wound 
healing process. 
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Chapter II 
Methods and materials
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2.1 Cells 
Two cell lines were used for in vitro model generation and functional assay 
investigation in this study (Table 2-1). The immmortalised human keratinocyte cell 
line (HaCaT) (Boukamp et al., 1988) was purchased from the German Cancer 
Research Centre (Heidelberg, Germany). The human HECV endothelial cell line 
was purchased from Interlab Cell Line Collection (Genova, Italy).  
HaCaT, a spontaneously transformed human epithelial cell line, is the first 
permanent epithelial cell line whose DNA fingerprint pattern is unaffected by 
long-term cultivation and this cell line exhibits normal differentiation despite the 
unlimited growth potential (Boukamp et al., 1988). In addition, investigation on 
wound healing has shown HaCaT as an competent in vitro cell model for 
transfection study (Goren et al., 2006a). HECV is a human vascular endothelial cell 
line orginated from human umbilical cord, and this cell line has been utilised as in 
vitro models for the investigations on endothelial cell function in both cancer and 
wound healing (Tan et al., 2015, Liu et al., 2013). Hence, in order to evaluate the 
potential regulatory role of SOCS-3 and SOCS-4 in wound healing, keratinocyte 
(HaCaT) and endothelial cell (HECV) were chosen for the further in vitro cell 
function study. 
Both HaCaT and HECV cell lines were routinely cultured in DMEM/Ham’s 
F12 with L-Glutamine medium (Sigma-Aldrich, Inc., Dorset, UK), supplemented 
with antibiotic antimycotic solution (Sigma-Aldrich, Inc. Dorset, UK), and 10% fetal 
calf serum (Sigma-Aldrich, Inc., Dorset, UK), and incubated at 37.0°C, 5% CO2 and 
95% humidity. Another 10 cell lines were used for SOCS-3 expression profile 
screening (Table 2-2). 
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Table 2-1: Cell lines used in in vitro study 
Cell line Organism Morphology Ethnicity Gender Sources and features Growth Conditions 
HaCaT 
Homo 
sapiens 
Epithelial Caucasian Male 
In vitro spontaneously transformed 
keratinocytes from histologically normal skin 
Grown in DMEM supplemented with 10% 
FCS and antibiotics at 37ᵒC in 5% CO2 
HECV 
Homo 
sapiens 
Endothelial Caucasian Female Umbilical cord 
Grown in DMEM supplemented with 10% 
FCS and antibiotics at 37ᵒC in 5% CO2 
Table 2-2: Cells used for SOCS-3 expression profile screening 
Tissue type Cell line name Origin Tissue type Cell morphology Other information 
Liver PLC-PRF-5  Hepatoma Epithelial 
Hepatitis virus B surface 
antigen positive expression 
Lung 
SKMES 65 year-old Caucasian male Squamous cell carcinoma Epithelial 
Derived from Metastatic 
Site: pleural effusion 
A549 58 year-old Caucasian male Carcinoma Epithelial  
MRC-5 
14-weeks gestation 
Caucasian male 
Normal lung fibroblast cell line Fibroblast Foetal 
Colon CaCo-2  Adenocarcinoma Epithelial  
Prostate 
CA-HPV-10 63 year-old Caucasian male 
Non-tumourigenic cell line derived from 
prostatic adenocarcinoma, transformed 
through HPV18 transfection 
Epithelial HPV-18 transformed 
PC-3 62 year-old Caucasian male Grade IV adenocarcinoma Epithelial  
PZ-HPV-7 70 year-old Caucasian male 
Non-tumourigenic epithelial cell line 
transformed through HPV18 transfection 
Epithelial HPV-18 transformed 
DU-145 69 year-old Caucasian male Carcinoma Epithelial  
hFOB 1.19 Fetus “Normal” foetal Osteoblast 
SV40 large T antigen 
transfected 
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2.2 Primers 
Specific primers were designed using Beacon designer software (PREMIER Biosoft 
International, Palo Alto CA, USA) and synthesised by Sigma (Dorest, UK). Details of 
the primers are oulined in Table 2-3. 
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Table 2-3: Primers designed and used in this study 
Function Target gene/sequence Name of Primer Sequence of Primer 
Screening of clinical 
samples and cell lines 
by q-PCR and 
conventional PCR 
SOCS-1 
SOCS-1 F1 5’-GATGGTAGCACACAACCAG 
SOCS-1 ZR1 5’-ACTGAACCTGACCGTACAGAGGAAGAGGAGGAAGGTT 
SOCS-2 
SOCS-2 F8 5’-GTCAGACAGGATGGTACTGG 
SOCS-2 R8 5’-CTGGAATTTATATTCTTCCAA 
SOCS2 F1 5’-GGATGGTACTGGGGAAGTAT 
SOCS2 ZR1 5’-ACTGAACCTGACCGTACATGGGAGCTATCTCTAATCAA 
SOCS-3 
SOCS-3 F8 5’-AAGACCTTCAGCTCCAAGA 
SOCS-3 R8 5’-GTCTTCCGACAGAGATGCT 
SOCS3 F2 5’-TCAAGACCTTCAGCTCCA 
SOCS3 ZR2 5’-ACTGAACCTGACCGTACAGTCACTGCGCTCCAGTAG 
SOCS-4 
SOCS-4 F8 5’-CAGCTGTTCATCCATTGAG 
SOCS-4 R8 5’-CCATTTGGGTTTGTTTCTT 
SOCS-4 F1 5’-GGCAGTGTTTTCCAATAAAG 
SOCS-4 ZR1 5’-ACTGAACCTGACCGTACAAGGTGGGAAAGGACACTTAT 
SOCS-5 
SOCS-5 F1 5’-AGTCAAAGCCTCTCTTTTCC 
SOCS-5 ZR1 5’-ACTGAACCTGACCGTACACATTTTGGGCTAAATCTGA 
SOCS-6 
SOCS-6 F1 5’-CCTTACAGAGGAGCTGAAAA 
SOCS-6 ZR1 5’-ACTGAACCTGACCGTACACGAAAAGAAAAGAACCATC 
SOCS-7 
SOCS-7 F9 5’-AGACTAACAGCTGCTCGGAA 
SOCS-7 R9 5’-CCCACTGATATCATCTAGGAGGC 
SOCS7 F1 5’-CAGGCCCTGAATTACCTC 
SOCS7 Zr1 5’-ACTGAACCTGACCGTACAGAGGTTGCTGCTGCTGCT 
Cytokeratin-19 (CK-19) CK-19 F8 5’-AGCCACTACTACACGACCAT 
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CK-19 ZR8 5’-ACTGAACCTGACCGTACATCGATCTGCAGGACAATC 
Ribozyme synthesis 
SOCS-4 
SOCS-4 rib F1 5’-CTGCAGTAAAGGCTAAATCTGATCGAGGTGGCTGATGAGTCCGTGAGGA 
SOCS-4 rib R1 5’-ACTAGTGAACTCATGTTAGATTAGTGTCCTTTTTCGTCCTCACGGACT 
SOCS-4 rib F2 5’-CTGCAGTTCACTGATATGAATTTTCCTTTTAGACGCTGATGAGTCCGTGAGGA 
SOCS-4 rib R2 5’-ACTAGTCGGCACTCTTCAGGGCTTTTCGTCCTCACGGACT 
Knockdown 
verification by q-PCR 
SOCS-4 F2 5’-GAGACTCAGCACAGGAGGAC 
SOCS-4 ZR2 5’-ACTGAACCTGACCGTACAGTCAGTGCATCAAAGCTAA 
Overexpression 
verification by q-PCR 
SOCS-3 
SOCS-3 F2 5’-TCAAGACCTTCAGCTCCA 
SOCS-3 ZR2 5’-ACTGAACCTGACCGTACAGTCACTGCGCTCCAGTAG 
SOCS-3 coding 
sequence 
amplification 
SOCS-3 coding sequence 
SOCS-3 exp F1 5’-ATGGTCACCCACAGCAAGTTTCCCGC 
SOCS-3 exp F2 5’-ATGGTCACCCACAGCAAGTTTCCC 
SOCS-3 exp F3 5’-ATGGTCACCCACAGCAAGTTTC 
SOCS-3 exp F4 5’-ATGGTCACCCACAGCAAGTT 
SOCS-3 exp F5 5’-ATGGTCACCCACAGCAA 
SOCS-3 exp R 5’-TTAAAGCGGGGCATC 
Screening  on cell lines 
by PCR Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) 
GAPDH F8 5’-GGCTGCTTTTAACTCTGGTA 
GAPDH R8 5’-GACTGTGGTCATGAGTCCTT 
Knockdown and 
overexpression 
verification by q-PCR 
GAPDH F2 5’-CTGAGTACGTCGTGGAGTC 
GAPDH ZR2 5’-ACTGAACCTGACCGTACACAGAGATGATGACCCTTTTG 
-Actin 
-Actin F10 5’-CATTAAGGAGAAGCTGTGCT 
-Actin ZR10 5’-ACTGAACCTGACCGTACAGCTCGTAGCTCTTCTCCAG 
Transgene/Coding 
sequence insertion 
and orientation check 
T7F promoter T7F 5’-TAATACGACTCACTATAGGG 
Ribozyme common sequence 
RbBMR 5’-TTCGTCCTCACGGACTCATCAG 
RbToPF 5’-CTGATGAGTCCGTGAGGACGAA 
BGHR site BGHR 5’-TAGAAGGCACAGTCGAGG 
 Z Sequence ‘ACTGAACCTGACCGTACA’ is highlighted in green colour and italic font
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2.3 Antibodies 
Full details of the antibodies used in this study are outlined in Table 2-4 and Table 
2-5 as follows: 
Table 2-4: Antibodies used for IHC analysis on chronic wound biopsies 
Antibody name 
Host 
species 
Antibody 
concentration 
Supplier and catalogue number 
SOCS-1 (H93) Rabbit 
2μg/ml 
Santa cruz biotechnology, SC-9021 
SOCS-2 (H74) Rabbit Santa cruz biotechnology, SC-9022 
SOCS-3 (H103) Rabbit Santa cruz biotechnology, SC-9023 
SOCS-4 (H-20) Goat 
Santa cruz biotechnology,  
SC-68827 
SOCS-5 (31-L) Mouse 
Santa cruz biotechnology,  
SC-100858 
SOCS-6 (H-251) Rabbit Santa cruz biotechnology, SC-5608 
SOCS-7 (C-19) Goat Santa cruz biotechnology, SC-8291 
SOCS-7 (E-8) Mouse 
Santa cruz biotechnology,  
SC-137241 
Table 2-5: Antibodies used for verification of SOCS-4 knockdown and SOCS-3 
expression  
Antibody 
name 
Host 
species 
Molecular 
Weight 
(kDa) 
Antibody 
concentration 
Supplier and catalogue 
number 
SOCS-4 Mouse 51 0.1μg/ml R&D Systems MAB5628 
SOCS-3 Rabbit 30 1:1,000 Abcam, Ab53984 
GAPDH 
(6C5) 
Mouse 37 1:4,000 
Santa cruz 
biotechnology, SC-32233 
GAPDH  
(FL-335) 
Rabbit 37 1:4,000 
Santa cruz 
biotechnology, SC-25778 
Actin (I-19) Goat 43 1:4,000 
Santa cruz 
biotechnology, SC-1616 
Anti-Mouse 
IgG 
Rabbit  1:100,000 Sigma-aldrich, A9044 
Anti-Rabbit 
IgG 
Goat  1:100,000 Sigma-aldrich, A0545 
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2.4 General reagents and solutions 
2.4.1 Reagents and chemicals 
2.4.1.1 Solutions and reagent for cell culture 
Ethylene Diaminetetraacetic Acid (EDTA) trypsin 
10X Tryspin-EDTA Solution (Product number T4174) was purchased from Sigma-
Aldrich, Inc. (Dorset, UK) and was diluted with distilled water to 1X. This solution 
was then aliquoted into 25ml aliquots and strored at -20°C until further use. 
 
Phosphate buffered saline (PBS) 
10X Phosphate buffered saline (P5943) was purchased from Sigma-Aldrich, Inc. 
(Dorset, UK) and was diluted with distilled water to 1X. This solution was then 
aliquoted into 25ml aliquots and strored at room temperature until further use.  
 
Antibiotics 
100X Antibiotic Antimycotic Solution (A5955) was purchased from Sigma-Aldrich, 
Inc. (Dorset, UK) and was aliquoted into 5ml aliquots and stored at -20°C until 
further use. Each of the aliquots was added into a 500ml bottle of medium to 
obtain a final 1X concentration.  
Fetal Calf Serum (FCS)  
Fetal Calf Serum was purchased from Sigma-Aldrich, Inc. (Dorset, UK). Such stocks 
were divided into 25ml aliquots and stored at -20°C for further use. 
 
2.4.1.2 Solutions and reagent for molecular biology 
Tris-Boric-Acid-EDTA (TBE) 
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TBE buffer 10X concentrate (T4415) was purchased from Sigma-Aldrich, Inc. 
(Dorset, UK), diluted with distilled water into 1X stock and stored at room 
temperature for further use. 
 
Diethyl Pyrocarbonate (DEPC) Water 
250ml of DEPC (Sigma-Aldrich, Inc., Dorest, UK) was added to 4.75L of distilled 
water. This solution was subsequently autoclaved, and stored at room 
temperature for further use. 
 
Loading buffer (used for DNA electrophoresis) 
25mg of bromophenol blue (Sigma-Aldrich, Inc., Dorset, UK) and 4g sucrose 
(Fisons Scientific Equipment, Loughborough, UK) were dissolved in 10ml of 
distilled water and stored at 4°C. 
 
2.4.1.3 Solutions and reagent for cloning 
LB Broth 
8g LB Broth low salt granulated powder (Melford Laboratories Ltd., Suffolk, UK) 
was dissolved in 400ml distilled water, and the pH value was adjusted to 7.0 
before being autoclaved. This solution was then stored at room temperature for 
further use. 
 
LB Agar 
LB agar was made by dissolving 10g of LB Broth low salt granulated powder 
(Melford Laboratories Ltd., Suffolk, UK) and 7.5g of agar (A1296) (Sigma-Aldrich, 
Inc., Dorset, UK) in 500ml of distilled water before adjusting the pH value to 7.0 
followed by autoclaving. This solution was then stored at room temperature in 
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the form of a solid gel for further use. Upon usage, the gel was heated by 
microwave until completely melted. 
 
Ampicillin 
Ampicillin was prepared by dissolving 1g of ampicillin (Melford Laboratories Ltd., 
Suffolk, UK) in 10ml of sterile PBS to give a concentration of 100mg/ml.  
 
2.4.1.4 Solutions and reagent for western blotting 
Lysis Buffer 
8.76g of NaCl (150mM), 6.05g of Tris (50mM), 200mg Sodium azaide (0.02%, w/v) 
and 5g Sodium deoxycholate (0.5%, w/v) was dissovled in 1L distilled water 
followed by the addition of 15ml Triton X-100 (1.5%, v/v) to make a 1L stock of 
protein lysis buffer and stored at 4°C. 50ml of the lysis buffer was then used to 
dissolve one of the cOmpleteTM, EDTA-free protease inhibitor cocktail tablet 
(Roche Diagnostics, Mannheim, Germany) followed by division to 1ml aliquots 
before being stored at -20°C for further use. If required, 100mM of Na3VO4 was 
added into the pre-made lysis buffer at the working concentration of 1mM upon 
the usage of lysis buffer. 
 
10% (w/v) Ammonium Persulphate (APS) 
1g Ammonium Persulphate (Melford Laboratories Ltd., Suffolk, UK) was dissovled 
in 10ml distilled water and stored at 4°C for further use. 
 
10% (w/v) Sodium Dodecyl Sulphate (SDS) 
50g Sodium Dodecyl Sulphate (Melford Laboratories Ltd., Suffolk, UK) was 
dissolved in 500ml distilled water and stored at room temperature for further use. 
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Tris Buffered Saline (TBS) 
1L of Tris Buffered Saline 10X soluiton (T5912) (Sigma-Aldrich, Inc., Dorset, UK) 
was diluted in 9L of distilled water and stored at room temperature for further 
use. 
 
Running buffer (for SDS-PAGE) 
1L of Tris-Glycine-SDS Buffer 10X concentrate (T7777) (Sigma-Aldrich, Inc., Dorset, 
UK) was diluted in 9L of distilled water and stored at room temperature for 
further use. 
 
Transfer buffer 
1L of Tris-Glycine Buffer 10X concentrate (T4904) (Sigma-Aldrich, Inc., Dorset, UK) 
was diluted in 9L of distilled water containing 2L methanol (Fisher Scientific UK, 
Loughborough, UK) and stored at room temperature for further use. 
 
Ponceau S stain 
Ponceau S staining solution was made by dissolving 0.1% Ponceau S (P3504) 
(Sigma-Aldrich, Inc., Dorset, UK) in 5% acetic acid (w/v), and was subsequently 
stored at room temperature for further use. 
 
2.4.1.5 Solutions and reagent for microarray protein lysis 
100mM Tris buffer was made by dissolving 6.0g of Tris powder in 1.5L distilled 
water. One of the cOmpleteTM, EDTA-free protease inhibitor cocktail tablet (Roche 
Diagnostics, Mannheim, Germany), 5ml of 2-mercaptoethonal (10%, v/v), 
nonident P-40 (1%, v/v) and 5ml of 500mM NaFl (50mM) were added to 50ml of 
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the Tris buffer, mixed and divided into 1ml aliquots before being stored at -20°C 
for further use. 
 
2.4.1.6 Solutions and reagents for immunohistochemical staining 
Avidin-biotin complex (ABC) 
The ABC complex was prepared using a VECTASTAIN® ABC Kit (Vector Laboratories, 
Inc., CA, USA). 4 drops of each reagent A and reagent B were added into 20ml of 
wash buffer and mixed thoroughly, and such combined solution was left for at 
least 30 minutes at 4°C before use.   
 
2.5 Cell culture, maintenance, storage and revival 
2.5.1 Preparation of growth medium and cell maintenance 
Cell culture medium (normal medium) was made by adding 10% heat inactivated 
FCS (inactivate the complement protein and kill mycoplasma) (Sigma-Aldrich, Inc., 
Dorset, UK) and antibiotics in Dulbecco’s Modified Eagle’s Medium (DMEM) 
Nutrient Mixture  F-12 Ham with 15mM HEPES, NaHCO3, pyridoxine and L-
glutamine  (Sigma-Aldrich, Inc., Dorset, UK). This medium was used for routine cell 
culture. 
Normal medium containing 5μg/ml blasticidin (Melford Laboratories Ltd., Suffolk, 
UK) (selection medium) were used to select the cell lines transfected with the 
pEF6/His plasmid or transgene incorporated plasmid vectors for 8-14 days. 
Subsequently, the transfectants were then cultured in normal medium 
supplemented with and 0.5μg/ml blasticidin (maintenance medium) for cell 
maintenance. 
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Cell lines were cultured in 25cm2 (T25) and 75cm2 (T75) culture flasks (Greiner 
Bio-One Ltd., Gloucestershire, UK), and the flasks were loosely capped and 
incubated at 37°C, 5% CO2 and 95% humidity. 
 
2.5.2 Trypsinisation (detachment) of adherent cells and cell counting 
When cells reached 80-90% confluency, they are growing exponentially (near the 
end of the log phase) and maintain healthy status. This confluency also improves 
overall cell viability. Therefore once cells reached 80-90% confluency, the medium 
was aspirated by a glass aspirator and rinsed and washed with sterile PBS to 
remove excess serum which could influence the efficiency of trypsin. Appropriate 
amounts of trypsin (1ml for T25 flask, 2ml for T75 flask) was pipetted into the 
flask and incubated at 37°C, 5% CO2 and 95% humidity for approximately 15 
minutes until cell detachment could be visually confirmed under the microscope.  
Once the cells were detached, equal amount of medium was pipetted into 
the flask to neutralise the excess trypsin, and the cell suspension was then 
transferred into a sterile 30ml univerisal centrifuge container (Greiner Bio-One 
Ltd,. Gloucestershire, UK) followed by being centrifuged at 1,700rpm for 5 
minutes to obtain a cell pellet. 
The supernatant was aspirated by a glass aspirator, and the cell pellet was 
re-suspended with an appropriate amount of medium based on the pellet size. 
Cell number was then counted and calculated with a Neubauer haemocytometer 
counting chamber (Mod-Fuchs Rosenthal, Hawksley, UK) using an Olympus CKX31 
microscope at a objective magnification of X10 (Olympus, Tokyo, Japan). 
  
106 
 
2.5.3 Storage and revival of cells 
Cells were detached, centrifuged to form a pellet and re-suspended in an 
appropriate volume, as described above. Cell suspensions were then divided into 
900μl aliquots and pipetted into pre-labelled 1ml CRYO.STM tube (Greiner Bio-One 
Ltd,. Gloucestershire, UK) before the addition of 100μl of Dimethylsulphoxide 
(DMSO) (Sigma-Aldrich, Inc., Dorset, UK) followed by screwing and tightening the 
cap of the CRYO.STM tube. These tubes were then wrapped in protective tissue 
paper and stored at -80°C or subsequently transferred to liquid nitrogen stores for 
long term storage. 
In order to revive the cells, the pre-stored CRYO.STM tube was removed 
from the -80°C freezer or liquid nitrogen stocks and thawed rapidly before being 
transferred into a universal container containing 4ml pre-warmed medium. Such 
universal containers were then centrifuged at 1700rpm for 5 minutes to obtain a 
cell pellet. The supernatant was aspirated by a glass aspirator to remove the 
medium containing DMSO, and the cell pellet was re-suspended with 5ml growth 
medium before being transferred into a pre-labelled fresh flask for further 
incubation. 
  
2.6 Tissue collection and processing 
Two wound cohorts were used for this study. For transcript analysis, the 
cohort used was came from a prospective study to investigate potential 
diagnostic/prognostic indicators of chronic wound healing in venous leg ulcer 
patients (Cohort 1) (Ref CT0101). Tissues were collected from patients who 
entered this study from 1990 to 1995, attending the University Hospital of Wales 
wound healing clinic. For the IHC analysis, tissues used were from another study 
that aimed to develop a diagnostic platform and novel therapies for non-healing 
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chronic wounds based on impaired keratinocyte re-epithelialisation (Cohort 2) 
(Ref 09/wse02/51). Tissues for this cohort were also collected from patients who 
attended the same wound clinics between 2010 and 2013 with chronic venous leg 
ulcer wounds. For both studies, ethical approval was granted by the Local 
Research Ethics Committee and written informed patient consent was obtained, 
before wound edge tissues were collected from the chronic venous leg ulcers.  
Venous disease was diagnosed by Duplex ultrasonography, and all wounds 
had been present for a minimum of 3 months. Other inclusion criteria included: 
no evidence of other diagnosis and no evidence of infection, as judged by the 
leading clinical physician. Where required, swabs were taken to confirm this.  
Following the application of a local anaesthetic (1% Lidocaine) and using 
an aseptic technique, a 6mm punch biopsy was taken at the wound margin, so 
that the resulting biopsy incorporated both epidermis and dermis at the wound 
edge and the adjacent distal tissue. Sample biopsies were frozen immediately to 
prevent morphological distortions and damage. The tissue was orientated onto a 
cork board by rotating the biopsy 90o in order to obtain a full section of both 
epidermis and dermis at the wound edge and distal to the wound edge, and then 
OCT medium (Optimal Cutting Temperature compound) was applied. The sample 
biopsy was then snap frozen in iso-pentane that had been pre-cooled and floated 
on liquid nitrogen, in order to prevent ice crystal formation that would damage 
the architecture of the tissue. The biopsies were then stored at -80°C before being 
placed for long term storage in liquid nitrogen prior to processing. Samples were 
sectioned on a cryostat (Leica Microsystems Ltd., Milton Keynes, UK) at 7µm 
thickness for immunohistochemical staining, and multiple sections cut at 20µm 
thickness were processed for RNA extraction, reverse transcription and transcript 
expression analysis using q-PCR. 
108 
 
The patients’ wounds were subsequently treated for 12 weeks as per best 
medical treatment. Specifically, this consisted of regular wound care with 
appropriate dressings and compression. The compression was produced with 3 
layers of Tubigrip™ bandages (Mölnlycke Health Care, Dunstable, UK) at an 
appropriate size to deliver 40 mmHg of pressure.  
At the end of the 12 week treatment period, the wounds were assessed 
and remeasured. The biopsies from patients whose wounds had reduced in size 
over this period or completely re-epithelialised were termed as "healing/healed" 
chronic wounds (Cohort 1 n = 20, Cohort 2 n=45) and those which remained static 
or grew in size were termed as "non-healing" chronic wounds (Cohort 1 n = 51, 
Cohort 2 n=45)). For the IHC part of the study, ten biopsies from each group 
(healing and non-healing) were chosen from Cohort 2 based on the quality of 
tissues as determined by H&E staining, and also the completeness of clinical 
information. The cohort has been described previously (Bosanquet et al., 2012, 
Jones et al., 2016), (Aravindan et al., 2017 in press). 
 
2.7 Total RNA isolation 
RNA was isolated using TRI-reagent (Sigma-Aldrich, Inc., Dorset, UK) under the 
manufacturer's instructions both for the multiple sections from the patient 
biopsies and the cells. 
 
Tissue lysate:  
Multiple sections from the same patient sample biopsy were combined 
and homogenised in 1ml of ice-cold TRI-reagent using a handheld homogeniser 
(Cole-Parmer, London, UK) with the lysate was then transferred into a 1.5ml 
microfuge tubemicrofuge tube. 
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Cell lysate: 
Once cells reached  80-90% confluency, the medium was removed by 
glass aspirator and 1ml of TRI-reagent (1ml TRI-reagent is sufficent for 80-90% 
confluent cells grown in T25 flask) was added to the cell monolayer. A 28cm 
length Cell Scraper (Greiner Bio-one, Frickenhausen, Germany) was used to 
maximise the harvest of the cell lysate, and the cell lysate was transferred into a 
1.5ml microfuge tube. Once lysate was obtained from cells or tissues the following 
procedure was undertaken: 
 
The homogenate was kept at room temperature (20-22°C) for 5 minutes 
before the addition of 100μl of 1-bromo-3-chloropane (Sigma-Aldrich, Inc., Dorset, 
UK) and subjections to vigorous shaking for 15 seconds. The mixture of the lysate 
and 1-bromo-3-chloropane was kept for 5-10 minutes at room temperature until 
the formation of two separate layers. Following centrifugation at 4°C and 12,000g 
for 15 minutes, the upper aqueous phase (clear transparent layer) containing RNA 
was carefully transferred into a fresh 1.5ml microfuge tube. An equal volume of 
isopropanol to the extracted upper aqueous phase was added into the microfuge 
tube followed by being shaked vigorously for 10 seconds to mix thoroughly. The 
microfuge tube was then centrifuged at  4°C and 12,000g for 10 minutes to obtain 
the RNA pellet which was visible in the bottom of the microfuge tube. The 
supernatum was discarded and the RNA pellet was washed twice with 75% 
ethanol DEPC water (prepared by mixing absolute ethanol with DEPC water in 1:3 
ratio). The wash stage consisted of adding 1ml of 75% ethanol DEPC water, 
votexing and subsequent centrifugtion at 7,500g for 5 minutes. After the final 
wash, as much ethonal as possible was removed through pipette aspiration and 
the microfuge tube was put into a Techne, Hybrdiser HB-1D drying oven at 50°C to 
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briefly dry out the remaining liquid. The RNA pellet was then dissolved in 20-100μl 
of DEPC water depending on the pellet size followed by being stored at -80°C for 
further use. DEPC water was used to minimise the effects of RNases by the 
inhibition of histidine active sites. 
 
2.8 Reverse transcription polymerase chain reaction (RT-PCR)  
The isolated RNA sample was quantified using a NanoPhotometerTM (IMPLEN; 
Geneflow ltd., Lichfield, UK) and standardised before undertaking reverse 
transcription using the GoScriptTM Reverse Transcription System kit (Promega 
Corporation, Madison, WI, USA) to generate cDNA. The reverse transcript 
protocol is outlined as follows: 
A sufficient volume of the quantified RNA sample containing 500ng RNA 
was mixed with 1µl of Oligo(dT)15  and was topped up to 5µl by DEPC water in a 
thin-walled 200µl tube. Such RNA and Oligo(dT)15 solution was heated in a 2720 
Thermal Cycler (Applied Biosystems, Paisley, UK) at 70ᵒC for 5 minutes followed 
by immediately being placed in ice for 5 minutes. After this initial step, the tube 
was removed from the thermal cycler and added with 15µl of reaction mix 
containing the following: 
 GoScriptTM 5X Reaction Buffer - 4µl 
 MgCl2 – 1.2µl 
 PCR Nucleotide Mix - 1µl 
 Recombinant RNasin Ribonuclease Inhibitor – 0.5µl 
 GoScriptTM Reverse Transcriptase - 1µl 
 Nuclease-Free Water – 7.3µl 
The 20µl reaction mix was centrifuged at 1000rpm for 20 seconds and was placed 
back to the thermal cycler to be heated under the condition outlined as follows: 
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 Step 1: Annealing stage - 25ᵒC for 5 minutes 
 Step 2: Extending stage - 42ᵒC for 60 minutes 
 Step 3: Inactivating reverse transcriptase stage - 70ᵒC for 15 minutes 
The generated cDNA sample was diluted 1 in 4 by PCR water and was stored at -
20ᵒC for further use. 
 
2.9 Polymerase chain reaction (PCR) 
Conventional PCR was carried out using GoTaq Green master mix (Promega, 
Madison, USA) and specific primers were designed using Beacon designer 
software (PREMIER Biosoft International, Palo Alto CA, USA) and synthesised by 
Sigma-Aldrich, Inc. (Dorset, UK). The primer was diluted to a  concentration of 
10pM before being added into the reaction mix. The reaction mix was briefly 
centrifuged and placed in a 2720 Thermal Cycler (Applied Biosystems, Paisley, UK). 
The 16µl reaction mix and the general PCR conditions that were used for cDNA 
amplification are shown as follows: 
PCR Reaction mix: 
 GoTaq Green master mix - 8µl 
 Specific forward primer - 1µl 
 Specific reverse primer - 1µl 
 PCR H2O - 5µl 
 Prepared cDNA sample - 1µl 
General PCR conditions:  
 Step 1: Initial denaturing period - 94ᵒC for 5 minutes 
 Step 2: Denaturing stage - 94ᵒC for 30 seconds 
 Step 3: Annealing stage - 54ᵒC for 40 seconds 
 Step 4: Extension stage - 72ᵒC for 1 minutes 
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 Step 5: Additional extension stage - 72ᵒC for 10 minutes 
 Hold at 4°C 
Step 2 - 4 were repeated for 30-36 cycles depending on differernt experiments. 
The predicted size of the PCR product was determined by Primer Blast, and the 
negative control reaction mix in all cases consisted of PCR water instead of cDNA 
samples. 
 
2.10 Agarose gel electrophoresis 
The cDNA samples amplified from the 2720 Thermal Cycler (Applied Biosystems, 
Paisley, UK) were separated by gel electrophoresis on a 0.8% or 2% agarose gel, 
and the gel concentration was determined by the predicted size of cDNA samples. 
The agarose gel was made by adding an appropriate amount of agarose (Melford 
Chemicals, Suffolk, UK) into 1X TBE buffer which was diluted from 10X stock 
(Sigma-Aldrich, Inc., Dorset, UK). The mixed buffer was heated thoroughly to fully 
dissolve the powder, forming a clear and transparent agarose solution, and was 
stained with SYBR safe DNA gel stain (Invitrogen, Paisley, UK) at a 1:10,000 
dilution in keeping with the manufacturers guidance. For example, for a typical 
150ml 0.8% gel, 1.2g of agarose was dissolved in 150ml 1X TBE buffer and, once 
cooled, 15µl of SYBR safe added and mixed. Such stained agarose TBE solution 
was poured into the electrophoresis tank assembled with plastic combs (SCIE-
PLAS, Cambridge, UK)(Figure 2-1) which enable the formation of loading wells. 
Once cooled down and polymerised, the agarose gel was submerged in 1X TBE 
buffer, and 4µl of PCR Ranger 100bp DNA Ladder/ Ranger 1000bp DNA Ladder 
(Geneflow, Fradely, Staffordshire, UK) and 8µl of amplified cDNA samples were 
loaded into designated wells followed by being electrophoretically separated at 
110V, 50mA and 50W for a sufficient amount of time (20-50 minutes). A EV243 
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power consort (Topac Inc., Cohasset, MA, USA) was utilised for agarose gel 
electrophoresis. Upon completion of electrophoresis, images were acquired, 
visualised and captured using Syngene gel doc system (Syngene, Cambridge, UK) 
on a blue light trans-illuminator. 
 
 
Figure 2-1: Agarose gel electrophoresis apparatus 
 
2.11 Generation of mutant HaCaT and HECV cell lines 
2.11.1 Discovery and the catalytic mechanism of ribozymes 
In order to achieve SOCS-4 knockdown, hammerhead ribozyme transgenes that 
specifically target GUC or AUC sites of SOCS-4 mRNA and cleave SOCS-4 
transcripts were designed according to the predicted secondary structure of 
SOCS-4 mRNA (Figure 2-2) by Zuker’s RNA mFold software (Zuker, 2003). The 
hammerhead ribozyme was first discovered by Forster and Symons in 1987 as a 
self-cleaving domain in the RNA genome in a variety of plant viroids and virusoids 
(Forster and Symons, 1987). Such hammerhead motifs are able to form short 
syntheic oligonucleotides, acting as multiple turnover catalysts which are capable 
of cleaving RNA targets (Uhlenbeck, 1987, Haseloff and Gerlach, 1988). A general 
univesal secondary structure which is integrated by several invariant nucleotides 
and consists of three helical stems (I, II and III) could be found in all hammerhead 
motifs. Stem II is incorportated intramolecularly in such secondary structure, 
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whereas stem I and III are formed by hybridisation based on the complementary 
sequences of the targeted substrate. Moreover, the best cleavage sites were 
discovered to be AUC, GUC and UUC (Figure 2-3).  
 
 
Figure 2-2: Diagram of the predicted secondary structure of human SOCS-4 
mRNA 
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Figure 2-3: Diagram of hammerhead ribozyme secondary structure 
Hammerhead ribozymes consist of three helices. Stem II, containing highly 
conserved sequences, is flanked by stem I and III that are adjacent to the cleavage 
site and are base-paired to the RNA substrate. Dash line indicates the Watson-
Crick base pairs. 
 
2.11.2 TOPO TA gene cloing and generation of stable transfectants 
The pEF6/V5-His TOPO® TA expression system (Invitrogen, Paisley, UK) provides a 
highly efficient one-step cloning technique which does not require ligase, post-
PCR procedures, or PCR primers containing specific sequences. Such an approch 
allows the direct insertion of Taq polymerase-amplified PCR products into a 
plasmid vector for consititutive expression in mammalian cells after transfection. 
The linearised pEF6/V5-His TOPO® vector in the kit consists of single, 
overhanging 3’ deoxythymidine (T) residues which allows Taq polymerase-
amplified PCR products, containing a single deoxyadenosine (A) at the 3’ ends, to 
ligate efficiently (Figure 2-4). The EF-1 promoter in pEF6/V5-His TOPO® then 
enables the consititutive expression of the PCR product after the transfection of 
the plasmid. 
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Figure 2-4: Diagram of the pEF6/V5-His TOPO® vector feature (from pEF6-His 
TOPO® TA Expression Kit manual) 
 
The PCR products were cloned into pEF6/V5-His TOPO® plasmid, and the total 6µl 
cloning reaction was mixed and stored on ice in advance to the One Shot Chemical 
Transformation (Invitrogen, Paisley, UK). The condition used for TOPO cloning 
reaction was as follows: 
 PCR product - 4µl 
 Salt solution - 1µl 
 TOPO vector - 1µl 
5µl of TOPO cloning reaction was added into each vial of One Shot TOP10 
Chemically Competent Escherichia coli (E. coli) (Invitrogen, Paisley, UK) and mixed 
gently by stirring using the pipette tip. The vial was stored on ice for 5-30 minutes 
(based on the product size) before heat-shocking at 42ᵒC for 30 seconds followed 
by immediately transferring into ice. To each vial, 250µl of room temperature 
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S.O.C medium was added and the tubes shaken at a 45ᵒ angle at 225rpm on a 
horizontal orbital shaker (Bibby Stuart Scientific, UK) at 37ᵒC for 1 hour. 
After the incubation period, the transformed products from each vial 
were spread in different seeding density on a pre-warmed agar petri dish 
containing 100µg/ml ampicillin followed by incubating overnight at 37ᵒC. 
Several colonies from each petri dish were randomly picked and the PCR 
product insertion and orientation of the incorporated PCR porduct was checked 
by PCR using primer combination of T7F vs BGHR and T7F vs specific forward or 
reverse primer respectively. The reaction mix is oultlined as follows: 
 
PCR product insertion primer pair mix (used for overexpression sequences) 
 GoTaq Green master mix - 8µl 
 T7F plasmid specific forward primer - 1µl 
 BGHR plasmid specific reverse primer - 1µl 
 PCR water -6µl 
Correct orientation primer pair mix 
 GoTaq Green master mix - 8µl 
 T7F plasmid specific forward primer - 1µl 
 PCR product specific reverse primer - 1µl 
 PCR water -6µl 
Incorrect orientation primer pair mix 
 GoTaq Green master mix - 8µl 
 T7F plasmid specific forward primer - 1µl 
 PCR product specific forward primer  - 1µl 
 PCR water -6µl 
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For ribozyme transgene insertion and orientation checking, the molecule 
specific forward and reverse primer were replaced in the above mixtures with 
forward (RbToPF) and reverse (RbBMR) sequences to the common region of the 
ribozyme transgene. 
Each colony was inoculated into both reaction mixes using a sterile 
pipette tip, and the reaction mixes were placed in a 2720 Thermal Cycler (Applied 
Biosystems, Paisley, UK). The PCR reaction conditions were used as follows: 94ᵒC 
for 5 minutes, followed by 30 cycles of 94ᵒC for 30 seconds, 55ᵒC for 40 seconds 
and 72ᵒC for 1 minute with a final extension step of 72ᵒC for 10 minutes. Gel 
electrophoresis on a 2% agarose gel stained with SYBR safe DNA gel stain were 
utilised to visualise the conventional PCR reaction products. 
Colonies with correctly orientated PCR product inserts were inoculated 
into universal tubes containing 5ml of selective LB broth (containing 100µg/ml 
ampicillin) followed by being incubated overnight at 37ᵒC whilst being shaken 
with 45ᵒ angle at 225rpm. 
 
2.11.3 Plasmid amplification and extraction 
Plasmid extraction was undertaken using the Sigma GenElute Plasmid MiniPrep 
Kit (Sigma, Dorset, UK) based on the protocol provided. The overnight incubated 
universal tubes containing the chosen colonies were centrifuged at 5,000RCF to 
acquire a bacterial pellet. The supernatant in each tube was discarded and the 
bacterial pellet was re-suspended thoroughly using 200µl Resuspension Solution 
containing RNase A and transferred into a 1.5ml microfuge tube. To the microfuge 
tube was added 200µl of Lysis Solution followed by 8 gentle inversions. This lysis 
stage was conducted within 5 minutes to avoid permanent plasmid denaturation. 
Then, 350µl of Neutralisation Solution was added and the microfuge tube was 
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gently inverted 6 times followed by centrifugation at 12,000g for 10 minutes to 
pellet the cell debris. The clear lysate in the microfuge tube was transferred into a 
Miniprep Binding Column which was placed into a Microcentrifuge Tube. Such 
Miniprep Binding Column was washed with Column Preparation Solution in 
advance to maximise plasmid binding capacity. The clear lysate added 
Microcentrifuge Tube was then centrifuged for 1 minute at 12,000g to enable the 
plasmid binding to Miniprep Binding Column. Flow-through liquid was discarded 
and 700µl of Wash Solution (containing ethanol) was added into the Miniprep 
Binding Column followed by centrifugation at 12,000g for 1 minute before 
discarding the flow-through liquid. The Microcentrifuge Tube was then 
centrifuged again at 12,000g for 1 minute to remove the remaining Wash solution 
before the Miniprep Binding Column was transferred into a fresh Collection Tube. 
Plasmid was eluted by adding 50µl of Elution Solution followed by spinning the 
fresh Collection Tube at 12,000g for 1 minute and was stored at -20°C for further 
use. 
 
2.11.4 Plasmid transfection via electroporation into HaCaT and HECV cell lines 
Wild type HaCaT and HECV cells were grown in T75 culture flasks until reaching 
approximately 80% confluency. Cells were trypsinised and transferred into a 
universal container which was subsequently centrifuged to obtain a cell pellet. 
The cell pellet was then re-suspended in normal medium and cell number was 
determined before preparing a suspension containing 1,000,000 cell/ml. 800µl of 
cell suspension was pipetted into a 4mm cuvette followed by the addition of 8µg 
of plasmid. The mixture of cell suspension and plasmid was gently mixed by finger 
flipping before electroporation. Transfection conditions consisted of 310V and 
1500µA. Transfected cell solutions were then transferred into a T25 flask 
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containing pre-warmed normal medium. Another 800µl of cell suspension was 
added into a different fresh cuvette without adding any plasmid followed by 
electroporation transfection at the same condition. Such electroporated cell 
suspension was transferred into a separate pre-warmed flask to act as a selection 
control. Both flasks were incubated overnight at 37.0°C, 5% CO2 and 95% humidity. 
On the following day, flasks were placed into selection medium (normal medium 
containing 5µg/ml blasticidin) for approximately 8 - 14 days until no viable cells 
remained in the selection control flask. Then, transfected HaCaT cells were placed 
into maintenance medium (normal medium containing 0.5µg/ml blasticidin), 
whereas, HECV cells remained in selection medium for further culture. 
 
2.11.5 siRNA transfection via DharmaFECT transfect reagent 1 into HaCaT and 
HECV cell lines 
Cells were trypsinised and transferred into a universal container followed by 
centrifugation to obtain a cell pellet. Complete medium (antibiotic-free DMEM 
plus 10% FCS) was used to re-suspend the cell pellet, and cell number was 
counted to make a cell suspension with appropriate cell density before seeded 
into a 24-well plate and an overnight incubation at 37.0°C, 5% CO2 and 95% 
humidity. 
ON-TARGETplus Non-targeting Pool (Non-targeting siRNA) and ON-
TARGETplus Human SOCS-4 (122809) siRNA (SOCS-4-targeting siRNA), purchased 
from the manufacturer (GE Healthcare Dharmacon Inc., UK), was centrifuged and 
re-suspended using 1x RNase-free siRNA Buffer to make 20μM stock before 
aliquoting into separate 0.5ml microfuge tubes, and were stored at -20°C for 
further experimentation. 
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The siRNA and DharmaFECT 1 transfect reagent (transfect reagent) (GE 
Healthcare Dharmacon Inc., UK) was diluted separately to 25nM and 1μl/well, in 
serum and antibiotic-free medium,  was gently mixed by pipetting carefully up 
and down followed by 20 minutes incubation at room temperature to obtain a 
ready-to-use transfection medium.  
Once the pre-seeded cell reached 80% confluency, the medium was 
aspirated and replaced by ready-to-use transfection medium followed by an 
appropriate period of incubation at 37.0°C, 5% CO2 and 95% humidity. 
Transfection medium was removed and replaced by normal medium after 24 
hours incubation to minimise the cytotoxicity of the transfect reagent. 
 
2.12 Real time quantitative polymerase chain reaction (q-PCR) 
q-PCR was undertaken to analyse the transcript expression level of target genes. 
Such technique is more sensitive than conventional RT-PCR and capable of 
detecting small quantities of cDNA and providing a more reliable value of the 
template copy number in each sample. This method requires a sequence specific 
DNA based fluorescent reporter probe which only quantifies the target transcript 
containing such probe sequence in order to greatly improve the specificity of the 
detection.   
AmplifluorTM UniprimerTM Universal system (Intergen company®, New 
York, USA) was used in this study. The amplifluor probe consists of a 3’ region 
specific to the Z-sequence, ACTGAACCTGACCGTACA, which presents on the target 
specific primers and a 5’ hairpin structure labelled with a fluoresent tag (FAM). 
Whilst in the hairpin structure, such fluorescent tag is linked to an acceptor 
moiety (DABSYL) which effectively quenches the fluorescence and produces no 
fluoresecnce signal. Primers were designed to the specific target transcrpit using 
122 
 
Beacon Designer Software. To each of the primer pairs specific to the target 
sequence, a Z-sequence was added to allow incorporation of the amplifluor 
uniprimer probe during PCR. Such Z-sequence incorporated DNA transcript acts as 
a template for the amplifluor uniprimer probe, and the hairpin structure in the 
probe is subsequently degraded and unfolded by DNA polymerase, therefore, 
disrupting the stable structure between fluorophore and quencher to enable 
sufficient fluorescence emission to be detected. The principle of this process is 
demonstrated in Figure 2-5. Pre-prepared cDNA samples were amplified and 
detected on a StepOne plus Real-Time PCR System (Applied Biosystems, Paisley, 
UK), using Precision FAST 2X q-PCR MasterMix (Primerdesign Ltd, Chandler’s Ford, 
UK), specific forward primer (10pM), reverse primer containing the Z sequence 
(1pM) and the FAM-tagged Uniprimer probe (10pM). Each sample was loaded into 
a 96-well plate and the reaction mixed. The q-PCR conditions used are shown 
below: 
q-PCR Reaction mix: 
 Precision FAST 2X q-PCR MasterMix - 5µl 
 Specific forward primer - 0.3µl 
 Specific reverse primer with Z-sequence - 0.3µl 
 Amplifluor probe – 0.3µl 
 PCR H2O – 3.1µl 
 Prepared cDNA sample - 1µl 
q-PCR conditions:  
 Step 1: Initial denaturation - 94ᵒC for 10 minutes 
 Step 2: Denaturation - 94ᵒC for 10 seconds 
 Step 3: Annealing - 55ᵒC for 30 seconds 
 Step 4: Extension - 72ᵒC for 10 minutes 
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Step 2 - 4 were repeated for 100 cycles. 
The fluorescent signal was detected at the annealing stage, and the 
fluorescent signal emitted druing PCR correlates to the amount of DNA template 
that has been incorporated with Z- sequence. The geometric increase of the 
fluorescent signal directly correlates to the exponential increase of DNA template, 
which is used to determine a threshold cycle for each reaction. The transcript 
copy number could be determined by the time/cycle number when fluorescent 
signal reaches a specific threshold. Expression of the target sequence was 
detected in conjunction with a range of standards of known transcript, PDPL, that 
are used to generate a standard curve to enable the calculation of transcript copy 
number in each unknown sample (Figure 2-6). Finally, the transcript copy number 
was normalised by the detected copy number of -Actin and/or GAPDH.
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Figure 2-5: Diagram indicating the principle of the Amplifluor Uniprimer Universal system.
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Figure 2-6: Diagram of standard curve generation 
A. Reaction curves for serial diluted standard samples (108 to 10 copy number) 
using StepOne plus Real-Time PCR System; B. The standard curve generated based 
on the threshold cycle and copy number of the serial diluted standard samples. 
Red line indicates the standard curve generated and blue dots stand for different 
standard samples with known copy number. 
 
2.13 Immunohistochemistry (IHC) 
Primary antibodies: Anti-SOCS-1 (sc-9021, polyclonal antibody), anti-SOCS2 (sc-
9022, polyclonal antibody), anti-SOCS3 (sc-9023, polyclonal antibody), anti-SOCS4 
(sc-68827, polyclonal antibody), anti-SOCS5 (sc-100858, monoclonal antibody), 
anti-SOCS6 (sc-5608, polyclonal antibody) and anti-SOCS7 (sc-8291, polyclonal 
antibody and sc-137241, monoclonal antibody) were purchased from Santa Cruz 
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(or Insight Biotechnology, UK). All antibodies were used at a final concentration of 
2μg/ml.  
Histological analysis was performed using a standard streptavidin-biotin 
peroxidase technique. The frozen sections were fixed for 15 minutes in dried 
acetone (10162180) (Fisher Scientific UK, Loughborough, UK) and then air dried 
for 15 minutes. The sections were then washed three times in TBS for 5 minutes 
each. This was then followed by a 30 minute permeabilisation wash with 0.1% 
Saponin/TBS (Sigma-Aldrich, Inc., Dorset, UK). Since this reaction is reversible all 
subsequent washes were performed with 0.1%saponin/TBS. The sections were 
then incubated with a blocking solution in a humidified box at room temperature 
for 1 hour. The blocking solution, which contained 0.1% bovine serum albumin 
(BSA)/0.1% saponin/10% horse serum (horse serum was used to minimise the 
background since secondary antibody was raised in horse) in TBS, was also used to 
dilute all subsequent reagents. Excess blocking solution was removed and the 
sections were then incubated with the relevant, previously optimised, primary 
antibody for 1 hour. Following washing with 0.1%saponin/TBS, the sections were 
then incubated for 30 minutes with the biotinylated secondary antibody raised in 
horse (Vector Laboratories, UK), followed by a 30 minute incubation with ABC 
reagent in VECTASTAIN® ABC Kit (Vector Laboratories, Inc., CA, USA). 3’3 
diaminobenzidine (DAB) substrate (5mg/ml) was used to develop the final 
reaction product, the sections were rinsed in tap water, counterstained with Gill’s 
haematoxylin (Vector Laboratories, UK), and rehydrated through a series of 
graded alcohols, cleared in xylene (Fisher, UK) and mounted in Distyrene 
Plasticizer Xylene (DPX) (Merck, UK). Negative controls were performed where 
primary antibody was replaced with wash buffer. 
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Staining was visualised with a Leica DM1000LED microscope equipped 
with a MC120 HD camera and Leica Application Suite version 3.0.0 software (Leica 
Microsystems, Milton Keynes, UK), and the localisation and intensity of staining 
for each antibody was assessed by myself and a senior wound healing technician 
at both the wound edge and area distal to the wound edge. 
 
2.14 Cellular lysis and protein extraction  
Upon reaching sufficient confluency, cells were harvested through two different 
methods as follows dependent on future experimental application.  
 Method 1. Cells were washed with 4°C sterile PBS twice and scraped from 
the flask using a sterile cell scraper in 5ml sterile PBS. The cell suspension 
was transferred to a 30ml universal container using a sterile pipette, 
followed by being centrifuged at 2500 rpm for 10 minutes to pellet the 
cells. The cell pellet was then lysed in 150-300µl (based on the pellet size) 
lysis buffer and transferred to a 1.5 ml microfuge tube using a sterile 
pipette.  
 Method 2. Cells were trypsinised before  being collected and centrifuged 
to obtain a pellet. PBS was used to wash the cell pellet twice through re-
suspending followed by centrifugation. 100μl of protein lysis buffer was 
used to re-suspend the pellet, and the protein lysate was transferred into 
a 1.5ml microfuge tube using a sterile pipette. 
 
The microfuge tube was subsequently placed on a Labinoco rotating 
wheel (Wolf laboratories, York, UK) (25rpm and 4°C) for no less than 40 minutes 
for sufficient extraction. After 15 minutes centrifugation at 13,000rpm, 
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supernatant (protein lysate) was transferred into a fresh 1.5ml sterile microfuge 
tube using a sterile pipette before being stored at -20°C. 
 
2.15 Protein sample quantification, denaturisation and normalisation 
A Bio-Rad DCTM protein assay kit (Bio-Rad, Laboratories, Hemel-Hempstead, UK) 
was used to determine the concentration of the extracted protein samples as 
outlined. Standard bovine serum albumin (BSA) protein samples (stock 
concentration of 10mg/ml) was made by dissolving BSA powder (Sigma-Aldrich, 
Inc., Dorset, UK) in PBS. Eight serially diluted BSA standard samples, ranging from 
10mg/ml to 0.078mg/ml, was made by mixing the appropriate amount of BSA 
original stock and PBS. 5μl of each serially diluted BSA standard samples and the 
protein extraction samples were aliquoted into a 96-well plate in triplicates. 
Sufficient amount of working reagent A’ was made by combining 1 portion of 
reagent S with 50 portions of reagent A. To the 5μl serially diluted standard BSA 
and extracted protein aliquots, 25μl of working reagent A’ was added before the 
addition of 200μl of reagent B. The plate was transferred onto a shaker and was 
left for 30 minutes to allow the completion of the colorimetric reaction. The 
absorbance of the serial concentration BSA standard protein and extracted 
protein samples were then detected at 630nm using an ELx800 plate reading 
spectrophotometer (Bio-Tek, Wolf laboratories, York, UK).  
A standard curve was generated based on the absorbance and the 
concentration of the serial diluted BSA standard protein samples. Subsequently, 
the concentration of the unkonwn concentration protein samples were calculated 
according to the standard curve before being normalised to the desired 
concentration of 2mg/ml through the addition of an appropriate amount of lysis 
buffer. Subsequently, such 2mg/ml samples were further diluted in a 1:1 ratio 
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with 2x Lamelli sample buffer to obtain a final concentration of 1mg/ml sample, 
and were denatured by being boiled at 100°C for 5 minutes before being stored at 
-20°C for further use. 
 
2.16 Protein extraction and fluorometric protein quantification for KinexusTM 
antibody microarrays 
In order to acquire high concentration protein lysate, each cell type was cultured 
in two T75 flask until reaching 80% confluency followed by serum starvation for 
24 hours before protein extraction. Upon protein extraction, cells were washed 
with 4°C sterile PBS twice and scraped from the flask using a sterile cell scraper in 
5ml sterile PBS. The cell suspension from two flasks was combined and 
transferred to a 30ml universal container using a sterile pipette, followed by being 
centrifuged at 2500 rpm for 10 minutes to pellet the cells. The cell pellet was then 
lysed in 600µl lysis buffer and transferred to a 1.5 ml microfuge tube using a 
sterile pipette. The microfuge tube was subsequently placed on a Labinoco 
rotating wheel (Wolf laboratories, York, UK) (25rpm and 4°C) for no less than 40 
minutes for sufficient extraction. After 15 minutes centrifugation at 13,000rpm, 
the supernatant (protein lysate) was transferred into a fresh 1.5ml sterile 
microfuge tube using sterile pipette before being stored at -20°C for further use. 
A fluorescence assay using fluorescamine was applied to quantify total 
protein since the Bio-Rad DCTM protein assay kit is not compatible with 2-
mercaptoethanol, one of the ingredients in the lysis buffer. Fluorescamine 
acetone was made by dissolving 15mg of fluorescamine (F9015)(Sigma-Aldrich, 
Inc., Dorset, UK) in 5ml absolute acetone (10162180) (Fisher Scientific UK, 
Loughborough, UK) in a glass vial and stored at 4°C for further use. Eight serially 
diluted BSA standard samples, ranging from 10mg/ml to 0.078mg/ml, was made 
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by mixing the appropriate amount of BSA original stock and PBS. The extracted 
protein samples were diluted 1 in 10 by adding 50μl of protein sample in 450μl of 
PBS. Then, 150μl of each serially diluted BSA standard samples and the 10X 
diluted protein extracted samples were aliquoted into a 96-well plate in triplicates 
before the addition of 50μl of fluorescamine acetone followed by being shaken 
for 1 minute. The fluorescence signal was then determined using a GloMax®-Multi 
Microplate Multimode Reader (Promega Biosystems Inc., Sunnyvale, CA, USA) 
with a 365nm excitation and 410-460nm emission filter. The concentration of the 
extracted protein samples were calculated based on the standard curve before 
being normalised to the desired concentration of 4mg/ml through the addition of 
an appropriate amount of lysis buffer to make 300μl stock followed by being 
stored at -20°C and sent for KinexusTM antibody microarray analysis (Kinexus 
Bioinformatics, Vancouver, British Columbia, Canada). 
 
2.17 Tris-glycine sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) and western blotting 
2.17.1 Gel preparation and gel running 
Tris-glycine SDS-PAGE was undertaken using an OmniPAGE VS10DSYS vertical 
electrophoresis system (OmniPAGE, Cleaver Scientific Ltd., Rugby, UK)(Figure 2-7). 
The vertical electrophoresis system was properly assembled according to the 
protocol provided by the manufacturer. 8% or 10% resolving gels and stacking gels 
were prepared in 15ml and 5ml aliquots respecitvely (enough for two gels) based 
on the size of the target protein. Ingredients used in the preparation of the 
stacking gel and resolving gel are outlined as follows (Table 2-6 and Table 2-7): 
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Figure 2-7: Acrylamide gel electrophoresis apparatus 
 
Table 2-6: Ingredients for 8% and 10% resolving gel 
Component 8% Resolving gel 10% Resolving gel 
Distilled water 6.9ml 5.9ml 
30% acrylamide mix  
(Sigma-Aldrich, Inc., Dorset, UK) 
4.0ml 5.0ml 
1.5M Tris-HCl buffer pH8.8  
(Bio-Rad Laboratories, Hammel 
Hempsead, UK) 
3.8ml 3.8ml 
10% SDS 0.15ml 0.15ml 
10% Ammonium persulphate 0.15ml 0.15ml 
TEMED  
(Sigma-Aldrich, Inc., Dorset, UK) 
0.009ml 0.006ml 
*8% gel was used to separate proteins with molecular weight higher than 100kDa, 
whereas 10% gel was used when protein size was less than 100kDa 
 
Table 2-7: Ingredients for stacking gel 
Component Stacking gel 
Distilled water 3.4ml 
30% acrylamide mix  
(Sigma-Aldrich, Inc., Dorset, UK) 
0.83ml 
0.5M Tris-HCl buffer pH6.8  
(Bio-Rad Laboratories, Hammel 
Hempsead, UK) 
0.63ml 
10% SDS 0.05ml 
10% Ammonium persulphate 0.05ml 
TEMED (Sigma-Aldrich, Inc., Dorset, UK) 0.005ml 
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Once prepared and mixed thoroughly, the polyacrylamide resolving gel 
was immediately loaded into the two glass plates until it reached a level 
approximately 2cm below the top edge of the smaller plate. Ethanol was used to 
gently top up  to ensure the formation of a smooth gel surface. The resolving gel 
was then left at room temperature for approximately 30 minutes to polymerase. 
The ethanol was then discarded by inverting the cassette after a clear interface 
was visible between the top ethanol layer and the bottom resolving gel layer. 
Subsequently, the stacking gel was prepared and loaded immediately on top of 
the polymerised resolving gel until it reached the top edge of the smaller plate. 
Well forming Teflon combs were subsequently inserted into the stacking gel 
without generating any air bubbles. After polymerisation of the stacking gel, the 
loading cassette was equipped into the electrophoresis tank. The central reservoir 
of the cassette and the electrophoresis tank was then filled with 1X running buffer 
to the appropriate level before the comb was removed. 20µl of the pre-prepared 
protein sample along with 8µl of the diluted Geneflow BLUeye Prestained Protein 
Ladder (Geneflow Limited, Fradley, Staffordshire, UK) were loaded into wells 
before gel running. EV243 power consort (Topac Inc., Cohasset, MA, USA) was 
used for acrylamide gel electrophoresis, and the electrophoresis condition used 
during the stacking gel running stage was 110V, 50mA and 50W, whereas the 
voltage was increased to 120V once the protein samples reached to the top edge 
of the resolving gel. The electrophoresis was undertaken for various length of 
time according to protein size and gel percentage. 
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2.17.2 Preparation and operation of gel transfer  
One piece of Immobilon-P PVDF transfer membrane (EMD Millipore Corporation, 
Billerica, MA, USA) and six sheets of filter paper (Sigma-Aldrich, Inc., Dorset, UK) 
for each gel was prepared in advance to the gel transfer stage. PVDF transfer 
membrane was cut into the dimensions of 7.5cm X 7.5cm, and was soaked in 100% 
methanol then distilled water both for 30 seconds followed by being immersed in 
1X transfer buffer for at least 5 minutes. Filter paper was cut into the dimensions 
of 8cm X 8cm followed by immersion in 1X transfer buffer for 10-20 minutes. 
Mini Trans-Blot cell (Bio-Rad, Laboratories, Hamel-Hempstead, UK) (Figure 
2-8 A) was used for protein transfer. Upon the completion of the electrophoresis, 
the power supply was disconnected and the gel running apparatus was 
disassembled. The glass plates were pried open using the spacer to expose the gel 
and the top portion of the gel, containing the stacking gel, was removed using the 
sharp edge of the spacer. The resolving gel, containing the fractionated protein 
samples, was carefully transferred on top of the pre-prepared polyvinylidene 
difluoride (PVDF) transfer membrane. Along with the filter paper and fibre pad, 
gel and membrane were assembled in a ‘sandwich’ shape and were tightened by 
the gel holder cassette (Figure 2-8 B). Such apparatus was then placed into the 
electrode assembly in the buffer tank along with a chilled pad, and 1X transfer 
buffer was then used to fill the buffer tank to the top edge of the gel holder 
cassette before being covered with lid. 
 Subsequently, the assembled buffer tank was placed into an ice box or 
cold room at 4°C, and EV202 power consort (Topac Inc., Cohasset, MA, USA) was 
utilised for protein transfer at the conditions of 100V, 200mA, 50W for 1-2 hours 
depending on the protein molecular weight (longer time for larger molecular 
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weight proteins). Transfer verification was undertaken by lifting one corner of the 
membrane and visualising if the gel was clear and transparent. 
 
 
Figure 2-8: Western blotting protein transfer equipment 
A. Mini Trans-Blot cell was used for protein transfer; B. Diagram of ‘sandwich’ 
protein transfer layout. 
 
2.17.3 Protein staining and immunoprobing 
2.17.3.1 Membrane staining 
In order to verify the successful protein transfer, Ponceau S, a reversible and 
reusable protein stain that does not interfere with any subsequent 
immunoprobing, was utilised to stain the membrane. After gel transfer was 
completed, the membrane was separated from the gel transfer apparatus and 
was immersed in Ponceau S in a weighing tray with the protein side up on a 
shaker for a few minutes at room temperature. The membrane was then washed 
with distilled water until the emergance of the protein bands. If required, the 
membrane was cut into several pieces using a dry sterile blade, and subsequently 
the remaining stain was washed off for further immunoprobing. 
 
2.17.3.2 Immunoprobing 
After the washing stage, the membrane was rolled into a 50ml 
centrifugecentrifuge tube (Nunc, Fisher-Scientific, Leicestershire, UK) containing 
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10ml of blocking solution (5% low fat milk and 0.1% Tween 20 in TBS), and 
incubated for one hour at room temperature on a roller mixer (Stuart, Wolf-
Laboratories, York, UK). The membrane surface that contacted with the gel was 
ensured to face the inside of the centrifuge tube with the other side in contact 
with the inner-surface of the tube.  
Once the blocking was complete, the primary antibody, prepared in 
blocking solution was pipetted into the centrifuge tube, and the tube was 
incubated on roller mixer at 4°C overnight. On the next day, the primary antibody 
was discarded and 10ml of wash solution (0.1% Tween 20 in TBS) was added into 
the tube before being rolled for 10 minutes to wash away the unbound primary 
antibody. Such wash stages were repeated three times. The membrane was then 
transferred into a fresh centrifuge tube containing 10ml of blocking solution with 
horseradish peroxidase (HRP) conjugated secondary antibody, and was incubated 
for two hours at room temperature on roller mixer followed by three washing 
steps (as above).  
Subsequently, the membrane was treated with EZ-ECL Chemiluminescent 
Detection Kit (Biological industries, Kibbutz Beit-Haemek, Israel) as outlined. The 
EZ-ECL solution A and B were mixed in equal volumes and incubated in the dark at 
room temperature for at least for 5 minutes to equilibrate.The volume of each 
solution was calculated according to the protocol (0.1ml of the mixed EZ-ECL 
solution was used to sufficiently cover 1cm2 membrane). Following the last wash, 
the excess wash solution on the membrane was drained off, and the membrane 
was placed on a clean weighing tray with the protein side facing up. The mixed EZ-
ECL solution was then gently added on the membrane using a pipette in a ‘S’ 
shape followed by incubation for 1 mintue in the dark at room temperature.  
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The excess EZ-ECL mixed solution was drained off from the membrane, and 
the chemiluminescent signal was then detected using a G:BOX Chemi XRQ imaging 
system (Syngene, Cambridge, UK) according to the protocol provided by the 
manufacturer. 
 
2.17.3.3 Semi-quantitative analysis on western blot results by 
densitometry 
Image J v1.50c was utilised for the semi-quantitative analysis of Western blot 
results. The rectangular selection tool was used to select a set area for each band 
on the Western blot image and the value of the integrated density for the 
selected area was then measured. The integrated density of the protein of 
interest was then normalised by the equation outlined:  
 Normalised integrated density = normalising factor x integrated density of 
the protein of interest 
 Normalising factor = GAPDH or Actin of control sample / GAPDH or Actin 
of treated sample 
  
2.18 Cell functional assays 
2.18.1 Electric cell-substrate impedance sensing (ECIS) based initial attachment 
and spreading, and migration assay   
Electric cell-substrate impedance sensing (ECIS) instruments (Applied Biophysics 
Inc., NJ, USA) were applied to investigate cell behaviour based on the impedance 
parameter detected from gold electrodes coated on the bottom of a 96-well array 
(Applied Biophysics Inc., NJ, USA). ECIS is an in vitro assay used to quantify cell 
behaviour through detection of impedance variation based upon the current flow 
change on the electrode that is cultured with cells. Such a technique enables the 
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measurement of impedance over a range of frequencies to study different 
functional and structural cell properties, based on cell-cell junctional contacts and 
cell-substrate interactions, during the same period of time. Moreover, there are 
two parameters, resistance and capacitance, derived from impedance 
measurements. Resistance, consisting para- and trans-cellular current flow (Figure 
2-9), is more likely to represent the quality and function of the cell barrier, 
whereas capacitance stands for the overall coverage of the electrodes (Szulcek et 
al., 2014). In this project, resistance measured in 4,000Hz were chosen to analyse 
cell function due to its best sensitivity to the current flow variation caused by cell 
behaviour change (Wegener et al., 2000). 
 
Figure 2-9: Diagram of current flow following cell attachment to the gold 
electrode 
The 96-channel array station was connected to ECIS instruments pre-
warmed at 37°C, 5% CO2 and 95% humidity in an incubator (Figure 2-10 A). 200μl 
of normal medium was pipetted into each well of the 96-well array in a biosafety 
cabinet, and the 96-well array was connected to the 96-channel array station 
followed by connection check and stablisation using Applied BioPhysics-ECIS 
Software V1.2.135 (Applied Biophysics Inc., NJ, USA). 
During the time required to complete stabilisation, the cell suspension 
solution with appropriate cell density was prepared based on the cell type. Once 
the array stabilisation was completed, the 96-well array was removed from the 
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array station and transferred into a biosafety cabinet where the medium was 
aspirated using a glass aspirator and replaced with 200µl of prepared cell 
suspension solution with appropriate cell density (HaCaT: 8 x 104cells/well; HECV: 
4 x 104cells/well). Each sample was seeded in six replicates. After the cell seeding, 
the 96-well array was equipped in the array station in the incubator.  
Following inoculation at time zero, resistance increases as the cells attach 
to the electrode and begin spreading (Koo and Yun, 2016, Szulcek et al., 2014, 
Wegener et al., 2000) and the resistance wil continue to increase until the cells 
reach confluence (Figure 2- 11). For the initial functional analysis of our cells, the 
resistance was measured at multiple frequencies, and the first four hours of data, 
obtained at 4,000Hz was taken to analyse the initial adhesion and spreading in 
line with the study by Wegener et al. (Wegener et al., 2000). 
In normal ECIS measurements, a current of less than 1µA is normally used. 
This is undetected by the cells, and, in its measurement mode, ECIS essentially 
eavesdrops on cell behaviour electrically. When the current is boosted 1000 fold 
to 1mA, the resulting voltages across the cell membranes result in electroporation. 
When this high current is applied for more than several seconds, cell death ensues 
due to severe electroporation and possible local heating effects. Therefore, 
wound migration assay could be performed once the resistance curve reached 
plateau (Figure 2-12, Figure 2- 13) (Koo and Yun, 2016, Szulcek et al., 2014). A 
lethal electroporation (electrical wounding) was applied to the cells covering the 
gold electrodes for 20 seconds at the conditions of 3000μA and 60,000Hz to 
generate a uniformed lesion (250 µm diameter). The resistance was measured 
following electrical wounding and used to analyse cell migratory function over a 
four hour period following wounding. The electrical wounding and the subsequent 
measurements were repeated twice. The resistance obtained for each hour was 
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used to subtract the initial value at hour zero to display the resistance change 
which represents the cell recoverage of the electrodes from the starting point. 
Experiments were repeated for at least three times. 
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Figure 2-10: Electric cell-substrate impedance sensing (ECIS) system and 
cultureware 
A. ECIS Z theta instrument connected to a 96-channel array station that was 
placed in a incubator; B. 96-channel array station equipped with a 96-well array; C. 
A 96W1E+ disposable electrode array coated with two electrodes on the bottom 
of each well. 
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Figure 2- 11: Diagram of ECIS based cell attachment and spreading assay-resistance trace following inoculation 
Following inoculation, resistance increases as the cells attach to the electrode and begin spreading. The resistance continues to increase until the cells reach 
confluence at the 2nd hours for cell A (blue curve) and the 10th hours for cell B (green curve). The small fluctuations in the curves are due to micromotion 
from the constant movement of the monolayer of cells on the electrode. 
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Figure 2-12: Diagram of ECIS based cell migration assay-resistance trace following lethal electroporation (electrical wounding) 
Cells were first grown as complete monolayers and the resistance traces from four confluent wells can be seen as different colours (control: green and blue; 
wounded: black and red). At the red arrow timepoint, an elevated lethal electroporation was applied to two of the wells (black and red), wounding the cells 
on the electrode (250µm diameter) and resulting in the drop of resistance to that of an open electrode. As the time flows, these two traces gradually return 
to control values, as the healthy cells outside of the electrode migrate inward to reover the wounded area (healing).
143 
 
 
Figure 2- 13: Diagram of the relationship between cell migration and resistance trace following electrical wounding 
Following electrical wounding, the resistance starts to increase as the cells outside of the electrode migrate to the open space until the wound has healed. 
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2.18.2 In vitro thiazolyl blue tetrazolium bromide (MTT) cell proliferation assay 
MTT (3-(4,5-dimetheylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium 
has been widely adopted in a variety of cell functional assays, especially cell 
viability assay. MTT could be converted into a purple coloured formazan product 
with absorbance near 570nm by viable cells with active metabolism.  Such 
formazan product, soluble in DMSO, accumulates as precipitate and distributes 
inside the cell as well as the culture medium near the cell surface. The amount of 
formazan product corresponds to the number of viable cells following linearity. 
Thus, the absorbance of formazan solution is comparable to the number of viable 
cells (Riss et al., 2004). MTT stock solution (5.5mg/ml) was made by adding 110mg 
thiazolyl Blue tetrazolium bromide powder (MTT) (Sigma-Aldrich, Inc., Dorset, UK) 
in 20ml PBS into a foil wrapped 30ml universal container, and the tube was then 
placed on a roller mixer (Stuart, Wolf-Laboratories, York, UK) until the powder 
was dissolved thoroughly. Once the powder was dissolved completely, the 
solution was filtered through a 0.2μm filter on top of a fresh foil wrapped sterile 
universal tube in a biosafety cabinet and stored at 4°C in fridge for further use.  
Once 80% confluency was obtained, cells were trypsinised, centrifuged 
and re-suspended with normal medium. Cell number was then counted manually 
and an appropriate amount and cell density of cell solution was prepared for cell 
seeding. 200µl of the cell suspension (2000 cells/200µl) was then pipetted into 
three 96-well plates in six replicates followed by incubation for 24 (1 day), 72 (3 
days) and 120 hours (5 days) at 37.0°C, 5% CO2 and 95% humidity respectively. 
20µl of sterile MTT stock solution was added at 24, 72 and 120 hours after cell 
seeding (working concentration of 0.5mg/ml MTT) and the plates were incubated 
at 37°C, 5% CO2 and 95% humidity for 4 hours. The MTT medium solution was 
then aspirated gently, using a glass aspirator, followed by the addition of 200µl of 
145 
 
DMSO. After 10 minutes incubation at 37.0°C, 5% CO2 and 95% humidity, the plate 
was taken out and tapped gently to thoroughly mix the DMSO solution.  
The absorbance of each well was read at 540nm using an ELx800 plate 
reading spectrophotometer (Bio-Tek, Wolf laboratories, York, UK). Experiments 
were repeated for a minimum of three times. The cell number in each well was 
determined by the absorbance and a percentage increase at each time point was 
calculated as follows:  
Percentage increase = [(day 3 or day 5 absorbance - day 1 
absorbance)/(day 1 absorbance-background absorbance)] x 100% 
 
2.18.3 In vitro MTT cell adhesion assay 
Cell adhesion assays were used to examine cell initial adhesive ability to matrigel 
matrix. Matrigel® Basement Membrane Matrix (Corning Incorporated, Flintshire, 
UK) was diluted with serum free medium (SFM) to 50µg/ml and 5µg of matrigel 
was added to the wells of 96-well plate under sterile conditions followed by 
dehydration at 55°C for 1 to 2 hours. The matrigel matrix coated wells were 
rehydrated by gently pipetting 100µl SFM and incubating at room temperature for 
at least 30 minutes before aspirating the SFM. Cells (40,000 cells in 200µl normal 
medium) were seeded on the rehydrated matrigel matrix in six replicates and the 
plate was incubated for 45 minutes. Subsequently, the medium was gently 
aspirated by glass aspirator and 100µl of PBS was used to gently wash the wells 
twice. MTT in 200µl normal medium (0.5mg/ml working concentration) was 
added to each well and the plate was incubated at 37.0°C, 5% CO2 and 95% 
humidity for 4 hours. The medium containing MTT was then aspirated followed by 
the addition of 200µl DMSO. After 10 minutes of incubation in DMSO at 37.0°C, 5% 
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CO2 and 95% humidity, the plate was taken out and tapped gently to let the 
DMSO solution mix thoroughly.  
The absorbance of each well was detected at 540nm using ELx800 plate 
reading spectrophotometer (Bio-Tek, Wolf laboratories, York, UK). Initially 
attached cell numbers in each well was determined by the absorbance. 
Experiments were repeated a minimum of three times.  
 
2.18.4 In vitro cell migration assay (wound healing assay) 
A EVOS® FL Auto Imaging System (Life technologies, CA, USA) equipped with 
EVOS® Onstage Incubator (Life technologies, CA, USA) (Figure 2-14) were used the 
in vitro cell migration assay. Such a system was used to capture images at certain 
time intervals at the same location in each monitored well and continuously 
maintain culture conditions for the cells being investigated.  
Cells in 1ml of normal medium were pre-seeded with appropriate density 
(HaCaT: 600,000 cells/well, HECV: 400,000 cells/well) in a 24-well plate and 
incubated until the formation of a monolayer on the next day. The cell monolayer 
was scraped by a 200µl pipette tip producing an approximately straight wound. 
The medium was aspirated by glass aspirator and the well was washed by 
pipetting and aspirating PBS twice to remove the detached cell debris. 2ml of 
normal medium was then gently pipetted into the well followed by 10 minutes of 
incubation at 37°C, 5% CO2 and 95% humidity for cell recovery. The 24-well plate 
was then placed in an EVOS® Onstage Incubator (Life technologies, CA, USA) 
equipped in an EVOS® FL Auto Imaging System (Life technologies, CA, USA). 
Integrated EVOS® FL Auto Imaging System Software was used to set up and adjust 
the chamber environment condition at 37°C, 5% CO2 and 80% humidity. Three 
views on each wound were set up to be captured in 30 minutes interval until the 
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15th and 20th hour for HaCaT and HECV respectively. The distance between two 
wound edges was measured using Image J v1.50c in pixels, and the distance 
change at every time interval was calculated by wound edge distance at minute 
zero subtracting wound edge distance at each time point. The mean and standard 
deviation was calculated using the three measurements per each wound, and was 
plotted on a scatter line chart. Experiments were repeated a minimum of three 
times. 
 
Figure 2-14: EVOS® FL Auto Imaging System installed with EVOS® Onstage 
Incubator 
 
2.18.5 Tubule formation assay 
Matrigel® Basement Membrane Matrix (Corning Incorporated, Flintshire, UK) was 
used in the tubule formation assay to investigate the vascular regeneration ability 
of endothelial cells on matrigel matrix. 50µl of neat matrigel matrix was gently 
pipetted into the bottom of each well in 96-well plate without generating any 
bubbles. The plate was kept in sterile condition for at least 40 minutes until 
polymerisation. Cells (40,000 cells in 200µl normal medium) were gently seeded 
on the polymerised matrigel matrix in six replicates and the plate was incubated 
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at 37°C, 5% CO2 and 95% humidity. The plate was then taken out, and images of 
each well was visualised and captured at X5 objective magnification at 2 hour 
intervals until the 10th hour, using a Leica DMi1 microscope equipped with a 
MC120 HD camera and Leica Application Suite version 3.0.0 software (Leica 
Microsystems, Milton Keynes, UK). The total perimeter of each formed tubule in 
every image was measured using Image J v1.50c, and mean and standard 
deviation was then calculated according to the values from each replicate. Results 
were subsequently plotted as a bar chart. Experiments were repeated a minimum 
of three times. 
 
2.19 Statistical analysis 
Statistical analysis was undertaken using the SigmaPlot 11 and Graphpad Prism 6 
statistical software packages.  Data was analysed using t-test or Mann Whitney 
test, depending on data parameters. Values of p < 0.05 (*), p < 0.01 (**), p < 0.001 
(***) and p < 0.0001 (****) were regarded as statistically significant. 
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Chapter III 
Expression of the suppressor of 
cytokine signalling (SOCS) family in 
human chronic wound tissues: 
potential implications for SOCS in 
chronic wound healing
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3.1. Introduction 
The area of chronic wound healing has drawn much attention from many 
healthcare professionals due to the high cost of healthcare resources for patients 
seeking appropriate treatment combined with the complexity of its underlying 
mechanisms. It has been demonstrated that a reduction in tissue growth factors, 
a proteinase / inhibitor imbalance, and the presence of senescent cells contribute 
to the pathphysiology in chronic wounds (Harding et al., 2002). A variety of 
treatments, such as dressings, topical growth factor application, autologous skin 
grafting and bioengineered skin equivalents have been applied to treat certain 
types of chronic wounds in addition to the basic treatments (Harding et al., 2002). 
However, the specific mechanisms of a number of these treament remain unclear 
and are currently under investigation. Therefore, additional insight into the 
mechanisms responsible are required to gain a better understanding of the 
wound-healing process. Further clarification of this complex system may 
contribute to the emergance of a prognisitc marker to predict the healing 
potential of chronic wounds which could benefit the management of patients 
suffering with this clinical problem. 
Chronic wounds have been defined as wounds that fail to follow the 
normal healing process in a timely and orderly manner, which severely disrupt the 
anatomic and funcitonal integrity of the skin (Lazarus et al., 1994). Chronic wound 
such as venous leg ulcers are constantly trapped within the inflammatory phase 
since the normal mechanisms responsible for swiching off inflammation are 
disrupted by their pathological status (Trengove et al., 2000). Studies have shown 
that the imbalance of MMP/tissue inhibitors of MMP (TIMP) is one of the key 
factors leading to non-healing chronic wounds (Trengove et al., 1999, Yager et al., 
1996). Elevated pro-inflammatory cytokines, IL-1, IL-6 and TNF-, were also found 
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in non-healing chronic wound compared to healing ones (Trengove et al., 2000). 
In addition, previous in vitro study has proved that the expression of MMP and 
TIMP was regulated by IL-1 and TNF-(Ito et al., 1990). Moreover, the abnormal 
distribution of growth factors was also found in chronic ulceration (Higley et al., 
1995). Therefore, the dysregulation of a range of pro-inflammatory cytokines and 
growth factors play critcal roles in the pathphysiology of wound healing.  
As discussed in the general introduction section of this thesis, the SOCS 
family of proteins are known to play key roles in the regulation of a range of 
growth factors and cytokines, and this regulation will likely have further 
implications in the process of wound healing (Feng et al., 2016). Indeed members 
of this family have been linked to wound healing, for example SOCS-1 and SOCS-3 
are induced by a number of pro-inflammatory cytokines including IL-2, IL-4 and IL-
6 and IFN, and subsequently act as a feedback negative regulator to suppress their 
inflammatory response and hence, have potential to aleviate the excacerbated 
inflammation in chronic wounds in order to restore the normal reparative process. 
In contrast to the inhibitory effect of SOCS-1 and SOCS-3 on IL-2 signalling, SOCS-2 
was found to restore IL-2 signalling through association and degradation of SOCS-
3 (Tannahill et al., 2005). Additionally, SOCS-2 and SOCS-6 have been found to 
associate with other SOCS family members (Piessevaux et al., 2006), suggesting a 
potential role in coordiantion of other SOCS proteins to maintain the balance of 
cytokine signalling during wound healing. Other members of the SOCS family have 
been poorly characterised in this context though SOCS-4 and SOCS-5 are known to 
be induced by EGF and negatively regulate EGF signalling through the interaction 
with EGFR (Kario et al., 2005). Additionally, SOCS-7 can be induced by pro-
inflammatory cytokines such as IL-1 and IL-6, and associate with EGFR (Matuoka 
et al., 1997). Given the role of EGF-like growth factor in the proliferation and re-
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epithelialisation phase (Clark, 1996) of wound healing these, more poorly 
characterised members, may also play important roles. 
Given the potential significance of this family in the wound healing 
process, the scale of healthcare issues caused by chronic wounds and the need to 
seek novel biomarkers or therapeutics to identify or treat non-healing chronic 
wounds, the current chapter aimed to explore the expression of SOCS-1 – SOCS-7 
in two clinical cohort of chronic wounds. Firstly, differences in gene expression of 
SOCS members was explored between healing/healed (n=20) and non-healing 
wounds (n=51) and subsequently a subset of an additional cohort of chronic 
healing/healed (n=45) and non-healing (n=45) wounds was used to explore 
protein distribution and expression. 
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3.2. Materials and methods 
3.2.1 Primers 
Specific primers were designed using Beacon designer software (PREMIER Biosoft 
International, Palo Alto CA, USA) and synthesised by Sigma (Dorest, UK). Details of 
the primers are oulined in Table 3-1. 
 
Table 3-1: Primers used for detection of SOCS family members and the CK-19 
house keeping gene in this study, ACTGAACCTGACCGTACA represents Z 
sequence  
Primer Forward Reverse 
SOCS 1 5’-GATGGTAGCACACAACCAG 5’-ACTGAACCTGACCGTACAGAGGAGGAGGAGGAAGGTT 
SOCS 2 5’-GGATGGTACTGGGGAAGTAT 5’-ACTGAACCTGACCGTACATGGGAGCTATCTCTAATCAA 
SOCS 3 5’-TCAAGACCTTCAGCTCCA 5’-ACTGAACCTGACCGTACAGTCACTGCGCTCCAGTAG 
SOCS 4 5’-GGCAGTGTTTTCCAATAAAG 5’-ACTGAACCTGACCGTACAAGGTGGGAAAGGACACTTAT 
SOCS 5 5’-AGTCAAAGCCTCTCTTTTCC 5’-ACTGAACCTGACCGTACACATTTTGGGCTAAATCTGA 
SOCS 6 5’-CCTTACAGAGGAGCTGAAAA 5’-ACTGAACCTGACCGTACACGAAAAGAAAAGAACCATC 
SOCS 7 5’-CAGGCCCTGAATTACCTC 5’-ACTGAACCTGACCGTACAGAGGTTGCTGCTGCTGCT 
CK-19 5’-AGCCACTACTACACGACCAT 5’-ACTGAACCTGACCGTACATCGATCTGCAGGACAATC 
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3.2.2 RNA extraction and reverse transcription 
RNA extraction was undertaken in accordance with the manufacturers 
instructions and as described in section 2.7 of chapter II before being resuspended 
in DEPC water, quantified using a NanoPhotometerTM (IMPLEN; Geneflow ltd., 
Lichfield, UK), standardised and reverse transcribed to generate cDNA, as 
described in section 2.8 of chapter II.  
 
3.2.3 q-PCR 
Primers were designed to each of the SOCS family members using the Beacon 
Designer Software (Bio-Rad, Hercules, CA, USA) and transcript expression in each 
of the wound samples quantified using qPCR. This method uses a Molecular 
Beacon / Amplifluor system as described in full in section 2.12 of chapter II 
 SOCS family members were detected in conjunction with the CK-19 
housekeeping gene and values were normalised against this gene. Details of 
primers used in this section of the thesis are outlined in Table 3-1. 
 
3.2.4 IHC 
Immunohistochemical analysis was undertaken to explore the staining pattern 
and intensity of the SOCS family members in the chronic wound cohort biopsies. 
Primary antibodies used were indicated in Table 2-4 Chapter II. All antibodies 
were purchased from Insight Biotechnologies (Wembly, England, UK) and were 
used at a final concentration of 2µg/ml. 
IHC analysis was performed, as described in section 2.13 of chapter II,  on 
a subset of chronic wound tissues that included healing/healed (n=10) and non-
healed (n=10) biopsies using a standard avidin-biotin peroxidase technique. 
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Staining was visualised with a microscope under a range of magnifications. 
The localisation and staining intensity for each antibody was assessed at both the 
wound edge and areas distal to the wound edge. Staining intensity was 
qualitatively graded as strong, moderate or negative. Full details regarding tissue 
collection, processing and the clinical cohorts are outlined in section 2.6 of 
Chapter II. 
 
3.2.5 Statistical analysis 
Statistical analysis was undertaken using the SigmaPlot 11 statistical software 
package (Systat Software Inc, London, UK). Data was analysed using Mann 
Whitney test as the data was not normally distributed. Values of p < 0.05 were 
regarded as statistically significant. 
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3.3. Results 
3.3.1 Gene expression levels of SOCS family members in healing/healed and 
non-healing chronic wounds 
The transcript expression levels of seven SOCS family members were quantified, 
using q-PCR, in a cohort of venous leg ulcer patients and compared between those 
chronic wounds defined as healed/healing (n=20) and those defined as non-
healing (n=51) (Figure 3-1, Figure 3-2). Compared to healing/healed chronic 
wounds, the non-healing chronic wound tissues had significantly enhanced level 
of of SOCS-3 gene expression, showing an 81% increase in expression (p = 0.0284). 
Similarly, significantly higher levels of SOCS-4 were also seen in non-healing 
chronic wounds compared to healing/healed chronic wounds, with a 93% increase 
in SOCS-4 gene expression (p = 0.0376).  
Similarly, enhanced gene expression levels of SOCS-1, 2, 5 and 6 were also 
observed in the non-healing chronic wounds compared to the healing/healed 
chronic wounds, accounting for 50%, 43%, 93% and 87% increases respectively. 
However, the results did not reach statistical significance (p > 0.05). Somewhat in 
contrast to this general trend, the expression levels of SOCS-7 transcript was 
found to be elevated 43% in the healing/healed chronic wounds when compared 
to that of the non-healing chronic wounds, though again, the results were not 
found to be statistically significant  (p > 0.05). 
Patients were also assessed for signs of clinical and microbiological 
infection. In the cohort, one of the 20 patients who are defined as healing/healed 
had signs of infection, whereas, 7 out of 51 non-healing patients had signs of 
infection. We further compared the levels of gene expression of all the seven 
SOCS members in the non-healing cohort. As shown in Table 3-2, there were no 
difference in all the gene expression leveles of SOCSs when the respective 
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subgroups were compared. Thus there did not appear to be a link between the 
infection of wound tissue and the expression levels of SOCSs. 
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Figure 3-1: The gene expression profile of SOCS-1, -2, -5 and -6 in clinical chronic 
wound biopies 
A, C, E, G Gene expression levels of SOCS-1, -2, -5 and -6 in chronic wound tissues 
(healing/healed n=20, non-healing n=51) are presented on a log scale as box plot; 
B, D, F, H Relative gene expression levels (median) of SOCS-1, -2, -5 and -6 as 
percentage of non-healing group. The expression of each SOCS family member is 
normalised by the expression of CK-19; data was analysed using a Mann Whitney 
test (non parametric t test). 
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Figure 3-2: The gene expression profile of SOCS-3, -4 and -7 transcript in clinical 
chronic wound biopies 
A, C, E Gene expression levels of SOCS-3, -4 and -7 in chronic wound tissues 
(healing/healed n=20, non-healing n=51) are presented on a log scale as box plot; 
B, D, F Relative gene expression levels (median) of SOCS-3, -4 and -7 as 
percentage of non-healing group. The expression of each SOCS family member is 
normalised by the expression of CK-19; * represents p < 0.05, data was analysed 
using a Mann Whitney test (non parametric t test). 
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Table 3-2: The relationship between expression of SOCS transcript and clinical infection in non-healing chronic wound tissues 
SOCS 
Infected (n=7) Non-infected (n=44) 
P value * 
Median IQR Median IQR 
SOCS-1 2 0.25-25.5 3 0-47.5 0.966 
SOCS-2 1.37 0.448-52.148 3.865 0.375-31.36 0.816 
SOCS-3 363 31.25-12173.75 659 159-15168 0.632 
SOCS-4 478 59-10378 606 15-3907 0.742 
SOCS-5 764 89.25-16537.5 475 21-8786 0.722 
SOCS-6 822.223 126.272-2088713.923 257.845 10.636-1901.7 0.268 
SOCS-7 0 0-53889.25 20.5 0-1356.5 0.898 
* Mann-Whitney U test was used for the statistical analysis 
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3.3.2 Protein expression levels of seven SOCS family members in chronic tissues 
Another clinical cohort (Cohort 2) of healing/healed (n = 45) and non-healing (n = 
45) chronic wound samples were used for IHC analysis. A subset of 10 
healing/healed and 10 non-healing chronic wound samples, taken from this 
cohort, were used to explore the protein expression and localisation of SOCS-1 to 
SOCS-7 within these two chronic wound sub-families. 
 
3.3.2.1 Negative staining in chronic tissues 
IHC analysis was performed on the chronic wound tissues from Cohort 2, 
detecting the distribution and expression levels of seven SOCS proteins. Negative 
control staining was precessed along with the experiment to testify the specificity 
of the secondary antibody. As shown in Figure 3-3 and Figure 3-4, there was no 
positive staining observed in all the negative controls in either non-healing chronic 
wound biopsies or healing/healed wound biopsies, suggesting correct secondary 
antibody specificity to the relative primary antibody used in this study. 
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Figure 3-3: Negative control staining in SOCS-1, -2 and -3 primary antibody group 
Pictures were captured at x10 objective magnification; representative images of 
healing/healed (n = 10) and non-healing (n = 10) chronic wound sections are 
shown. 
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Figure 3-4: Negative control staining in SOCS-4, -5 and -6 primary antibody group 
Pictures were captured at x10 objective magnification; representative images of 
healing/healed (n = 10) and non-healing (n = 10) chronic wound sections are 
shown. 
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3.3.2.2 SOCS-1 staining in chronic tissues 
IHC analysis revealed that the majority of chronic wounds tested stained postively 
for SOCS-1 protein (15/20 chronic wounds). The expression of SOCS-1 was 
observed in 7/10 healing/healed and 8/10 non-healing chronic wounds, and 
therefore there was no distinct differences between the two groups. The majority 
of the positive biopsies expressed moderate levels of SOCS-1, with the exception 
of one non-healing chronic wound where the expression was defined as strong 
(Figure 3-5, Figure 3-6).  
A comparison of SOCS-1 expression at the wound edge to that observed 
distal to the wound  (towards normal tissue) revealed  that 6/20 biopsies 
demonstrated an increased expression of SOCS-1 distal to the wound edge, 
although no difference was evident between the healing/healed and non-healing 
groups (3/10 healing/healed and 3/10 non-healing).  
Generally in these chronic wounds, diffuse cytoplasmic staining was 
observed in the mature keratinocytes of the epidermis, although increasing 
nuclear and cytoplasmic intensity was seen in the basal layer distal to the wound 
edge. Most blood vessels were found to be weakly postive for SOCS-1 in all the 
biopsies analysed. Positive staining was also observed in the dermal inflammatory 
infiltrate of some biopsies. 
According to the IHC results, SOCS-1 was predominantly exppresed in 
epidermis, and weakly expressed in dermis in both healing/healed and non-
healing chronic wound biopsies, although no difference was observed on either 
the expression intensity or the distribution patterns of SOCS-1 between the two 
groups. 
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Figure 3-5: The expression pattern of SOCS-1 at the wound edge of clinical chronic wound biopsies 
IHC evaluation of the SOCS-1 protein at the wound edge of healing/healed wounds (left two panels) and non-healing wounds (right three panels), with 
‘distribution’ panels indicating the expression pattern of SOCS-1 in the two groups. Overall, non-healing sections demonstrate areas of strong and moderate 
staining as well as protein distribution (right three panels), whereas healing/healed wound biopsies only indicate moderate staining and protein distribution 
(left panels). Pictures were captured at two objective magnifications (x10 and x20); representative images of healing/healed (n = 10) and non-healing (n = 
10) chronic wound sections are shown; arrows indicate positive staining. 
168 
 
169 
 
Figure 3-6: The expression pattern of SOCS-1 distal to the wound edge in clinical chronic wound biopies 
IHC evaluation of the SOCS-1 protein distal to the wound edge of healing/healed wounds (left two panels) and non-healing wounds (right three panels), 
with ‘distribution’ panels indicating the expression pattern of SOCS-1 in the two groups. Overall, non-healing sections demonstrate areas of strong and 
moderate staining as well as protein distribution (right three panels), whereas healing/healed wound biopsies only indicate moderate staining and protein 
distribution (left panels). Pictures were captured at two objective magnifications (x10 and x20); representative images of healing/healed (n = 10) and non-
healing (n = 10) chronic wound sections are shown; arrows indicate positive staining. 
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3.3.2.3 SOCS-2 staining in chronic wound tissues 
Positive SOCS-2 staining was identified in 17/20 chronic wound biopsies, 8/10 
healing/healed and 9/10 non-healing biopsies respectively. The majority of these 
positively stained biopsies exhibited SOCS-2 expression of moderate intensity, 
albeit 3/20 revealed stronger intensity (2/10 healing/healed, 1/10 non-healing) 
(Figure 3-7, Figure 3-8). Three of the positively stained biopsies showed SOCS-2 
expression in the dermal cell infiltrate, while no expression was observed in the 
epidermis.  
SOCS-2 protein expression was uniform throughout the whole biopsy, 
with only four chronic wounds showing differences between the wound edge and 
distal to the wound (3/10 healing/healed, 1/10 non-healing). Within the 
healing/healed subset, two of these biopsies showed an increased expression 
distal to the wound edge, whereas the other subset demonstated an increased 
SOCS-2 in the dermal infiltrate directly below the leading migratory epidermis 
(which was negatively stained). 
Expression of SOCS-2 protein was generally observed as diffuse 
cytoplasmic in mature keratinocytes, or nuclear in the lower keratinocytes of the 
basal layer. Membranous staining was observed in the very mature keratinocytes 
of some biopsies. SOCS-2 portein was also found in demis. 
In summary, SOCS-2 was observed in both the nucleus and cytoplasm of 
keratinocyte in the epidermis, whereas relatively lower expression of SOCS-2 was 
seen in dermis in both healing/healed and non-healing chronic wound biopsies. 
However, no expressional difference of SOCS-2 was found between 
healing/healed or non-healing wounds and likewise there was no preference of 
SOCS-2 to the wound edge location. 
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Figure 3-7: The expression pattern of SOCS-2 at the wound edge in clinical chronic wound biopies 
IHC evaluation of the SOCS-2 protein at the wound edge of healing/healed wounds (left three panels) and non-healing wounds (right three panels), with 
‘distribution’ panels indicating the expression pattern of SOCS-2 in the two groups. Overall, both healing/healed and non-healing sections demonstrate 
areas of strong and moderate staining as well as protein distribution. Pictures were captured at two objective magnifications (x10 and x20); representative 
images of healing/healed (n = 10) and non-healing (n = 10) chronic wound sections are shown; arrows indicate positive staining. 
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Figure 3-8: The expression pattern of SOCS-2 distal to the wound edge in clinical chronic wound biopies 
IHC evaluation of the SOCS-2 protein distal to the wound edge of healing/healed wounds (left three panels) and non-healing wounds (right three panels), 
with ‘distribution’ panels indicating the expression pattern of SOCS-2 in the two groups. Overall, both healing/healed and non-healing sections demonstrate 
areas of strong and moderate staining as well as protein distribution. Pictures were captured at two objective magnifications (x10 and x20); representative 
images of healing/healed (n = 10) and non-healing (n = 10) chronic wound sections are shown; arrows indicate positive staining. 
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3.3.2.4 SOCS-3 staining in chronic wound tissues  
Positive SOCS-3 staining was observed in all of the non-healing chronic wounds 
(10/10) tested, and in the majority of healing/healed chronic wounds (8/10). Most 
of the positively stained biopsies exhibited SOCS-3 staining of a moderate 
intensity (5/10 healing/healed, 8/10 non-healing), but strong staining was 
observed in 3/10 healing/healed and 2/10 non-healing wounds (Figure 3-9, Figure 
3-10). 
Five of the chronic wounds studied showed increased expression of SOCS-3 
protein in the epidermis distal to the wound edge, and interestingly the majority 
of these were non-healing chronic wounds (1/10 healing/healed, 4/10 non-
healing), suggesting a potential trend of enhanced expression and relocalisation of 
SOCS-3 in the non-healing wound environment. The remaining 15/20 chronic 
wounds studied had uniform epidermal staining throughout the biopsies.  
SOCS-3 expression was seen as diffuse cytoplasmic staining in the mature 
keratinocytes or nuclear in the lower basal and suprabasal layers, particularly 
distal to the wound edge. Many inflammatory cells within the dermis also 
expressed SOCS-3, particularly below the leading wound edge (migratory 
epidermis) and around blood vessels. 
Therefore, SOCS-3 was expressed in all of the non-healing biospsies and 
80% of the healing/healed tissues, and was primarily expressed in epidermis and 
several parts of dermis. Uniformed distribution of SOCS-3 was observed in 
majority (13/18) of the positively stained biopsies, whereas 5 samples (4 non-
healing versus 1 healing/healed) demonstrated elevated SOCS-3 expression in the 
epidermis distal to the wound edge.  
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Figure 3-9: The expression pattern of SOCS-3 at the wound edge in clinical chronic wound biopies 
IHC evaluation of the SOCS-3 protein at the wound edge of healing/healed wounds (left three panels) and non-healing wounds (right three panels), with 
‘distribution’ panels indicating the expression pattern of SOCS-3 in the two groups. Overall, both healing/healed and non-healing sections demonstrate 
areas of strong and moderate staining as well as protein distribution. Pictures were captured at two objective magnifications (x10 and x20); representative 
images of healing/healed (n = 10) and non-healing (n = 10) chronic wound sections are shown; arrows indicate positive staining. 
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Figure 3-10: The expression pattern of SOCS-3 distal to the wound edge in clinical chronic wound biopies 
IHC evaluation of the SOCS-3 protein distal to the wound edge of healing/healed wounds (left three panels) and non-healing wounds (right three panels), 
with ‘distribution’ panels indicating the expression pattern of SOCS-3 in the two groups. Overall, both healing/healed and non-healing sections demonstrate 
areas of strong and moderate staining as well as protein distribution. Pictures were captured at two objective magnifications (x10 and x20); representative 
images of healing/healed (n = 10) and non-healing (n = 10) chronic wound sections are shown; arrows indicate positive staining. 
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3.3.2.5 SOCS-4 staining in chronic wound tissues 
SOCS-4 protein expression was observed in almost all of the chronic wound 
biopsies studied (18/20), and no distinct differences were evident between the 
two subsets (9/10 healing/healed, 9/10 non-healing). The majority of chronic 
wounds had uniform staining of moderate intensity throughout the biopsies 
(16/20), and only two samples exhibited increased (strong) staining for SOCS-4 
(1/10 healing/healed, 1/10 non-healing) (Figure 3-11, Figure 3-12). 
Increased expression of SOCS-4 distal to the wound edge was evident in 
5/10 chronic wounds examined, and this was observed in the healing and non-
healing wounds (3/10 healing/healed, 2/10 non-healing). 
SOCS-4 expression was mostly localised to the nucleus of the lower basal 
and suprabasal cells of the epidermis, but diffuse cytoplasmic staining was also 
observed in the very mature upper keratinocyte layers. SOCS-4 protein was also 
located in demis. 
In summary, SOCS-4 was expression in the epidermis in 90% of each 
healing/healed and non-healing chronic wounds, however, no difference was 
observed between the two groups regarding expression levels or distribution 
patterns. 
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Figure 3-11: The expression pattern of SOCS-4 at the wound edge in clinical chronic wound biopies 
IHC evaluation of the SOCS-4 protein at the wound edge of healing/healed wounds (left three panels) and non-healing wounds (right three panels), with 
‘distribution’ panels indicating the expression pattern of SOCS-4 in the two groups. Overall, both healing/healed and non-healing sections demonstrate 
areas of strong and moderate staining as well as protein distribution. Pictures were captured at two objective magnifications (x10 and x20); representative 
images of healing/healed (n = 10) and non-healing (n = 10) chronic wound sections are shown; arrows indicate positive staining. 
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Figure 3- 12: The expression pattern of SOCS-4 distal to the wound edge in clinical chronic wound biopies 
IHC evaluation of the SOCS-4 protein distal to the wound edge of healing/healed wounds (left three panels) and non-healing wounds (right three panels), 
with ‘distribution’ panels indicating the expression pattern of SOCS-4 in the two groups. Overall, both healing/healed and non-healing sections demonstrate 
areas of strong and moderate staining as well as protein distribution. Pictures were captured at two objective magnifications (x10 and x20); representative 
images of healing/healed (n = 10) and non-healing (n = 10) chronic wound sections are shown; arrows indicate positive staining. 
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3.3.2.6 SOCS-5 staining in chronic tissues 
A generally weaker staining intensity of SOCS-5 protein was observed compared 
to that seen for the other SOCS proteins, but was still identified in almost all the 
chronic wounds studied (8/10 healing/healed, 8/10 non-healing) (Figure 3-13, 
Figure 3-14). Uniform expression was observed in both subsets, albeit 2/10 non-
healing biopsies showed an increased SOCS-5 expression distal to the wound edge. 
SOCS-5 staining was mainly cytoplasmic, and observed in all layers of the epidemis, 
whereas, distribution of SOCS-5 was also found in dermis. 
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Figure 3-13: The expression pattern of SOCS-5 at the wound edge in clinical chronic wound biopies 
IHC evaluation of the SOCS-5 protein at the wound edge of healing/healed wounds (left panel) and non-healing wounds (right two panels), with 
‘distribution’ panels indicating the expression pattern of SOCS-5 in the non-healing wounds. Overall, the healing/healed sections demonstrate areas of 
moderate staining, whereas non-healing biopsies display moderate staining of SOCS-5, as well as showing its protein distribution. Pictures were captured at 
two objective magnifications (x10 and x20); representative images of healing/healed (n = 10) and non-healing (n = 10) chronic wound sections are shown; 
arrows indicate positive staining. 
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Figure 3-14: The expression pattern of SOCS-5 distal to the wound edge in clinical chronic wound biopies 
IHC evaluation of the SOCS-5 protein distal to the wound edge of healing/healed wounds (left panel) and non-healing wounds (right two panels), with 
‘distribution’ panels indicating the expression pattern of SOCS-5 in the non-healing wounds. Overall, the healing/healed sections demonstrate areas of 
moderate staining, whereas non-healing biopsies display moderate staining of SOCS-5, as well as showing its protein distribution. Pictures were captured at 
two objective magnifications (x10 and x20); representative images of healing/healed (n = 10) and non-healing (n = 10) chronic wound sections are shown; 
arrows indicate positive staining. 
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3.3.2.7 SOCS-6 staining in chronic tissues 
SOCS-6 protein expression was observed in 12/20 chronic wounds, equally in the 
healing/healed (6/10) and non-healing chronic wounds (6/10). The IHC analysis 
revealed the staining to be of moderate intensity in most biopsies (5/10 
healing/healed, 5/10 non-healing), with only two biopsies showing particularly 
stronger expression of SOCS-6 (1/10 healing/healed, 1/10 non-healing (Figure 3-
15, Figure 3-16). 
Increased SOCS-6 expression was identified in the epidermal layers distal 
to the wound edge in 4/20 biopsies examined (2/10 healing/healed, 2/10 non-
healing), although the remaining biopsies showed uniform staining throughout 
the tissue samples. 
The nucleus of basal and suprabasal keratinocytes were particularly 
positive for SOCS-6. However, cytoplasmic staining in other layers was also 
observed. In addtion, dermal expression of SOCS-6 was also observed. 
Although SOCS-6 was observed in both epidermis and dermis in both 
healing/healed and non-healing chronic wounds, there was no difference 
between the two groups in terms of either the expression levels or distribution 
patterns of SOCS-6. 
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Figure 3-15: The expression pattern of SOCS-6 at the wound edge in clinical chronic wound biopies 
IHC evaluation of the SOCS-6 protein at the wound edge of healing/healed wounds (left three panels) and non-healing wounds (right three panels), with 
‘distribution’ panels indicating the expression pattern of SOCS-6 in the two groups. Overall, both healing/healed and non-healing sections demonstrate 
areas of strong and moderate staining as well as protein distribution. Pictures were captured at two objective magnifications (x10 and x20); representative 
images of healing/healed (n = 10) and non-healing (n = 10) chronic wound sections are shown; arrows indicate positive staining. 
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Figure 3-16: The expression pattern of SOCS-6 distal to the wound edge in clinical chronic wound biopies 
IHC evaluation of the SOCS-6 protein distal to the wound edge of healing/healed wounds (left three panels) and non-healing wounds (right three panels), 
with ‘distribution’ panels indicating the expression pattern of SOCS-6 in the two groups. Overall, both healing/healed and non-healing sections demonstrate 
areas of strong and moderate staining as well as protein distribution. Pictures were captured at two objective magnifications (x10 and x20); representative 
images of healing/healed (n = 10) and non-healing (n = 10) chronic wound sections are shown; arrows indicate positive staining. 
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3.3.2.8 SOCS-7 staining in chronic tissues 
SOCS-7 expression was examined throughout the healing/healed and the non-
healing chronic wound tissue sections. The sections demonstrated no significant 
staining profiles when tested with either of the two antibodies avaliable within 
our laboratories. Thus, this molecule appears to demonstrate weak to no 
expression in the tissues tested in the present study.  Typical negative staining 
patterns obtained for this molecule using one of the antibodies (sc-8291) are 
shown in Figure 3-17. 
 
 
Figure 3-17: The expression pattern of SOCS-7 in clinical chronic wound biopies 
IHC evaluation of the SOCS-7 protein in healing/healed wounds (left panel) and 
non-healing wounds (right panel). Negative staining was seen throughout the 
cohort tested. Representative images of healing/healed (n = 10) and non-healing 
(n = 10) chronic wound sections are shown. 
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3.4. Discussion 
The present data highlighted differences in gene expression of SOCS family 
members between the healing/healed and non-healing chronic wounds. Notably, 
significant differences were obtained for the gene expression of SOCS-3 and -4 
between these two groups, accounting for 81% and 93% decreases in the 
healing/healed group. In addition, gene level screening performed in this study 
demonstrated 50%, 43%, 93% and 87% higher, albeit not significant, expression of 
SOCS-1, 2, 5 and 6 respectively in non-healing chronic venous leg ulcer patients, 
whereas a 43% decreased gene expression of SOCS-7 was observed in this group, 
yet not statistically significant either. Hence, the gene expression profiles suggests 
an association between SOCS-3 and SOCS-4 and the healing potential of chronic 
wounds. In order to examine the protein expression and localisation of SOCS 
family members IHC analysis was undertaken. However, the significance of the 
gene expression data was not supported by the protein level and the IHC analysis 
did not reveal any obviously distinct differences in SOCS expression between the 
non-healing and healing/healed chronic wounds. This is contadictory to the 
transcript analysis, though such differences between transcript and IHC analysis 
may be partially explained by the smaller subset of samples used in the IHC 
analysis than in the q-PCR analysis resulting to the more finate avaliability and 
suitability of clinical sections for staining in comparison to the relative ease of 
generating large amounts of cDNA for gene expression analysis. This discrepancy 
may also have arisen due to the qualitative nature of the IHC study or may be 
some aspect of post-transcriptional regulation. Additional clarification of this 
observation is required in a larger cohort of chronic wounds and is also warrented 
within cohorts of acute and chronic wounds, though such resources were not 
available for this study.  
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In the current study, SOCS-1 to SOCS-6 were all found to be expressed in 
both epidermal keratinocytes and dermal area. This suggested the extensive 
expression of the SOCS proteins in several cell types involved in wound healing. 
Moreover, this finding potentially suggested that SOCS proteins may play distinct 
regulatory roles in different cells in the healing process, although further 
investigation is required to identify the specific molecule(s) or downstream 
signalling pathway(s) which may be regulated by SOCS. Efforts to elucidate 
aspects of this will be undertaken in two such cell types, keratinocytes and 
endothelial cells, within the remainder of this study. 
Regarding the expression patterns of SOCS protein in different cell types 
in chronic wounds, SOCS-1 was observed in mature keratinocytes and dermal 
inflammatory infiltrate cells, and surrounding blood vessels despite the weak 
expression level. SOCS-2 was found expressed in cytoplasm of mature 
keratinocytes in the epidermis and the nuclear compartment of lower 
differentiated keratinocytes in the basal layer. Of note, SOCS-3 was found 
extensively expressed in all layers of keratinocytes of the epidermis, inflammatory 
infiltrate cells and surrounding blood vessels in dermis in all positive stained 
chronic wounds, whereas SOCS-4, SOCS-5 and SOCS-6 were only expressed in all 
layers of keratinocytes of epidermis. The positive expression of SOCS-1 to 6 in 
keratinocytes suggested the existence of the cytokine receptors which could lead 
to the synthesis of SOCS-1 to 6 in this cell type, as well as the potential regulatory 
role of these SOCS proteins in the epidermis of chronic wound. For example, a 
previous study has demonstrated that human keratinocytes are highly susceptible 
to IFN-, and following induction SOCS-1 acts as a feedback negative regulator to 
protect keratinocytes from excessive IFN-stimulation (Madonna et al., 2008). 
This is in agreement with our finding, and may imply that the positive expression 
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of SOCS-1 in the epidermis of the chronic wounds in our study may in part due to 
the IFN- stimulation. 
SOCS family members have been previously linked to inflammation due to 
their regulatory roles in pro-inflammatory cytokine signalling. For example, 
studies suggested that SOCS-1 negatively regulates the pro-inflammatory cytokine 
IFN-, and inhibits IFN--dependent STAT-1 activation (Alexander et al., 1999, 
Tanaka et al., 2008). Another SOCS protein, SOCS-3, acting as a anti-inflammatory 
regulator, mediates IL-6-gp130 signalling by preventing the activation of STAT-3 
(Croker et al., 2003, Lang et al., 2003). In addition, SOCS-3 was also found to be a 
negative regulator of IFN--induced STAT-1 activation (Song and Shuai, 1998). 
Therefore, the expression of SOCS-1 and SOCS-3 in the dermal infiltrate may 
suggest that they are induced in the recruited infiltrating cells to regulate pro-
inflammatory cytokine signalling. However, dual fluorescent staining would be 
required to identify whether these positive stained cells were T-lymphocytes, 
macrophages, fibroblasts or other cells.Furthermore, direct evidence indicates 
that SOCS proteins may hold the potential to influence the wound-healing process 
by regulating the function of wound site resident cells. A study by Linke et al. has 
shown that keratinocyte proliferation and migration are strongly disturbed by the 
presence of SOCS-3, which contributes to impaired wound healing (Linke et al., 
2010b). Other study demonstrated that the exacerbated inflammation which 
characterises chronic wounds is shown to be associated with overexpression of 
SOCS-3 (Linke et al., 2010a). These data may explain the significantly increased 
gene expression of SOCS-3 transcript levels in the non-healing chronic wound 
biopsies compared to that in the healing/healed chronic wound biopsies, 
suggesting that the upregulation of SOCS-3 correlated with impaired keratinocyte 
migration and proliferation as well as poor healing results. In addition, according 
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to the SOCS-3 IHC staining pattern, the distinct proportion (1 : 4) of increased 
SOCS-3 protein expression in the epidermis distal to the wound edge throughout 
20 chronic wound biospies (1/10 healing/healed, 4/10 non-healing) are 
noteworthy. This suggest the loss of SOCS-3 expression on the leading migratory 
epidermis in the healing/healed chronic wound or/and the relocation of SOCS-3 
protein between healing/healed and non-healing chronic wounds. Taken together, 
SOCS-3 may potentially act as biomarkers and/or potential therapeutics to 
manage chronic wounds, although additional study is required to fully elucidate 
this role. Thus, establishment of a larger cohort of these tissues, as well as 
exploring SOCS function and expression across acute and chronic wound tissue 
and normal skin would be of interest and benefit. 
SOCS-4 has been previously demonstrated to be induced by EGF and 
inhibit the EGFR signalling by competing for the binding motif on EGFR with STAT-
3 (Kario et al., 2005, Bullock et al., 2007). According to the IHC staining results, 
SOCS-4 was found to be expressed in 18 chronic wounds biopsies out of 20, and 
the expression of SOCS-4 primarily localised in the nucleus of the lower basal and 
suprabasal layers in epidermis. This is in agreement with the distribution of EGFR 
which is located in the basal layer and first suprabasal layer of adult epidermis 
(Nanney et al., 1990). Taken together, this may represent a link where SOCS-4 
expression in these chronic wounds could potentially be induced by EGF 
stimulation, and subsequently negatively regulate EGFR signalling and STAT-3 
activation, contributing to the modulation of keratinocyte behaviour, though 
further study is needed to fully explore this link. Although SOCS-5, the greatest 
sequence homolgy to SOCS-4, is also documented to be induced by EGF as a 
feedback negative suppressor of EGFR signalling (Kario et al., 2005), the 
expression pattern, diffuse cytoplasmic expression in almost all layers of 
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epidermis, in the chronic wound biopsies was different from SOCS-4. This result 
may suggest an alternative role of SOCS-5 to SOCS-4 in keratinocytes in chronic 
wounds. 
In summary, this initial chapter explored the expression profiles of SOCS-1 
to SOCS-7 in chronic healing/healed and non-healing samples. Whilst many of 
these members do not appear to be differentially expressed or localised between 
these two chronic sub-types, it does support a differential gene expression of 
SOCS-3 and -4. There is also evidence to suggest that SOCS-3 may undergo 
relocalisation between the two chronic subtypes. Thus, whilst limited by cohort 
size, this early data suggests involvement of SOCS-3 and -4, either functionally or 
as potential genetic biomarkers, in these chronic samples. To follow on from this, 
further characterisation of the cellular role of SOCS-3 and SOCS-4 in human 
keratinocytes and endothelial cells wil be undertaken throughout the remainder 
of the thesis to support or clarify the potential of SOCS-3 and SOCS-4 in chronic 
wounds highlighted in this chapter. 
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Chapter IV 
Establishment of SOCS-3 expression 
and SOCS-4 knockdown models
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4.1 Introduction 
SOCS-3 is one of the most extensively studied SOCS family members. A previous in 
vivo study has indicated that knockdown of SOCS-3 in epithelial basal 
keratinocytes contributes to severe skin inflammation, indicating its important 
role in skin homeostasis (Uto-Konomi et al., 2012). However, the basal 
keratinocyte-specific overexpression of SOCS-3 also led to impaired wound 
healing due to the suppression of keratinocyte proliferation and migration in a 
transgenic mouse overexpressing SOCS-3 (Linke et al., 2010b). Moreover, in 
addition to disrupting acute wound healing, mice overexpressing SOCS-3 also 
exhibits a prolonged inflammation phenotype that resembled the characteristics 
of chronic wounds (Linke et al., 2010a). Taken together, these data demonstrate 
the important regulatory role of SOCS-3 in the wound healing process, and 
highlight the importance of maintaining the balance of SOCS-3 expression in 
wound healing.  
SOCS-4 is the most poorly investigated member of the SOCS family. 
Studies have indicated that SOCS-4 plays a regulatory roles in inflammation 
caused by influenza and parasite infection (Kedzierski et al., 2014, Hu et al., 2010), 
suggesting its regulatory potential in inflammation, and hence a potential link to 
inflammatory stage of wound healing. Another investigation on genetic alteration 
and evolution in animals which live in high-altitude environments suggested that 
SOCS-4 may hold the potential to regulate HIF-1,a mediator involved in the 
adaptation to hypoxia (Wang et al., 2015). Since hypoxia occurs in the early 
wound stages, such evidence provides another clue as to the potential role of 
SOCS-4 in the early stage of wound healing. 
Keratinocytes are of importance to injury response and are involved in 
secreting cytokines for the recruitment of other cells, producing growth factors to 
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improve collagen formation and angiogenesis, and undergoing migration and 
proliferation to fully enable epithelialisation (Pastar et al., 2008). Endothelial cells 
are another key cell type that is involved in the wound healing process, especially 
in angiogenesis. In response to a variety of chemotactic and angiogenic signals, 
the proliferation and migration of endothelial cells occurs, and various tube-like 
structures and new capillary networks are formed to supply sufficient nutrient 
and oxygen to the surrounding environment involved in the wound healing 
process, therefore relieving the hypoxic pressure of the lesion. 
The previous chapter has highlighted the differential gene expression of 
SOCS-3 and SOCS-4 between chronic healing/healed and non-healing wounds and 
also indicated potential relocalisation of SOCS-3 between these wound types, 
though, contrastingly, IHC analysis does not suggest any differential expression. 
Whilst the initial chapter raises a number of questions, when the results are 
viewed in conjunction with the literature there appears potential for SOCS-3 and 
SOCS-4 to influence the process of wound healing. 
The distribution of SOCS-3 and SOCS-4 in the chronic wounds biopsies 
from the IHC results in Chapter III indicated that SOCS-3 and SOCS-4 were 
predominently expressed in keratinocytes of epidermis, whereas the positive 
expression of SOCS-3 and -4 in dermis suggested their potential expression in 
endothelial cells. In addition, previous studies has shown that knockdown and 
overexpression of SOCS-3 in keratinocytes resulted in severe disruption of 
inflammation homeostasis and skin repair (Linke et al., 2010a, Linke et al., 2010b, 
Uto-Konomi et al., 2012). Therefore, SOCS-3 and -4 may hold the potential to 
regulate function of keratinocytes and endothelial cells, subsequently contributing 
to the wound healing process.  
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To investigate the potential biological and regulatory role of SOCS-3 and 
SOCS-4 in wound healing, human epithelial keratinocytes (HaCaT) and endothelial 
cells (HECV) were chosen to establish in vitro models to explore the cellular 
importance of SOCS-3 and SOCS-4. The current chapter focuses on establishment 
of in vitro models using both ribozyme and siRNA SOCS-4 knockdown techniques, 
as well as SOCS-3 expression, through coding sequence synthesis and transfection. 
Successful established models will subsequently be used to characterise and 
discuss the fucntional importance of SOCS-3 and SOCS-4 in later chapters. 
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4.2 Methods and materials 
4.2.1 Synthesis of SOCS-4 targeting ribozyme by touchdown PCR 
Touchdown PCR was carried out using REDTaq® Ready MixTM PCR Reaction Mix 
(Sigma-aldrich, Dorset, UK) with MgCl2 and two specific primer pairs, SOCS-4 rib 
F1 vs rib R1 and SOCS-4 rib F2 vs rib R2, to synthesise two different transgene, 
labelled as ribozyme 1 and ribozyme 2, which target different specific GUC or AUC 
sites to the mRNA of SOCS-4. PCR reaction conditions were used as follows:  
 Step 1: Initial denaturing period - 94ᵒC for 5 minutes 
 Step 2: Denaturing stage - 94ᵒC for 20 seconds 
 Step 3: Series of annealing stages - 70ᵒC for 30 seconds, 60ᵒC for 30 
seconds, 58ᵒC for 30 seconds, 54ᵒC for 30 seconds, 50ᵒC for 30 seconds 
 Step 4: Extension stage - 72ᵒC for 30 seconds 
 Step 5: Additional extension stage - 72ᵒC for 10 minutes  
 Step 2 - 4 were repeated over 40 cycles with 8 cycles for each 5 different 
annealing temperature. 
2% agarose gel stained with SYBR safe DNA gel stain was used for gel 
electrophoresis to verify the presence of the synthesised transgene. GenScript 
PCR DNA Ladder (Range 100-2000bp) was used as ladder. 
 
4.2.2 TOPO TA cloning of SOCS-4 targeting ribozyme into the pEF6/V5-His-TOPO 
plasmid vector and incorporated transgene orientation check 
This methodology is described in section 2.11.2 of Chapter II. 
Specifically for orentation analysis of SOCS-4 ribozyme plasmid colonines, 
there are 90bp between the T7F promoter and the beginning of the transgene 
insert. Primer RbBMR and RbToPF, holding complementary sequences, recognise 
and bind to a central catalytic region of each ribozyme transgene sequences that 
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are common in both ribozymes used. Reactions utilising the T7F vs RbBMR primer 
pairs with the predicted size of 143bp (ribozyme 1) and 147bp (ribozyme 2) was 
used to verify the correct orientation for each inserted transgene, whereas the 
reaction containing the combination of T7F vs RbToPF primers with the predicted 
size of 144bp (ribozyme 1) and 136bp (ribozyme 2), was used to identify incorrect 
orientation. The absence of a band from both reactions indicated a closed plasmid 
configuration with no ribozyme insert, whereas the presence of a band in both 
reactions indicated a mixed orientation of the ribozyme. 
 
4.2.3 Amplification of complete coding sequence of SOCS-3 using PCR 
4.2.3.1 SOCS-3 coding sequence primer pair specificity check and annealing 
temperature confirmation 
Five primer pairs, SOCS-3 exp F1 vs exp R, exp F2 vs exp R, exp F3 vs exp R, exp F4 
vs exp R and exp F5 vs exp R, that correspond to the SOCS-3 coding sequence 
were used to amplify PLC-PRF-5 and SKMES cDNA samples at the same PCR 
condition to initial screening stage in order to test their specificity.  
Furthermore, primer pairs of SOCS-3 exp F4 vs exp R and SOCS-3 exp F4 vs exp R 
were used following similar conditions to the initial PCR screen but over a range of 
four differing annealing temperature, each reaction corresponding to either 52°C, 
54°C, 56°C or 58°C annealing, to determine the optimal annealing temperature. 
 
4.2.3.2 Secondary screening of SOCS-3 on normal cell lines/tissues and SOCS-3 
coding sequence amplification with high fidelity enzyme mix kit 
Eight RNA reverse transcribed cDNA samples from different normal tissue and cell 
lines (Table 2-2) were amplified using SOCS-3 F8 vs R8 primer pair to detect the 
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expression of SOCS-3. The PCR conditions were the same as those used for SOCS-3 
initial screening. 
A High fidelity enzyme mix kit (Fisher Scientific UK, Loughborough, UK) 
was used to amplify SOCS-3 coding sequence. The reaction mix and PCR 
conditions were used as follows: 
PCR reaction mix: 
 10x High Fidelity PCR Buffer with MgCl2 - 2.5μl 
 dNTP Mix 2.5nM - 2.5μl 
 Forward Primer: SOCS-3 exp F4 - 2.5μl 
 Reverse Primer: SOCS-3 exp R- 2.5μl 
 High Fidelity PCR Enzyme Mix - 1.3μl 
 MRC-5 cDNA - 1μl 
 Nuclease-free water - 12.7μl 
PCR reaction conditions: 
 Step 1: Initial denaturing period - 94ᵒC for 3 minutes 
 Step 2: Denaturing stage - 94ᵒC for 30 seconds 
 Step 3: annealing stage - 58ᵒC for 30 seconds 
 Step 4: Extension stage - 72ᵒC for 1 minutes 
 Step 5: Additional extension stage - 72ᵒC for 10 minutes 
Step 2 - 4 were repeated for 35 cycles. 
 
4.2.4 Extraction of PCR product from agarose gel 
The extraction of PCR product was undertaken using GenEluteTM Gel Extraction Kit 
(Sigma-aldrich, Dorset, UK). The excised gel slice containing PCR product was 
weighted as 220mg. After calculation, 660μl of Gel Solubilisation Solution was 
added into the PCR product containing microfuge tube before incubation at 60ᵒC 
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for 10 minutes to completely dissolve the gel. Then, 220μl of absolute isopropanol 
was mixed with the gel dissolved solution until homogenous. GenElute Binding 
Column was placed into a 2ml collection column followed by the addition of 500μl 
Column Preparation Solution. The collection column was then centrifuged for 1 
minute, and the flow-through liquid was removed. The mixture of isopropanol 
and gel dissolved solution was then loaded into the pre-prepared binding column 
followed by centrifuging for 1 minute, and the flow-through liquid was discarded. 
700μl of Wash Solution was added into the binding column, and the flow-through 
liquid was again discarded after 1 minute of centrifuging. Such wash step was 
repeated once, without the addition of any Wash Solution to remove the excess 
liquid completely. The binding column was then transferred into a fresh collection 
column. 50μl of Elution Solution was pre-warmed at 65ᵒC and was added into the 
binding column before centrifuging for 1 minute to obtain the purified SOCS-3 
coding sequence product. The concentration of the extracted DNA product was 
measured using a  NanoPhotometerTM (IMPLEN; Geneflow ltd., Lichfield, UK). 
 
4.2.5 TOPO TA cloning of SOCS-3 coding sequence into the pEF6/V5-His-TOPO 
plasmid vector and incorporated transgene orientation check  
The total 5µl cloning reaction was mixed and stored on ice for 20 minutes in 
advance to One Shot Chemical Transformation, and the condition used for TOPO 
cloning reaction was as follows: 
 Purified SOCS-3 coding sequence - 3µl 
 Salt solution - 1µl 
 TOPO vector - 1µl 
5µl of TOPO cloning reaction was added into one vial of One Shot TOP10 
Chemically Competent E. coli. and mixed gently by stirring using pipette tip. The 
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vial was stored on ice for 30 minutes before heat-shocking at 42ᵒC for 30 seconds 
followed by immediately transferring to ice. To the vial was added 250µl room 
temperature SOC medium and shaked at a 45ᵒ angle at 225rpm at 37ᵒC for 1 hour. 
After the incubation period, the transformed products from the vial were 
spread in two seeding density on a pre-warmed agar petri dish containing 
100µl/ml ampicillin followed by incubating overnight at 37ᵒC. 
Ten colonies from the petri dish were randomly picked and the SOCS-3 
coding sequence insertion and the orientation of the incorporated SOCS-3 coding 
sequence was checked by RT-PCR reaction using primer combination of T7F vs 
BGHR (predicted size of 942bp, indicative of product insertion), T7F vs SOCS-3 exp 
F4 (predicted size of 768bp, indicative of incorrect orientation) and T7F vs SOCS-3 
exp R (predicted size of 768bp, indicative of correct orientation). The details of the 
PCR reaction mix was as follows: 
SOCS-3 coding sequence incorporation check mix 
 GoTaq Green master mix - 8µl 
 T7F plasmid specific forward primer - 1µl 
 BGHR plasmid specific reverse primer - 1µl 
 PCR water -6µl 
Correct orientation primer pair mix 
 GoTaq Green master mix - 8µl 
 T7F plasmid specific forward primer - 1µl 
 SOCS-3 coding sequence specific reverse primer (SOCS-3 exp R) - 1µl 
 PCR water -6µl 
Incorrect orientation primer pair mix 
 GoTaq Green master mix - 8µl 
 T7F plasmid specific forward primer - 1µl 
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 SOCS-3 coding sequence specific forward primer (SOCS-3 exp F4) - 1µl 
 PCR water -6µl 
Each colony was inoculated into all reaction mixes using a sterile pipette, 
and the reaction mixes were placed in a thermal cycler. The PCR reaction 
conditions were used as follows: 94ᵒC for 5 minutes, followed by 30 cycles of 94ᵒC 
for 30 seconds, 55ᵒC for 40 seconds and 72ᵒC for 1 minute with a final extension 
step of 72ᵒC for 10 minutes. Gel electrophoresis on a 0.8% agarose gel stained 
with SYBR safe DNA gel stain was used to separate the RT-PCR reaction products, 
and the gel was visualised under UV light followed by image capture. 
There are 264bp between the first base pair of T7F promoter to the last 
base pair of the BGHR site in the empty plasmid. Since the full length of SOCS-3 
coding sequence is 678bp, the predicted product size that the T7F vs BGHR primer 
pair amplified from the SOCS-3 coding sequence incorporated plasmid is 942bp. 
Based on the length of 90bp between the T7F promoter and the beginning of the 
incorporated transgene as well as 678bp of SOCS-3 coding sequence, the primer 
pair of T7F vs SOCS-3 exp R and T7F vs SOCS-3 exp F4, both amplifying the product 
with the predicted size of 768bp, were used to verify the correct and incorrect 
orientation for the inserted transgene. 
 
4.2.6 Statistical analysis 
Statistical analysis was undertaken using the SigmaPlot 11 and Graphpad Prism 6 
statistical software packages. Data was found to be normalised as was therefore 
analysed using t-test. Values of p < 0.05 (*), p < 0.01 (**), p < 0.001 (***) and p < 
0.0001 (****) were regarded as statistically significant. 
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4.3 Results 
4.3.1 Expression profile of seven SOCS family members (SOCS-1 to SOCS-7) in 
epithelial and endothelial cell line candidates 
The expression levels of SOCS-3 and -4 were examinied along with the other five 
SOCS members (SOCS-1, -2, -5, -6 and -7) to determine the strategy for the 
establishment of in vitro models. RNA was isolated from HaCaT and HECV wild-
type cells followed by reverse transcription to cDNA. Such cDNA samples were 
used as templates for amplification using GoTaq Green Master Mix and the primer 
pairs of SOCS-1 F1 vs ZR1, SOCS-2 F8 vs R8, SOCS-3 F8 vs R8, SOCS-4 F8 vs R8, 
SOCS-5 F1 vs ZR1, SOCS-6 F1 vs ZR1, SOCS-7 F9 vs R9 and GAPDH F8 vs R8 (Table 
2-3). The PCR products were loaded on 0.8% agarose gel, and were separated by 
gel electrophoresis followed by being visualised under blue light and image 
capture (Figure 4-1). 
SOCS-2, SOCS-4, SOCS-5 and SOCS-6 were expressed in both HaCaT and 
HECV cell, furthermore, the gene expression levels of such four SOCS family 
members exhibited higher expression in HECV cells to that of in HaCaT cells. 
However, there was no expression of SOCS-1, SOCS-3 and SOCS-7 in either HaCaT 
or HECV cells. 
Following the gene expression profile of SOCS-3 and -4 in the clinical 
cohort in Chapter III and the expression levels of these two molecules in HaCaT 
and HECV cells, it was decided to establish knockdown and expression strategies 
for SOCS-4 and SOCS-3 respectively to further explore the significance of these 
SOCS members in HaCaT and HECV cell wound model systems. 
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Figure 4-1: Screening of SOCS-1 to SOCS-7 in HaCaT and HECV cell lines 
HaCaT and HECV cDNA samples were screened for seven SOCS family members and GAPDH. The predicted product size of each PCR product is: SOCS-1 
(108bp), SOCS-2 (461bp), SOCS-3 (521bp), SOCS-4 (541bp), SOCS-5 (117bp), SOCS-6 (131bp), SOCS-7 (590bp) and GAPDH (475bp), -ve represents 
amplification of PCR water instead of cDNA 
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4.3.2 Generation of SOCS-4 knockdown models and SOCS-3 expression models 
4.3.2.1 Generation of SOCS-4 knockdown models using ribozyme transgene 
Touchdown PCR was carried out to synthesise two different transgenes, labelled 
as ribozyme 1 and ribozyme 2. Two products were visualised below 100bp which 
is in agreement with the size of the two transgene, ribozyme 1 (85bp) and 
ribozyme 2 (81bp) (Figure 4-2 A). 
The synthesised transgenes (ribozyme 1 and ribozyme 2) were cloned into 
a pEF6/V5-His-TOPO plasmid vector, and the transgene orientation was checked 
using PCR and a combination of plasmid specific and ribozyme specific primers as 
previously described in the methodology sections (Figure 4-2 B, C). Colony 1, 2, 7 
and 8 from the ‘Ribozyme 1 petri dish’ and colony 4 and 8 from the ‘Ribozyme 2 
petri dish’ showed positive expression following amplification with the incorrect 
orientation (T7F vs RbToPF) primer pair rather than the correct orientation pair 
(T7F vs RbBMR), indicating that the transgene was mostly incorporated into those 
colonies in the incorrect orientation. Moreover, colony 3 from ‘Ribozyme 1 petri 
dish’ showed positive expression with both primer pairs, demonstrating a mixture 
of correct and incorrect transgene inserts in such colony, whereas no expression 
was found in both lanes for colony 3 picked from ‘Ribozyme 2 petri dish’, 
suggesting no desired transgene was incorporated into the plasmid. However, 
colony 4 and 5 from the ‘Ribozyme 1 petri dish’ and colony 1, 2, 5, 6 and 7 from 
the ‘Ribozyme 2 petri dish’ exhibited positive expression following amplification 
with the correct orientation primer pair and negative expression following 
amplification with the incorrect orientation primer pair. This showed that the 
majority of the plasmids in those colonies were incorporated with the correct 
orientation of the transgene inserts.  
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Two of the eight randomly picked colonies with correctly orientation 
transgene inserts from each petri dish were chosen for further incubation. Thus, 
colony 4 and 5 from the ‘Ribozyme 1 petri dish’ and colony 1 and 2 from the 
‘Ribozyme 2 petri dish’ were inoculated into two universal tubes containing 5ml of 
selective LB broth (containing 100µg/ml ampicillin) before plasmid extraction was 
undertaken. Following this, the extracted plasmid was run on a 0.8% agarose gel 
to confirm the presence and the size of the plasmid (Figure 4-2 D). The predicted 
sizes of ribozyme 1 and ribozyme 2 incorporated into plasmids are 5925bp and 
5921bp respectively which was indicated for all samples. The concentration of 
each plasmid sample was measured and shown as follows (Table 4-1): 
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Figure 4-2: Ribozyme transgene synthesis, incorporation and plasmid extraction 
A. Ribozyme transgenes, synthesised by touchdown PCR, were loaded on 2% 
agarose gel and separated by gel electrophoresis and two bands were visualised 
below 100bp marker. The predicted size of ribozyme 1 and ribozyme 2 transgene 
are 85bp and 81bp respectively; B, C. Colonies picked from petri dishes spread 
with E. coli. that had been transfected with ribozyme 1 and 2 incorporated 
plasmid were inoculated into PCR reaction mix for transgene orientation check. 
The ’√’ mark represents correct orientation that was verified by primer 
combination of T7F vs RbBMR (143bp for ribozyme 1 and 147bp for ribozyme 2), 
whereas, ‘X’ indicates the incorrect orientation which was confirmed by primer 
pair of T7F vs RbToPF (144bp for ribozyme 1 and 136bp for ribozyme 2). The ‘□’ 
mark was used to indicate colonies which were chosen for further plasmid 
amplification; D. The extracted plasmid containing ribozyme 1 or ribozyme 2 were 
mixed with loading buffer and loaded on 0.8% agarose gel for gel electrophoresis. 
The predicted size of ribozyme 1 incorporated plasmid (rib 1 col4, rib1 col5) is 
5925bp, whereas, the predicted size of the plasmids inserted with ribozyme 2 
(rib2 col1, rib2 col2) is 5921bp. 
Table 4-1: Concentration measured for the ribozyme incorporated plasmids 
No. Plasmid A260/280 Concentration (ng/µl) 
1 Ribozyme 1 colony 4 1.862 540 
2 Ribozyme 1 colony 5 1.914 550 
3 Ribozyme 2 colony 1 1.873 665 
4 Ribozyme 2 colony 2 1.895 540 
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4.3.2.2 Verification of SOCS-4 knockdown by ribozyme transgene in epithelial 
and endothelial cell models through RT-PCR, q-PCR and western blotting  
SOCS-4 targeting ribozyme transgene incorporated plasmids and control plasmids 
(pEF6) were transfected via electroporation. After the blasticidin selection period, 
RT-PCR, q-PCR and western blot were used to verify knockdown of SOCS-4 in 
HaCaT and HECV. RNA was isolated from HaCaT and HECV cells transfected with 
control plasmid (pEF6) and ribozyme incorporated plasmids before reverse 
transcription to obtain cDNA samples respectively. SOCS-4 and GAPDH transcripts 
were amplified through RT-PCR in such cDNA samples, and the amplified products 
were loaded on a 0.8% agarose gel for gel electrophoresis followed by being 
visualised and images captured. Primer combination of SOCS-4 F8 vs R8, SOCS-4 
F2 vs ZR2, GAPDH F8 vs R8, GAPDH F2 vs ZR2 and Actin F10 vs ZR10 were used for 
RT-PCR and q-PCR amplification. 
SOCS-4 knockdown was achieved using ribozyme transgene technology in 
both epithelial and endothelial cell models (HaCaT and HECV). Transcript 
expression levels of SOCS-4 in the transfected cells were examined using RT-PCR 
(Figure 4-3 A, B). The expression of SOCS-4 in two of the four transfected HaCaT 
cell lines (rib1 col4, rib2 col1) was reduced 36% and 51% respectively comparing 
to the respective control cells (transfected with empty pEF6 plasmids alone), 
whereas all four of the transfected HECV cell line (rib1 col4, rib1 col5, rib2 col1, 
rib2 col2) showed a 30%, 33%, 18% and 23% decreased expression of SOCS-4 in 
compared to the control cells (transfected with empty pEF6 plasmids alone). 
SOCS-4 knockdown in the cells which were transfected with ribozyme 2 colony 1 
plasmid were further verified using q-PCR (Figure 4-3 C, D, E, F) and western 
blotting (Figure 4-3 G, H) to explore transcript and protein level respectively. 
Transfected HaCaT and HECV cells containing the ribozyme transgene plasmids 
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were routinely tested to confirm continued knockdown of SOCS-4 expression in 
comparison to control cells. HaCaT and HECV cells transfected with control and 
transgene plasmid (rib2 col 1) were designated as HaCaT pEF6, HaCaT SOCS-4KD, 
HECV pEF6, HECV SOCS-4KD. 
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Figure 4-3: Verification of SOCS-4 knockdown in HaCaT and HECV by RT-PCR, q-
PCR and western blotting 
A, B. The transcript expression levels of GAPDH and SOCS-4 from different 
plasmid transfected cells was detected and displayed. The size of the sequences 
that SOCS-4 and GAPDH primer pairs amplified is 541bp and 475bp respectively. 
Representative images shown (n=3); C, D, E, F. The transcript level of SOCS-4 in 
HaCaT and HECV cells transfected with control plasmid and ribozyme sequence 
transgene incorporated plasmids were detected by q-PCR and normalised by the 
expression level of GAPDH and Actin respectively (*: p < 0.05, **: p < 0.01, ***: p 
< 0.001, error bars represent standard deviation). Representative data is shown 
(n=3); G, H. The protein expression level of SOCS-4 and GAPDH in HaCaT and HECV 
cells transfected with control plasmid and ribozyme transgene incorporated 
plasmids were detected by western blotting. Representative images are shown 
(n=3). 
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4.3.2.3 Generation of SOCS-4 knockdown cell models by siRNA 
4.3.2.3.1 Initial investigation on SOCS-4 knockdown in HaCaT and HECV by 
siRNA 
The transfection efficacy of siRNA transfection technique was firstly tested on 
gene level expression. The expression levels of SOCS-4 in wild type, transfect 
reagent-treated only, non-targeting siRNA and SOCS-4-targeting siRNA 
transfected cells were examined using q-PCR, and normalised by the expression of 
GAPDH and Actin respectively. Primer pairs of SOCS-4 F2 vs ZR2, GAPDH F2 vs ZR2 
and Actin F10 vs ZR10 were used for the cDNA product amplification. 
As shown in Figure 4-4 A, B, following normalisation with GAPDH and 
Actin expression, the expression of SOCS-4 in SOCS-4-targeting siRNA transfected 
HaCaT was found to be decreased by more than 60% compared to the non-
targeting siRNA transfected control (GAPDH normalisation p < 0.01, Actin 
normalisation p < 0.01), whereas the transcript levels of SOCS-4 in SOCS-4-
targeting siRNA transfected HECV showed downregulation by approximately 85% 
in comparison with the non-targeting siRNA control cell (GAPDH normalisation p < 
0.0001, Actin normalisation p < 0.0001)(Figure 4-4 C, D). There was no significant 
change of SOCS-4 expression between transfect reagent-treated only cell and 
non-targeting siRNA transfected cells for both HaCaT and HECV (Figure 4-4 A, B, C, 
D). No significant difference in SOCS-4 expression was found between wild type 
HaCaT and transfect reagent-treated only or non-targeting transfected HaCaT 
cells following normalisation with the expression of Actin (Figure 4-4 B), whereas, 
once normalised by GAPDH expression, SOCS-4 expression decreased significantly 
both in those transfect reagent-treated only and non-targeting siRNA transfected 
HaCaT compared to the wild type (WT vs transfect reagent p < 0.01, WT vs non-
targeting p < 0.01), though expression levels were much more substantially 
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decreased in the HaCaT SOCS-4 siRNA group (Figure 4-4 A). However, SOCS-4 
expression in HECV cells normalised by GAPDH demonstrated no significant 
changes between wild type and transfection reagent-treated only and non-
targeting siRNA transfected cells (Figure 4-4 C). Moreover, interestingly, SOCS-4 
expression normalised by Actin in transfect reagent-treated only and non-
targeting siRNA transfected HECV were both upregulated to that of wild type cells 
(WT vs transfect reagent p < 0.05, WT vs non-targeting p < 0.05; 48 hour of 
treatment of 25nM siRNA and 1 μl transfect reagent per well) (Figure 4-4 D). 
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C D 
  
Figure 4-4: Initial investigation on SOCS-4 knockdown in HaCaT and HECV by 
siRNA 
A, B. The transcript levels of SOCS-4 in wild type HaCaT, transfect reagent-treated 
only HaCaT and 25nM of non-targeting and SOCS-4-targeting siRNA transfected 
HaCaT cells were detected by q-PCR and were normalised to the expression of 
GAPDH and Actin respectively; C, D. The transcript levels of SOCS-4 in wild type 
HECV, transfect reagent-treated only HECV and 25nM of non-targeting and SOCS-
4-targeting siRNA transfected HECV were examined by q-PCR and were 
normalised to the expression of GAPDH and Actin respectively. (****: p < 0.0001, 
***: p < 0.001, **: p < 0.01, *: p < 0.05, error bar represent standard deviation, 
representative data is shown, n=3)  
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4.3.2.3.2 Transfect reagent concentration optimisation on HaCaT and HECV 
Optimisation of transfect reagent concetration allows more efficient SOCS-4 
knockdown. Therefore, experiments were designed to seek an optimal transfect 
reagent concentration for siRNA transfection in HaCaT and HECV. Transfection 
medium was made by mixing 25nM of either non-targeting or SOCS-4 targeting 
siRNA and serial concentration of transfect reagent using serum free and 
antibiotic-free medium. Different transfect reagent concentration was used for 
HaCaT (1μl/well, 1.5μl/well, 2μl/well) and HECV (0.5μl/well, 0.75μl/well, 1μl/well) 
based on the sensitivity of the cells towards the transfect reagent observed 
previously (data now shown).  
After normalised by the expression of GAPDH and Actin, significantly 
decreased SOCS-4 expression was detected in the SOCS-4-targeting siRNA 
transfected HaCaT cells compared to the non-targeting siRNA control in all 
different transfect reagent concentration treated groups (GAPDH normalisation p 
< 0.001, Actin normalisation 1μl/well, 1.5μl/well: p < 0.01, 2μl/well: p < 
0.001)(Figure 4-5 A-F). Moreover, the transfect reagent concentration of 2μl/well 
group showed a greater knockdown efficiency than the other two groups, which 
held an approximately 80% knockdown ratio. As indicated in Figure 4-6 A-F, in 
HECV cells, significant decreases in SOCS-4 expression were found from only one 
(0.75μl/well) of all three different transfect reagent concentration treated groups 
once normalised to both GAPDH and Actin expression in HECV (p < 0.01), and the 
knockdown ratio was approximately 85%. 
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Figure 4-5: Transfect reagent concentration optimisation for HaCaT 
A, B, C. The expression levels of SOCS-4 in non-targeting and SOCS-4-targeting siRNA with different concentrations (1μl/well, 1.5μl/well and 2μl/well) of 
transfect reagent transfected HaCaT were examined by q-PCR and normalised to the transcript levels of GAPDH; D, E, F. The expression levels of SOCS-4 in 
non-targeting and SOCS-4-targeting siRNA with different concentrations (1μl/well, 1.5μl/well and 2μl/well) of transfect reagent transfected HaCaT were 
detected by q-PCR and normalised to the transcript levels of Actin; (***: p < 0.001, **: p < 0.01, error bar stands for standard deviation, representative data 
is shown, n=3) 
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Figure 4-6: Transfect reagent concentration optimisation for HECV 
A, B, C. The expression levels of SOCS-4 in non-targeting and SOCS-4-targeting siRNA with different concentrations (1μl/well, 0.75μl/well and 0.5μl/well) of 
transfect reagent transfected HECV were examined by q-PCR and normalised to the transcript levels of GAPDH; D, E, F. The expression levels of SOCS-4 in 
non-targeting and SOCS-4-targeting siRNA with different concentrations (1μl/well, 0.75μl/well and 0.5μl/well) of transfect reagent transfected HECV were 
detected by q-PCR and normalised to the transcript levels of Actin. (**: p < 0.01, *: p < 0.05, error bar stands for standard deviation, representative data is 
shown, n=3) 
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4.3.2.3.3 Time point evaluation on siRNA generated SOCS-4 knockdown 
siRNA has been recognised as a transient method to temporarily downregulate 
gene expression levels in mammalian cells. Therefore, the detection of the 
effecetive duration of SOCS-4 knockdown by siRNA would be essential for the 
further functional assay design. Hence, the gene level expression of SOCS-4 after 
siRNA treatment in HaCaT and HECV were tested at the time of 48 hour and 72 
hour following transfection. 
HaCaT and HECV cells were treated with transfection medium containing 
25nM of siRNA and 2μl/well or 0.75μl/well transfect reagent respectively and 
were incubated at 37.0°C, 5% CO2 and 95% humidity for 48 hours and 72 hours 
before undertaking RNA extraction and reverse transcription according to the 
respective protocols. 
SOCS-4 expression normalised to GAPDH was decreased by approxmiately 
50% in SOCS-4-targeting siRNA treated HaCaTs compared to the non-targeting 
siRNA treated controls after 48 hours (p < 0.05)(Figure 4-7 A), whereas no 
significant change on SOCS-4 was found between wild type, transfect reagent-
treated only and non-targeting siRNA transfected cells (Figure 4-7 A). However, 
once normalised by Actin, there was no significant change between any paired 
groups after 48 hours siRNA treatment (Figure 4-7 B). Furthermore, no significant 
change on SOCS-4 expression level was detected after 72 hours of siRNA 
treatment to HaCaT (Figure 4-7 C, D).  
The transcript level of SOCS-4 was downregulated in SOCS-4-targeting 
siRNA transfected HECV in comparison with the non-targeting siRNA transfected 
cells following normalisation against both GAPDH and Actin expression (GAPDH 
normalisation p < 0.001, Actin normalisation p < 0.001) after 48 hour of siRNA 
transfection, accounting for approximately 70% decrease in both cases (Figure 4-8 
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A, B). Although the GAPDH and Actin normalised SOCS-4 expression was found to 
be significantly decreased between SOCS-4-targeting siRNA to non-targeting 
siRNA transfected HECV (GAPDH normalisation p < 0.01, Actin normalisation p < 
0.001), the knockdown ratio dropped down to around 40 - 50% reduction after 72 
hours of siRNA treatment (Figure 4-8 C, D). Moreover, the transcript level of SOCS-
4 in transfect reagent-treated only and non-targeting siRNA transfected HECV 
were both significantly higher than the wild type cells once normalised to GAPDH 
expression, representing a respective 67% and 27% increase in comparison to the 
wild type (WT vs transfect reagent p < 0.0001, WT vs non-targeting p < 0.01) 
(Figure 4-8 C), whereas, transfect reagent-treated only HECV cells had a 46% 
increase in SOCS-4 expression compared to wild type cells following normalisation 
against Actin, which was found to be significant (WT vs transfect reagent p < 0.001, 
WT vs non-targeting p > 0.05) (Figure 4-8 D). Interestingly, SOCS-4 expression in 
non-targeting siRNA transfected HECV cells was decreased by 32% and 43 % 
respectively compared to transfect reagent-treated only HECV cells when SOCS-4 
expression was normalised to both GAPDH and Actin (GAPDH normalisation p < 
0.01, Actin normalisation p < 0.01) (Figure 4-8 C, D). 
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A B 
  
C D 
  
Figure 4-7: Time point evaluation of siRNA generated SOCS-4 knockdown in 
HaCaT 
A, B, C, D. RNA was isolated and reverse transcribed to cDNA from wild type 
HaCaT, transfect reagent-treated only HaCaT, 25nM of non-targeting andSOCS-4-
targeting siRNA transfected HaCaT cells after 48 and 72 hours. The transcript 
levels of SOCS-4 in these cDNA samples was detected by q-PCR and normalised to 
the expression of GAPDH and Actin respectively; (*: p < 0.05, error bar stands for 
standard deviation, representative data is shown, n=3) 
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Figure 4-8: Time point evaluation of siRNA generated SOCS-4 knockdown in 
HECV 
A, B, C, D. RNA was isolated and transcribed to cDNA from wild type HECV, 
transfect reagent treated only HECV, 25nM of non-targeting and SOCS-4-targeting 
siRNA transfected HECV after 48 and 72 hours. The transcript levels of SOCS-4 in 
these cDNA samples was examined by q-PCR and normalised to the expression of 
GAPDH and Actin respectively. (*: p < 0.05, **: p < 0.01, ***: p < 0.001, ****: p < 
0.0001, error bar stands for standard deviation, representative data is shown, n=3)
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4.3.2.3.4 Protein expression detection via western blotting on siRNA 
transfected HaCaT and HECV  
In previous sections, the gene level expression of SOCS-4 in HaCaT and HECV was 
decreased by approximately 50% and 70% respectively after 48 hours siRNA 
transfection. Subsequently, the protein expression level was detected in both 
siRNA transfected cell lines using western blotting following 48 hour transfection. 
The siRNA transfection medium consisted of 25nM of siRNA and 2μl/well or 
0.75μl/well of transfect reagent in serum and antibiotic-free medium for HaCaT 
and HECV respectively. After 24 hours of incubation at 37.0°C, 5% CO2 and 95% 
humidity, the medium containing transfect reagent was replaced by normal 
medium, and the plate was incubated for another 24 hours before protein 
extraction. 
Equal amount of samples were loaded on the stacking gel and western 
blotting was undertaken to detect the total protein expression of SOCS-4, GAPDH 
and Actin. The protein expression level of SOCS-4, GAPDH and Actin in wild type 
and siRNA transfected HaCaT and HECV cells was detected through western 
blotting (Figure 4-9 A, B). Semi-quantitative analysis was undertaken using image J 
to measure the integrate-density of each protein band indicating the protein 
expression level of the specific protein probed (Figure 4-9 C, D, E, F).   
There was more than 40% increase on the protein expression of SOCS-4 in 
SOCS-4-targeting siRNA transfected HaCaT cells compared to the non-targeting 
siRNA transfected samples once normalised to GAPDH (Figure 4-9 C), whereas, 
Actin normalised SOCS-4 expression demonstrated less than 5% downregulation 
(Figure 4-9 D). However, the SOCS-4 protein expression in non-targeting siRNA 
transfected HaCaT, normalised to both GAPDH and Actin, was increased 
approximately 10% compared to wild type HaCaT cells (Figure 4-9 C, D). The 
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protein level of SOCS-4 in SOCS-4-targeting siRNA transfected HECV cells showed 
upregulation, accounting for approximately a 10% increase to that of in non-
targeting siRNA transfected ones when normalised to GAPDH and Actin (Figure 4-
9 E, F). Interestingly, GAPDH normalised SOCS-4 protein expression levels in non-
targeting siRNA HECV showed nearly 5% decrease to wild type HECV cells, 
whereas, once normalised to Actin, it demonstrated a greater than 30% increase 
(Figure 4-9 E, F). 
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A 
 
B 
 
C D 
   
E F 
  
Figure 4-9: siRNA knockdown verification by western blotting 
A, B. The normalised protein lysate from wild-type HaCaT, HECV, 25nM of non-
targeting and SOCS-4-targeting siRNA transfected HaCaT, HECV were fractionated 
by SDS-PAGE and transferred to PVDF membrane. Anti-SOCS-4, anti-GAPDH and 
anti-Actin primary antibodies and anti-mouse as well as anti-goat IgG secondary 
antibodies were used for probing. Chemiluminescent reagent was used to detect 
the protein expression. Representative data was shown (n=3); C, D, E, F. The 
protein levels of SOCS-4 were quantified by semi-quantitative analysis using 
Image J, and normalised by the expression levels of GAPDH and Actin. Such 
normalised SOCS-4 expression levels in wild-type and SOCS-4-targeting siRNA 
transfected cells were compared with that of the non-targeting siRNA transfected 
cells and are represented graphically by percentage change. 
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4.3.2.4 Generation of SOCS-3 overexpression HaCaT and HECV models 
4.3.2.4.1 Initial screening for SOCS-3 on various types of cell lines 
Based on the literature review and the information from NCBI database, 8 cell 
lines available in our laboratory were selected screen for SOCS-3 expression 
together with HECV and HaCaT. 
Positive SOCS-3 expression was found in the PLC-PRF-5, SKMES, A549, 
CAHPV-10, PC-3 and DU-145 cDNA samples, although SOCS-3 expression was 
much less in A549 compared to the other five cell lines tested. However, SOCS-3 
expression was not detected in HaCaT, HECV, CaCo-2 and PZ-HPV-7 cell lines. 
Therefore, PLC-PRF-5 and SKMES were chosen for SOCS-3 coding sequence primer 
pair specificity test based on their high expression profile of SOCS-3 (Figure 4-10 
A).  
 
4.3.2.4.2 SOCS-3 coding sequence primer pair specificity check and annealing 
temperature confirmation 
Five SOCS-3 coding sequence primer pairs were designed, and their amplification 
specificty were tested in the two cell lines displaying the greatest expression of 
SOCS-3, PLC-PRF-5 and SKMES. The primer combination of SOCS-3 exp F4 vs exp R 
was identified to be the most specific primer pairs since this primer pair amplified 
a single specific product at the correct size following 36 cycles of amplification 
both in PLC-PRF-5 and SKMES. Moreover, the amplification efficacy of SOCS-3 
coding sequence was higher in PLC-PRF-5 than in SKMES when they were both 
amplified by such primer pairs under the same PCR conditions (Figure 4-10 B).  
Furthermore, the appropriate annealing temperature was identified by 
the amplification of PLC-PRF-5 cDNA sample. It showed that 58°C was the most 
efficient annealing temperature in comparison to 52°C, 54°C and 56°C as this 
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temperature resulted in the strongest amplification of SOCS-3 coding sequence 
PCR product (Figure 4-10 C). 
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A 
 
B 
 
C 
 
Figure 4-10: Initial screening for SOCS-3 expression on 10 potential cell lines 
A. cDNA samples, reverse transcribed from the RNA from 10 cell lines, were 
amplified using the SOCS-3 F8 vs R8 primer pair and GAPDH F8 vs R8 respectively, 
and the PCR products were separated through gel electrophoresis. The predicted 
product size of SOCS-3 and GAPDH products are 521bp and 475bp respectively; B. 
cDNA samples reverse transcribed from RNA from PLC-RPF-5 and SKMES were 
amplified using four different primer pairs that all target SOCS-3 coding sequence, 
and the PCR products were separated by gel electrophoresis. The predicted size of 
all four PCR products is 678bp; C. cDNA sample reverse transcribed from RNA 
from PLC-RPF-5 was amplified using the of SOCS-3 exp F3 vs exp R and SOCS-3 exp 
F4 vs exp R primer pairs at four different annealing temperatures, and the PCR 
products were separated by gel electrophoresis. The predicted size of the two PCR 
products is 678bp. 
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4.3.2.4.3 Secondary screening of SOCS-3 on normal cell lines/tissues and SOCS-3 
coding sequence amplification with high fidelity enzyme mix kit 
The cDNA of six normal tissues and two normal cell lines preserved in our 
laboratory was selected according to the literature review and the information 
from NCBI database to test for potential SOCS-3 expression for further use in 
generating SOCS-3 coding sequence amplification. The cDNA from the MRC-5 and 
hFOB 1.19 was chosen because they are normal cell lines and exhibited the 
highest expression of SOCS-3 (Figure 4-11 A). A high fidelity enzyme mix kit was 
used to amplify SOCS-3 coding sequence and the PCR product was loaded on a 0.8% 
agarose gel and separated by gel electrophoresis followed by image capture. The 
amplified PCR product from MRC-5 cDNA was chosen for sample purification 
though excision and gel extraction due to it yielding the greater concentration of 
product (Figure 4-11 B). 
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A B 
 
 
C D 
 
 
Figure 4- 11: SOCS-3 coding sequence synthesis, amplification and purification 
A. cDNA samples, reverse transcribed from the RNA of 6 normal tissues and two 
normal cell lines were amplified by the primer pair of SOCS-3 F8 vs R8 and GAPDH 
F8 vs R8 respectively, and the PCR products were separated through gel 
electrophoresis. The predicted product size of SOCS-3 and GAPDH are 521bp and 
475bp respectively; B. RNA samples from MRC-5 and h-FOB 1.19 were reverse 
transcribed to cDNA, and SOCS-3 coding sequence was amplified from these  
cDNA samples using the primer pair of SOCS-3 exp F4 vs exp R using high fidelity 
PCR enzyme mix followed by separation through gel electrophoresis. The 
predicted size of PCR products is 678bp; C. The high fidelity PCR enzyme mix and 
primer combination of SOCS-3 exp F4 vs exp R amplified SOCS-3 coding sequence 
product (predicted size: 678bp) from MRC-5 cell line were loaded on 0.8% agarose 
gel in triplicates followed by gel electrophoresis; D. The PCR product containing 
SOCS-3 coding sequence amplified from MRC-5 cell line and the purified SOCS-3 
coding sequence product by gel extraction kit were both amplified using the 
primer pair of SOCS-3 F8 vs R8 and GoTaq Green master mix before being 
separated by gel electrophoresis to confirm presence of SOCS-3 sequence. The 
predicted product size is 521bp. 
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8μl of amplified PCR product from MRC-5 cDNA was loaded on three 
different lanes of a 0.8% agarose gel and separated by gel electrophoresis before 
being excised at the predicted size (Figure 4-11 C), then transferred into a 1.5ml 
microfuge tube. Such PCR product was extracted based upon the protocol 
provided by the manufacturer and detailed in Chapter II section 2.11.3. The 
concentration of such DNA product was measured and shown as follows (Table 4-
2): 
Table 4-2: Concentration measured for the purified SOCS-3 coding sequence 
product 
Product name A260/280 
Concentration 
(ng/µl) 
Sample volume (µl) 
Purified SOCS-3 
coding sequence 
2.600 13 50 
 
Each of the High Fidelity PCR Buffer amplified PCR product from MRC-5 
cDNA sample and the SOCS-3 coding sequence from gel extraction were amplified 
by SOCS-3 F8 vs R8 primer pair using conditions identical to the initial screening 
excluding cycle numbers which was changed to 30 cycles. Subsequently, PCR 
products were loaded on a 0.8% agarose gel followed by gel electrophoresis and 
image capture (Figure 4-11 D). A more specific and clearer band was visualised on 
the purified SOCS-3 coding sequence sample lane. The presence of correctly sized 
products following SOCS-3 F8 vs R8 amplification gave initial confirmation that the 
amplified coding sequence was correct for SOCS-3, though more thorough 
confirmation was also undertaken following insertion and amplification of the 
SOCS-3 expression plasmid. 
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4.3.2.4.4 SOCS-3 coding sequence incorporation, transgene orientation check 
and plasmid extraction 
The purified SOCS-3 coding sequence was incorporated into pEF6/V5-His-TOPO 
plasmid vector according to the cloning protocol outlined in the methodology 
section 2.11.2 to 2.11.3. These colonies were subject to orientation analysis using 
a combination of plasmid specific and sequence specific pairs to examine 
sequence insertion (T7F vs BGHR), incorrect orientation (T7F vs SOCS-3 exp F4) 
and correct orientation (T7F vs SOCS-3 exp R). As shown in Figure 4-12, the 
negative expression on both T7F vs SOCS-3 exp R and T7F vs SOCS-3 exp F4 
combination lane and the positive expression but incorrect size on T7F vs BGHR 
primer pair lane, detecting from colony 1, 2, 4, 5, 6 and 8, indicated that there was 
no SOCS-3 coding sequence incorporated plasmids in those colonies. Colony 3, 7, 
9 and 10 expressed the correct product size of SOCS-3 coding sequence insertion. 
Moreover, colony 7 and 10 showed positive expression in the incorrect primer 
pair lane, more so than in the correct orientation pair, indicating that the 
expression sequence was mostly inserted in the incorrect orientation. However, 
colony 3 and 9 exhibited positive expression in the correct orientation primer pair 
and negative expression in the incorrect orientation primer combination. This 
demonstrated that the majority of the plasmids in these two colonies were 
incorporated with the correct orientation of SOCS-3 coding sequence. 
Colony 3 and 9 were then inoculated into two universal tubes containing 
5ml of selective LB broth (containing 100µg/ml ampicillin) respectively, and both 
tubes were incubated overnight before plasmid extraction. The concentration of 
each extracted plasmid sample was measured and shown as follows (Table 4-3): 
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Figure 4-12: SOCS-3 coding sequence incorporation/orientation analysis 
Colonies picked from the E. coli. Transformed with SOCS-3 coding sequence 
incorporated plasmid were inoculated into PCR reaction mixes for insertion and 
orientation checking. ‘+’ represents SOCS-3 coding sequence insertion (T7F vs 
BGHR reaction with correctly sized product), ‘-’ represents no SOCS-3 coding 
sequence incorporation (T7F vs BGHR reaction with incorrectly sized product). 
The ’√’ mark represents correct orientation which was detected using primer 
combination of T7F vs SOCS-3 exp R (predicted size: 768bp), whereas, ‘X’ indicates 
incorrect orientation that was verified using the primer pair of T7F vs SOCS-3 exp 
F4 (predicted size: 768bp). The ‘□’ mark was used to indicate colonies which were 
chosen for further plasmid amplification. 
 
Table 4-3: Concentration measured for the SOCS-3 coding sequence 
incorporated plasmids 
No. Plasmid A260/280 Concentration (ng/µl) 
1 SOCS-3 coding 
sequence colony 3 
(SOCS-3 exp1) 
1.900 333 
2 SOCS-3 coding 
sequence colony 9 
(SOCS-3 exp2) 
1.953 420 
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4.3.2.4.5 SOCS-3 coding sequence verification by sequencing 
The appropriate concentration of the SOCS-3 coding sequence incorporated 
plasmids and purified SOCS-3 coding sequence PCR products were prepared with 
PCR water according to the protocol detailed in the methodology section and 
were sent for Sanger Sequencing (Source BioScience, Nottingham, UK). The 
sequencing results for the samples were queried by Homo sapiens (human) 
Nucleotide BLAST and indicated that all three tested sample were 100% identical 
to the targeted SOCS-3 coding sequence (Figure 4-13). 
 
 
Figure 4-13: SOCS-3 coding sequence verification 
Sequencing results of the three samples sent for Sanger Sequencing were 
visualised and interpreted by Chromas Version 2.5.0 (Technelysium Pty Ltd), and 
were then checked by Homo sapiens (human) Nucleotide BLAST (NCBI). Two 
SOCS-3 coding sequence incorporated plasmids which were extracted from the 
orientation verified colonies were labelled as ‘colony 3’ and ‘colony 9’ respectively, 
and the purified SOCS-3 coding sequence sample was labelled as ‘purified PCR 
product’. The ‘black rectangular’ and ‘red rectangular’ highlighted area indicate 
the coverage rate and identity rate of the tested samples to the targeted SOCS-3 
coding sequence respectively. 
  
244 
 
4.3.2.4.6 SOCS-3 overexpression verification in HaCaT and HECV models 
SOCS-3 coding sequence incorporated plasmid and control plasmid (pEF6) were 
transfected using electroporation. Following the blasticidin selection period, RT-
PCR, q-PCR and western blot were used to verify SOCS-3 overexpression in HaCaT 
and HECV. RNA was isolated from HaCaT and HECV cells transfected with control 
plasmid (pEF6) and SOCS-3 coding sequence incorporated plasmids (SOCS-3 exp1, 
SOCS-3 exp2) before reverse transcription was undertaken to obtain cDNA 
samples respectively. SOCS-3 and GAPDH transcript, targeted by primer pairs of 
SOCS-3 exp F4 vs R and GAPDH F8 vs R8, were amplified for 30 cycles by 
conventional PCR and the amplified products were loaded on 0.8% agarose gel for 
gel electrophoresis followed by visualising and image capture (Figure 4-14 A). 
SOCS-3 expression was achieved through continuous synthesis of SOCS-3 
coding sequence by T7F promoter in the pEF6/v5-His-TOPO plasmid in both 
transfected epithelial and endothelial cells (HaCaT and HECV). After 30 cycles of 
amplification, the transcript levels of SOCS-3 in both SOCS-3 coding sequence 
incorporated plasmid transfected HaCaT and HECV cell lines (SOCS-3 exp1 and 
SOCS-3 exp2) was obviously elevated (HaCaT SOCS-3exp1: 244%, HaCaT SOCS-
3exp2: 223%; HECV SOCS-3exp1: 274%, HECV SOCS-3exp2: 232%) compared to 
the respective control cells (transfected with empty pEF6 plasmids alone), 
whereas, the expression level of GAPDH was approximately consistent throughout 
the samples (Figure 4-14 A). SOCS-3 exp2 plasmid transfected HaCaT and HECV 
cells were further verified using western blotting (Figure 4-14 B) and q-PCR (Figure 
4-15 A, B, C, D), both methods demonstrating a good efficiency of SOCS-3 
overexpression in comparison to the respective plasmid control cell lines, with q-
PCR indicating an upregulation of greater than 4500% in HaCaT SOCS-3 expression 
cell lines and a greater than 8500% increase in HECV SOCS-3 expression cell lines 
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in comparison to respective plasmid controls. Fluctuation in percentage 
upregulation were obtained dependent on whether q-PCR was normalised to 
GAPDH or Actin housekeeping gene, though in all cases the enhanced expression 
of SOCS-3 in comparison to respective control cells was highly significant (p < 
0.001 in all cases). Transfected HaCaT and HECV cells containing the SOCS-3 
coding sequence plasmids were maintained in medium supplemented with 
blasticidin to promote stable expression of SOCS-3. Such cell lines were routinely 
tested to confirm SOCS-3 expression in comparison to empty vector controls. 
HaCaT and HECV cells transfected with control and SOCS-3 coding sequence 
plasmid were designated as HaCaT pEF6, HaCaT SOCS-3exp, HECV pEF6, HECV 
SOCS-3exp. 
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Figure 4-14: Verification of SOCS-3 expression in HaCaT and HECV by RT-PCR and western blotting 
A. The transcript expression levels of SOCS-3 and GAPDH from different plasmid transfected cells was detected. Predicted product sizes for SOCS-3 and 
GAPDH primer pairs are 678bp and 475bp respectively; B. The protein expression level of SOCS-3 and GAPDH in HaCaT and HECV cells transfected with 
control plasmid and SOCS-3 coding sequence transgene incorporated plasmids were detected by western blotting (representative data is shown, n=3).
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Figure 4-15: Verification of SOCS-3 expression in HaCaT and HECV by q-PCR 
A, B, C, D. The transcript level of SOCS-3 in HaCaT and HECV cells transfected with control plasmid and SOCS-3 coding sequence transgene incorporated 
plasmids was detected using q-PCR and normalised by the expression levels of GAPDH and Actin respectively ( ***: p < 0.001, ****: p < 0.0001, error bars 
represent standard deviation; representative data is shown, n=3). 
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4.4 Discussion  
The initial screening of the transcript levels of seven SOCS family members in 
chronic wound biopsies suggested that the gene levels of SOCS-3 and SOCS-4 
exhibited higher expression in non-healing chronic wounds to that in the 
healing/healed chronic wound tissues. Moreover, the difference of SOCS-3 
protein relocation between chronic non-healing and healing/healed wounds. The 
gene expression data, even though contrasted by protein expression analysis, 
when taken together with the literature highlights potential regulatory role of 
SOCS-3 and SOCS-4 during the chronic wound healing process. Hence, in order to 
further explore these highlighted proteins, the current chapter aimed to generate 
in vitro model systems for further functional characterisation in keratinocyte and 
endothelial cell lines. The establishment of SOCS-4 knockdown and SOCS-3 
expression cell models in HaCaT and HECV cell lines respectively was determined 
based on the transcript expression profile of SOCS-3 and SOCS-4 which showed 
moderate expression of SOCS-4 and no expression of SOCS-3 in both HaCaT and 
HECV wild-type cell lines by RT-PCR. Two methodologies (ribozyme transgene and 
siRNA) were applied and optimised to generate SOCS-4 knockdown models in 
HaCaT and HECV cell lines. The SOCS-4 knockdown efficacy was verified by RT-PCR 
and q-PCR at transcript level and using western blotting at protein level. All three 
techniques successfully verified knockdown of SOCS-4 in both HaCaT and HECV 
cell lines by ribozyme transgene transfection. Routine verification of SOCS-4 
knockdown was undertaken, and stable knockdown lines were used in future 
functional analysis. 
Similar SOCS-4 targeting-ribozyme transgene incorporated plasmids that 
were extracted from different E. coli. colonies (rib1 col4/rib1 col5 and rib2 
col1/rib2 col2) were used to transfect HaCaT and HECV cells separately. After the 
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selection period, SOCS-4 knockdown ratio was verified by RT-PCR. Both HaCaT and 
HECV cells that received either ribozyme (ribozyme 1 or ribozyme 2) exhibited 
successfully decreased SOCS-4 transcript expression. This indicated that both 
ribozyme 1 and ribozyme 2 had an effect on the decrease of SOCS-4 transcript 
expression. However, HaCaT cells that acquired ‘rib1 col4’ plasmid showed 
obvious SOCS-4 downregulation at transcript level, whereas, those that were 
transfected with the ‘rib1 col5’ plasmid exhibited little decrease in SOCS-4 levels. 
This discrepancy could possibly be due to the different amount of plasmids that 
the cell acquired during the electroporation transfection stage and/or the 
selection stage, resulting in differential knockdown efficiencies.  
The q-PCR results from the initial investigation on SOCS-4 knockdown by 
siRNA showed that, after 48 hours of siRNA transfection, SOCS-4 transcript levels 
were decreased in SOCS-4-targeting siRNA transfected HaCaT and HECV cells 
compared to that of the non-targeting transfected control cells. Interestingly, the 
transfect reagent seemed to have an effect on the expression level of GAPDH in 
HaCaT cells and Actin on HECV cells, since either decreased or increased SOCS-4 
expression was seen in transfect reagent treated cells to that in wild-type cells 
once it was normalised to GAPDH or Actin expression respectively.  
However, the q-PCR results from the different time point evaluation 
showed that, after 48 hours of siRNA treatment, there was no significant 
difference in SOCS-4 expression between HaCaT and HECV wild-type and transfect 
reagent treated cells following normalisation against either GAPDH or Actin. This 
was not in agreement with the results obtained from the initial investigation, 
suggesting the transfect reagent may affect the house-keeping gene expression by 
chance. Moreover, GAPDH normalised SOCS-4 transcript expression in SOCS-4-
targeting siRNA transfected HaCaT exhibited significant knockdown, accounting 
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for less than 50% compared to non-targeting siRNA transfected cells. Comparing 
to the knockdown effect seen in the initial investigation, such low knockdown 
ratio indicated the poor reproducibility of the siRNA technique in the HaCaT cell 
line. Furthermore, after 72 hours of siRNA treatment, no differences in SOCS-4 
expression could be found in any group following the normalisation of either 
GAPDH or Actin. This was in agreement with the traits of the siRNA technique, 
which only provides transient knockdown of the target gene. The western blotting 
results demonstrated siRNA transfection had a poor SOCS-4 protein knockdown 
efficiency in HaCaT cells after 48 hours treatment. 
In summary, the poor SOCS-4 knockdown stability and the unpredicted 
house-keeping gene variation suggested that siRNA transfection technique may 
be not suitable for the generation of SOCS-4 knockdown HaCaT cell models. 
Another transfect reagent is required to be used to test the stability of house-
keeping gene expression on HaCaT cells and to seeking optimised siRNA 
transfection conditions. 
The results from different time point evaluation on siRNA transfected 
HECV groups showed that both GAPDH and Actin normalised SOCS-4 expression in 
SOCS-4-targeting siRNA transfected HECV cells decreased significantly in 
comparison to the non-targeting siRNA transfected ones following 48 hours 
transfection. This is consistent with the result from the initial investigation, 
although the knockdown ratio is approximately 15% less. This may be due to the 
lower concentration of transfect reagent applied for the time point evaluation 
experiment.  
Furthermore, in agreement to the transient knockdown characteristics of 
siRNA, the SOCS-4 transcript knockdown ratio in HECV cell dropped 20% after 72 
hours siRNA transfection. Interestingly, distinct from the initial investigation 
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results, the Actin normalised SOCS-4 expression in the transfect reagent treated 
HECV cells did not show any significant difference to that of wild-type cells after 
48 hours treatment. However, the transfect reagents effect on house-keeping 
genes was observed after 72 hours of treatment, although such influence did not 
dramatically affect the SOCS-4 knockdown efficiency. Moreover, instead of 
achieving SOCS-4 knockdown at protein level, upregulation of SOCS-4 protein was 
observed following the normalisation against GAPDH and Actin expression after 
48 hours of siRNA transfection. Therefore, different time points for protein 
screening, after 48 hours, is suggested to test the potentially delayed SOCS-4 
protein decrease following SOCS-4 transcript level knockdown.  
In brief, the HECV SOCS-4 knockdown model could potentially be achieved 
by siRNA technique after transfection condition optimisation and the verification 
of protein level downregulation for different time point. However, further cell 
functional assays and investigation of downstream mechanisms in long term 
experimentation may be affected due to the transient traits of such methodology, 
therefore, such characteristics needs to be taken into consideration while 
designing experiments based on HECV knockdown models utilising siRNA.  
 Additionally, the result presented here demonstrate an efficient model for 
SOCS-3 expression in the two cell lines chosen, HaCaT and HECV. SOCS-3 coding 
sequence was sucessfully generated and verified using a wide range of technique 
and sequencing and also confirmed substantial and signaificant expression of 
SOCS-3 in keratinocyte and endothelial cell models. 
In conclusion, the HaCaT and HECV SOCS-4 knockdown model established 
by ribozyme transgene was considered to be the more robust of the tested 
techniques and, hence, was taken forward, in addition to the SOCS-3 expression 
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models, to conduct future experiments for cell functional assays and downstream 
mechanism investigations. 
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Chapter V 
Functional significance of SOCS-4 
knockdown in HaCaT and HECV 
models and potential downstream 
mechanisms
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5.1 Introduction 
According to the q-PCR and IHC screening on chronic wound biopsies reported 
and discussed in Chapter III, SOCS-4 is expressed primarily in all layers of 
keratinocytes of the epidermis and additionally distribution of SOCS-4 in 
microvesscular-like structures in demis also suggested its expression and 
implication in endothelial cells. Moreover, whilst in contrast to the protein data, 
higher gene expression of SOCS-4 was observed in non-healing chronic wound 
biopsies compared to that of in the healing/healed ones. Thus, this early data, 
whilst raising a number of questions, also raises the potential involvement of 
SOCS-4 in chronic wound biology or that its gene expression may be useful as a 
biomarker for chronic wound healing potential. 
In order to further clarify the impact of SOCS-4 in wound biology the 
previous chapter established SOCS-4 knockdown models in keratinocyte (HaCaT) 
and endothelial (HECV) cells. Such knockdown was brought about by ribozyme 
transgenes as this method provided the more efficient/consistent knockdown 
efficiency and generated stable cell lines. HECV and HaCaT cell lines were chosen 
for the in vitro models since they have been successfully used in previous wound 
healing in vitro studies (Goren et al., 2006a, Liu et al., 2013, Tan et al., 2015) and 
represent two key cell types involved in healing. 
The current chapter focuses on supplementing the previous clinical data 
with functional characterisation of the cellular impact of SOCS-4 knockdown, with 
regards to cell adhesion, proliferation, migration, spreading and angiogenic 
potential, within these keratinocyte and endothelial cell lines. 
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5.2 Methods and materials 
5.2.1 In vitro MTT cell adhesion assay 
This methodology is described in full in section 2.18.3 of Chapter II. In this chapter, 
the relative absorbance was normalised against the control group and transferred 
into percentage to the control in each repeat. The mean value was then 
calculated before being plotted in a bar chart as the final results. 
 
5.2.2 In vitro MTT cell proliferation assay 
This methodology is described in full in section 2.18.2 of Chapter II. In this chapter, 
the relative absorbance was normalised against the control group and transferred 
into a percentage relative to the control in each repeat. The mean value was then 
calculated before being plotted in a bar chart. 
 
5.2.3 Kinexus protein array and data analysis 
HaCaT pEF6 and HaCaT SOCS-4 KD protein samples were extracted as outlined in 
section 2.16 of chapter II. Such samples were subsequently sent to Kinexus 
Bioinformatics, Canada for protein microarray analysis. 
The protein microarray used consisits of 2 identical fields, allowing two 
samples to be analysed side by side at a time. Within each field, there are 16 
subgrids of 11 x 10 spots. Diameters of spots average between 120 and 150μm. 
(Figure 5-1) 50μg of lysate protein from each sample are covalently labeled with a 
proprietary fluorescent dye combination. Free dye molecules are then removed at 
the completion of labeling reactions by gel filtration. After blocking non-specific 
binding sites on the array, an incubation chamber is mounted onto the microarray 
to permit the loading of control and SOCS-4 knockdown protein samples side by 
side on the same chip and prevent mixing of the samples. Following sample 
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incubation , unbound proteins are washed away. Each array produces a pair of 16-
bit images, which are captured with a Perkin-Elmer ScanArray Reader laser array 
scanner (Waltham, MA). Signal quantification is perfromed with ImaGene 9.0 
from BioDiscovery (El Segundo, CA) with predetermined settings for spot 
segmentation and background correction. The background-corrected raw 
intensity data are logarithmically transformed with base 2 for further Z scores 
calculation.  
Globally Normalised Signal Intensity - Background corrected intensity 
values are globally normalised.  The Globally Normalised Signal Intensity is 
calculated by summing the intensities of all the net signal median values for a 
sample. This is done for all samples within a comparison to find the average net 
signal median. Once the average net signal median is calculated, the sum of the 
net signal median for each sample is divided by the average net signal median to 
obtain a co-efficient for normalisation; using the co-efficient, the net signal mean 
for each sample is divided by the co-efficient to obtain the globally normalised 
signal intensity value.  
%CFC (change from control in percentage) - The precent change of the 
treated sample in Normalised Intensity from the specified control. For example, 
a %CFC value of 100% corresponds to a 2-fold increase in signal intensity with the 
treatment.  A negative %CFC value indicates the degree of reduction in signal 
intensity from the selected control.   
Z Scores - Z scores represent where each signal falls in the overall 
distribution of values within a given sample, and they are calculated by 
subtracting the overall average intensity of all spots within a sample from the raw 
intensity of each spot, and dividing it by the SD of all of the measured intensityies 
within each sample. Z score transformation corrects data internally within a single 
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sample. The background corrected spot intensity values for individual proteins are 
expressed as a unit of standard deviation (SD) from the normalised mean of zero. 
Since the transformation is done before sample-to-sample comparison, it is 
therefore comparison-independent.  
Z Score Difference and Z ratio - The difference between the observed 
protein Z scores in samples in comparision.  Z Ratios - Divide the Z Score 
Differences by the SD of all the differences for the comparision. Follow-up studies 
should be based largely on the values of the Z-Score Ratios as they reveal the 
most reliable changes between the control and treated samples.  
This methodology has been described previously (Owen et al., 2016). 
 
5.2.4 Statistical analysis 
Statistical analysis was undertaken using the SigmaPlot 11 and Graphpad Prism 6 
statistical software packages.  Data was analysed using t-test or Mann Whitney 
test, depending on data parameters. Values of p < 0.05 (*), p < 0.01 (**), p < 0.001 
(***) and p < 0.0001 (****) were regarded as statistically significant. 
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Figure 5-1: Diagram of protein microarray plate 
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5.3 Results 
5.3.1 ECIS based initial attachment & spreading and migration assay 
ECIS has been recognised as a synthetic cell function assay platform which relieves 
labour force and enables multiple functional assays in one experiment. Therefore, 
the adhesive and spreading as well as migratory ability of HaCaT and HECV SOCS-4 
knockdown cells were tested using ECIS.  
The initial attachment and spreading ability of HaCaT on gold eletrode 
was attenuated by SOCS-4 knockdown, in comparision to respective control, and 
such trend was consistent over four hours following inoculation (1st to 3rd hour: p 
< 0.01, 4th hour: p < 0.0001; Figure 5-2 A). Moreover, at the 4th hour the HaCaT 
SOCS-4KD line showed 1897+73 ohm average resistance change, representing 25% 
decrease compared to the HaCaT pEF6 line which had average resistance change 
of  2529+194 ohm. Additionally, a similar trend was also found following the initial 
(1st hour: p < 0.001, 2nd to 4th hour: p < 0.0001) and the secondary (1st hour: p < 
0.001, 2nd to 4th hour: p < 0.0001) electrical wounding, suggesting impaired 
migration of keratinocyte to the open gold electrode following SOCS-4 knockdown 
(Figure 5-2 B, C). Following the 1st electrical woudning, the average resistance 
change of HaCaT pEF6 and HaCaT SOCS-4KD were 2659+65 ohm and 2173+98 
ohm respectively at the 4th hour, indicating 18% decrease following SOCS-4 
knockdown. Furthermore, the 4th hour resistance change of HaCaT pEF6 and 
HaCaT SOCS-4KD were 2768+110 ohm and 2021+128 ohm respectively following 
the 2nd electrical wounding, displaying a 27% decrease in SOCS-4 deficient line. 
However, contrasting results were observed in endothelial cells, indicating 
that SOCS-4 knockdown elevated the initial attachment and spreading of HECV on 
the gold eletrode following cell seeding (1st to 4th hour: p < 0.0001; Figure 5-3 A). 
At the 4th hour following inoculation, the average resistance change of HECV 
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SOCS-4KD (4037+1116 ohm) was 108% elevated compared to that of HECV pEF6 
(1944+482 ohm). In addition, the migration of HECV onto the open electrode was 
also enhanced by SOCS-4 deficiency following electrical wounding (1st to 4th hour: 
p < 0.0001; Figure 5-3 B), and such trend was also observed and validated 
following the second electrical wounding (1st to 4th hour: p < 0.0001; Figure 5-3 C). 
The average resistance change of HECV SOCS-4KD (4576+837 ohm) was incrased 
116% compared to HECV pEF6 (2116+622 ohm) at the 4th hour following the initial 
wounding, whereas such trend was enhanced as 172% at the 4th hour following 
the second wounding (HECV SOCS-4: 1948+450 ohm vs HECV pEF6: 716+195 ohm). 
Taken together, SOCS-4 knockdown affected the initial attachment and 
spreading as well as migration of both keratinocytes and endothelial cells to gold 
electrode, ableit in an opposite manner. 
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A B C 
 
  
Figure 5-2: ECIS based initial adhesion and migration assay on SOCS-4 mutant HaCaT line 
A. The resistance change at 4000Hz over the first four hours following inoculation; B. The resistance change at 4000Hz over the first four hours following the 1st 
electrical wounding; C. The resistance change at 4000Hz over the first four hours following the 2nd electrical wounding. (n=7; error bars represent standard 
deviation; representative data is shown; **: p < 0.01, ***: p < 0.001, ****: p < 0.0001). 
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Figure 5-3: ECIS based initial adhesion and migration assay on SOCS-4 mutant HECV line 
A. The resistance change at 4000Hz over the first four hours following inoculation; B. The resistance change at 4000Hz over the first four hours following the 1st 
electrical wounding; C. The resistance change at 4000Hz over the first four hours following the 2nd electrical wounding. (n=3; error bars represent standard 
deviation; representative data is shown; ****: p < 0.0001). 
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5.3.2 In vitro MTT cell adhesion assay 
In vitro MTT cell adhession assay was performed to determine if SOCS-4 affects 
the adhesive ability of HaCaT and HECV on matrigel matrix. Following 45 minutes 
incubation, the non-adherent cells were washed off, and the adherent viable cells 
were incubated in medium containing MTT for 4 hours to produce a purple 
coloured formazan product. Since the viable cell number conrresponds to the 
amount of formazan product, following solublisation with DMSO, the absorbance 
could be read and used to represent adherent cell numbers.  
The in vitro MTT cell adhesion assay was repeated five times in HaCaT and 
HECV SOCS-4 knockdown cell models. The combined results from five repeats 
indicated that SOCS-4 knockdown did not significantly affect the adhesive ability 
of HaCaT, with only a 3% change in adherence noted (p > 0.05) whereas, the 
adhesion of HECV was decreased by 16% following the downregulation of SOCS-4 
in comparison to control cells and this observation was found to be statistically 
significant (p < 0.01). (Figure 5-4) 
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 A    
 
 B    
 
Figure 5-4: In vitro MTT cell adhesion assay on SOCS-4 mutant HaCaT and HECV 
lines 
A. The absorbance, representing adherent HaCaT cell number, was analysed as a 
percentage against the control group in each repeat. Mean values are shown; B. 
The absorbance, representing adherent HECV cell number, was analysed as 
percentage against the control group in each repeat. Mean values are shown. 
(HaCaT, HECV: n=5; error bars represent standard error of the mean; **: p < 0.01)
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5.3.3 In vitro MTT cell proliferation assay 
In order to examine the impact of SOCS-4 knockdown on the proliferative ability 
of HaCaT and HECV cells, an in vitro MTT cell proliferation assay was conducted on 
the HaCaT and HECV SOCS-4 knockdown cell models. 
SOCS-4 knockdown did not seem to influence the proliferative rates of the 
HaCaT cell line over a 3 or 5 day incubation. SOCS-4 knockdown resulted in a 8% 
increase at day 3 and a 6% decrease at day 5 in comparison to the HaCaT pEF6 
control lines and neither change was seen to be statistically significant (Figure 5-5 
A&B; p > 0.05). Similar SOCS-4 knockdown did not significantly influence the 
proliferative rates of HECV cells (day 3: 10% decrease; day 5: 2% decrease) in 
comparison to the HECV pEF6 control (Figure 5-5 C&D; p > 0.05)   
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A B 
  
C D 
  
Figure 5-5: In vitro MTT cell proliferation assay on SOCS-4 mutant HaCaT and 
HECV lines  
A. The proliferative rate of HaCaT cell on day 3 was analysed as percentage 
against the control group in each repeat. Mean values are shown; B. The 
proliferative rate of HaCaT cell on day 5 was analysed as percentage against the 
control group in each repeat. Mean values are shown; C. The proliferative rate of 
HECV cell on day 3 was analysed as percentage against the control group in each 
repeat. Mean values are shown; D. The proliferative rate of HECV cell on day 5 
was analysed as percentage against the control group in each repeat. Mean values 
are shown. (n=5; error bars represent standard error of the mean) 
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5.3.4 In vitro cell migration assay (wound healing assay) 
An in vitro wound healing assay was conducted to investigate the effect of SOCS-4 
knockdown on HaCaT and HECV cells. The distance moved between two wound 
edges of wounded HaCaT pEF6 and HaCaT SOCS-4KD monolayers did not show 
any significant differences within the first eight hours (p > 0.05). However, starting 
from the 8th hour, the wound edges of HaCaT pEF6 began to migrate at a faster 
rate than that of HaCaT SOCS-4KD (8th hour to 10.5th hour: p < 0.05, 11th hour to 
13th hour: p < 0.01), and such a trend was consistently significant until the 13th 
hour when at least one point of the two wound edges of HaCaT pEF6 met each 
other, with 91% of wound healed in general (Figure 5-6 A, B), whereas, the wound 
edges of HaCaT SOCS-4KD were still far from each other with only 57% wound 
healed (Figure 5-6 C). 15.5 hours following wounding, the wound front of HaCaT 
pEF6 was approximately closed, whereas, the wound of HaCaT SOCS-4KD 
remained open (Figure 5-6 B, C). 
Similar trends were observed between HECV pEF6 and HECV SOCS-4KD 
though significant differences only appeared until the 12.5th hour following 
wounding (p < 0.05), and the wound of HECV pEF6 did not close within a 20 hour 
period when the experiment concluded (Figure 5-7 A, B). In addition, the wound 
of control line and SOCS-4 knockdown line were cloused by 87% and 58% 
respectively at the 20th hour. Images captured at each critical time point (0, 12.5th 
and 20th hour) also demonstrated that the movement of the two wound edges of 
HECV pEF6 was faster than that of HECV SOCS-4KD at least between the 12.5th 
hour and the 20th hour following wounding (Figure 5-7 B, C). 
In summary, downregulation of SOCS-4 decreased the migratory ability of 
epithelial cell by 34% at the 13th hour, and impaired the migration of endothelial 
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cell by 25% at 20th hour. Therefore, SOCS-4 knockdown attenuated the migration 
of both keratinocyte and endothelial cell. 
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Figure 5-6: In vitro cell migration assay on SOCS-4 mutant HaCaT line 
A. The distance migrated by wound edge at each hour are plotted on a line chart; B. Representative pictures of the wounded HaCaT pEF6 monolayer at the 0, 8th, 
13th and 15.5th hour following wounding; C. Representative pictures of the wounded HaCaT SOCS4-KD monolayer at 0, 8th, 13th and 15.5th hour following wounding. 
(n=3, representative data is shown, error bars represent standard error of the mean; **: p < 0.01, *: p < 0.05; image was captured at X10 objective magnification; 
the red line indicates boundary of wound edge) 
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Figure 5-7: In vitro cell migration assay on SOCS-4 mutant HECV line 
A. The distance migrated by wound edge at each two hours and at the 12.5th hour are plotted on a line chart; B. Representative pictures of the wounded HECV 
pEF6 monolayer at 0, 12.5thand 20th  hour following wounding; C. Representative pictures of the wounded HECV SOCS4-KD monolayer at 0, 12.5th and 20th hour 
following wounding (n=3, representative data is shown, error bars represent standard error of the mean; *: p < 0.05; image was captured at X10 objective 
magnification; the red line indicates boundary of wound edge) 
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5.3.5 Tubule formation assay 
An in vitro Matrigel tubule formation assay was conducted to explore the 
potential of SOCS-4 to impact on the microtubule formation capacity of HECV cells 
to investigate its potential to influence angiogenesis. 
Two hours following inoculation, the control cells started to aggregate, 
showing the begining of tube-like structures, whereas the SOCS-4 knockdown 
endothelial cells were more likely to cluster together. Furthermore, a general 
distribution of microtubule network with several complete tubes were obviously 
observed in the control line at the 4th hour, however, there was only a slight 
indication of tubule formation in the SOCS-4 knockdown cell at the same time 
point. This trend was more obvious over the next 6 hours until the conclusion of 
the experiment (Figure 5-8 A, B). After 10 hours of incubation, the number of 
tubules formed by the HECV SOCS-4KD line on matrigel matrix was much less 
compared to that of by HECV pEF6 according to the direct observation. In order to 
quantify this observed phenomenon, total perimeter, used as a quantification of 
total vessel coverage, was measured and compared between control and SOCS-4 
knockdown lines. The total perimeter of the tubules formed by HECV SOCS-4KD 
was significantly less at the experimental end point (10 hours), representing a 31% 
decrease, than that of HECV pEF6 control line (p < 0.01: Figure 5-8 C). Therefore, 
SOCS-4 knockdown impaired the tubule formation ability of endothelial cells on 
matrigel matrix. 
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A  HECVpEF6-control  
 
B  HECV SOCS-4KD  
 
  C   
 
Figure 5-8: Tubule formation assay on SOCS-4 mutant HECV lines 
A. Representative pictures of the formed tubules of HECV pEF6 at the 2nd, 4th, 6th, 
8th and 10th hour; B. Representative pictures of the formed tubule of HECV SOCS-
4KD at the 2nd, 4th, 6th, 8th and 10th hour; C. The perimeter of the formed tubules 
on each image at the experimental end point was manually traced and the total 
perimeter in pixels was quantified. The mean value was then calculated from the 
multiple replicates as the total average perimeter before being normalised to the 
value of the control line. Images were captured at X5 objective magnification. 
(n=3; representative data is shown; error bars represent standard deviation; **: p 
< 0.01) 
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5.3.6 Potential downstream signalling investigation 
To explore global signalling event in HaCaT cells following SOCS-4 knockdown, a 
protein array analysis was carried out on the Kinexus850 platform (please refer to 
section 2.16 of Chapter II and section 5.2.3 of Chapter V). The array includes over 
850 antibodies that recognise both total protein and phospho-proteins of a rather 
number of signalling proteins. Figure 5-9 shows a representative images from the 
array. 
The results from the KinexusTM antibody microarray indicated that there 
were thirteen protein candidates which demonstrated a significantly decreased 
levels of phosphorylation following HaCaT SOCS-4 knockdown (Figure 5-10 A). 
One of the most signficant changes was focal adhesion kinase (FAK) (Figure 5-10 B, 
C, D). 
In the light of the signficant role of FAK in cell signalling, matrix adhesion 
and cell migration, further investigation was focused on the verification of the 
protein expression level of total FAK and its phosphotyrosine site 397 (FAK Y397) 
between HaCaT pEF6 and HaCaT SOCS-4KD as this may be a key molecule 
governing the effects brought about by SOCS-4 suppression. It was found that 
downregulation of SOCS-4 correlated with the increase of total FAK and the 
decrease of FAK Y397 (Figure 5-11 A, B). Interestingly, the expression of SOCS-4 
and FAK Y397 demonstrated similar expression pattern following the semi-
quantitative analysis (Figure 5-11 C, D, E). 
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Figure 5-9: Kinexus 850 images in comparing proteins from HaCaT pEF6 (bottom, 
C1) and HaCaT SOCS-4KD (top, C2) cells. 
The protein expression level correlates with the signal intensity. Different colours 
represent different signal intensity and decreasing signal intensity corresponds 
with a red to orange to yellow to green to blue transition. 
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Figure 5-10: Investigation of potential molecular significance in HaCaT SOCS-4 
mutant line 
A. Significant protein phosphorylation decreases were seen in HaCaT SOCS-4KD 
compared to HaCaT pEF6 by the KinexusTM antibody microarray. The red circle 
indicates the molecule chosen to be further investigated; B, C, D. The magnitude 
changes of FAK in the two cell models. Global signal of the respective protein (B), 
the Z ratio (C) and %CFC (D) of the respective protein. 
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C D 
  
 E   
 
Figure 5-11: Investigation of potential downstream signalling events in HaCaT 
SOCS-4 mutant line 
A, B. Western blotting verification on the protein expression level of SOCS-4, FAK 
and FAK Y397 in protein extracts from HaCaT pEF6 and HaCaT SOCS-4KD (n=1) C, 
D, E. Semi-quantitative analysis undertaken by Image J v1.50c on the western 
blotting results, the expression ratio is indicated as percentage control and 
plotted in bar charts. 
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5.4 Discussion 
Keratinocytes are one of the pivotal cell types involved in the wound healing 
process, primarily exerting their function on re-epithelialisation. After activation, 
keratinocytes alter integrin expression to enable their migration over the wound 
bed and produce cyotkines and chemokines to recruit and acitvate other cells to 
benefit the healing process (Pastar et al., 2008). Vascular endothelial cells are 
another important cell type involved in angiogenesis. The migration and 
proliferation of the activated vascular endothelial cell along with the interaction 
between ECM and such cell type contribute to neovascularisation and the 
formation of a vascular network in order to meet the significant increase in 
oxygen and nutrient requirement for local cell metabolism (Senger and Davis, 
2011, Clark, 1996). Therefore, cell functional assays were conducted following the 
generation of HaCaT and HECV SOCS-4 knockdown mutant cell lines by ribozyme 
transgene to further investigate the potential effect of SOCS-4 to the behaviour of 
these critical cell types during the wound healing process.  
The ECIS based initial attachment and spreading assay and migration 
assay demonstrated that the downregulation of SOCS-4 suppressed both HaCaT 
initial attachment and spreading as well as migratory ability to the gold electrode 
approximately 25%, whereas elevated initial attachment and spreading as well as 
migraion were found in HECV SOCS-4 knockdown mutant lines, accounting for 
more than two times to the control line. This may imply that SOCS-4 potentially 
plays different roles in regulating adhesion, spreading and migration of HaCaT and 
HECV cells on gold electrode. Additionally, in contrast to the ECIS based initial 
adhesion assay, the MTT matrigel adhesion assay indicated that SOCS-4 
knockdown had no effect on HaCaT cell matrigel adhesive ability, whereas the 
adhesive ability of HECV to the matrigel matrix was decreased by the 
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downregulation of SOCS-4. Such a discrepancy may account for the variant 
adhesive ability of HaCaT and HECV lines to the different matrix surface in the 
above two methodologies since different substratum matrix has been proved to 
modulate the expression profile of integrin differently, leading to altered cell 
mophology and adhesive ability (Delcommenne and Streuli, 1995). Again, the data 
suggests that SOCS-4 may differentially impact adhesion and spreading dependent 
on cell type and matrix conditions. 
The results from the MTT proliferation assay indicated that SOCS-4 
knockdown did not affect the cell proliferation within 5 days in both HaCaT and 
HECV lines. Whilst there is little data currently available as to SOCS-4’s role in 
proliferation in wound healing models, a previous study, focusing on IL-23, 
miRNA-25 and SOCS-4 in thyroid cancer has suggested that SOCS-4 expression 
brought about minimal impact on cell growth in this model system (Mei et al., 
2015). Hence, the observed effect in HaCaT and HECV cell lines appears to be in 
line with the limited data available within the literature. 
The results from the scratch assay (cell migration assay) showed that the 
cell migration rates of HaCaT and HECV was not significantly affected by SOCS-4 
knockdown at the initial migratory stage. Such results were again different from 
that seen in the ECIS based migration assay, which showed significant difference 
between the control and SOCS-4 mutant lines at the first hour following cell 
seeding. Such a discrepancy may be due to the different sensitivity of the 
measurement between the two methods or the variant migratory behaviour of 
the cells to different matrix surface. Together, both ECIS and EVOS scratch 
methodologies demonstrate a role for SOCS-4 in regulating keratinocyte and 
endothelial cell migration, though these do contrast between ECIS and EVOS in 
terms of the HECV cell line and time following wounding before this trait 
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demonstrates significance. The previously mentioned in vitro study on thyroid 
cancer cell lines demonstrated that SOCS-4 negatively regulated IL-23 induced cell 
migration, and such effect could be diminished by the presence of microRNA-25 
through targeting the 3’-UTR of SOCS-4 (Mei et al., 2015). The discrepancy of the 
cellular impact of SOCS-4 between this study and the findings presented here may 
be due to the variant downstream effect of SOCS-4 in different cell types, 
suggesting multiple regulatory roles of SOCS-4 in different cellular 
microenvironments.  
The tubule formation assay on the HECV pEF6 and HECV SOCS-4KD lines 
indicated that SOCS-4 knockdown potentially decreased tubule formation by 
endothelial cell on matrigel matrix, and increased the cell-cell and cell-membrane 
attachment. Again, this observation seems more in line with the EVOS migration 
results, with such a negative impact on migration and tubule formation linking 
reduced SOCS-4 levels with a poor angiogenic response and again potentially 
implicating SOCS-4 in the wound healing process. 
In order to further clarify the role of SOCS-4 and to identify potential 
mechanisms which bring about its observed functional effects a protein 
microarray was undertaken to compare control HaCaT and SOCS-4 knockdown 
HaCaT cell lines. This initial data has highlighted a number of molecules of interest 
which may aid in the explaination of the functional characterisation of SOCS-4 
knockdown cell lines. 
The screening of protein changes between HaCaT control line and HaCaT 
SOCS-4 deficient line showed a decrease of FAK Y397 was apparent following the 
downregulation of SOCS-4, indicating the potential effect of SOCS-4 on FAK 
activation. FAK Y397 is a key auto phosphorylation site wich is able to be activated 
by many stimulus (such as integrin binding) and contributes to various 
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downstream signalling cascades including cell migration (Zhao and Guan, 2011). It 
has been documented that FAK activation promoted the migratory ability of 
keratinocyte during wound healing (Gates et al., 1994). In addition, decreased Src 
activation on Y418 was observed in the protein array results in this study. Previous 
studies indicatd that Src activaion requires FAK Y397 activation, and a well 
characteriased pathway that FAK modulate cell migration is through the 
interaction of FAK/Src complex and p130cas (Cary et al., 1996, Cary et al., 1998). 
Taken together, a potential mechanism of the attanuated migration of SOCS-4 
deficient HaCaT in wound healing assay in this chapter may due to the 
suppression of FAK/Src/p130cas pathway by the reduced FAK Y397 activation 
following SOCS-4 knockdown. Moreover, EGFR phosphorylation on Y1110 was 
also found reduced in the SOCS-4 knockdown keratinocytes. As previously 
discribed in the literature, the ligand binding, and subsequent activation of EGFR 
modulates a variety of keratinocyte functions (Schneider et al., 2008). Amongst 
the seven ligands of EGFR, heparin-binding EGF-like growth factor (HBEGF) has 
been demonstrated in promoting keratinocyte migraion (Shirakata et al., 2005). 
Therefore, together with the result from wound healing assay in this chapter, 
decreased keratinocyte migration could potentially be explained as SOCS-4 
deficiency reduced HBEGF production by keratinocyte, which in turn decreased 
EGFR activation. A previous study has also demonstrated that IGF-1 facilitated 
keratinocyte membrane protrusion and spreading, two prerequiste of cell 
migration, through stimulating PI3K (Haase et al., 2003). Given that the decreased 
IGF1R activation in SOCS-4 knockdown keratinocytes seen in the protein array and 
the reduced migration of SOCS-4 deficient HaCaT in wound healing assay, SOCS-4 
may also potentiate IGF-1 signalling to improve keratinocyte migratory ability 
through the maintenance of PI3K activation. Furthermore, another growth factor 
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receptor, VEGFR-2, has been decumented to be expressed in both HaCaT and a 
human primary keratinocytes and in vitro work on these two cell lines indicated 
that VEGFR-2 phosphorylation by VEGF stimulation could induce the migration of 
keratinocyte (Man et al., 2006, Yang et al., 2006). Therefore, based on the results 
of decreased phosphorylation of VEGFR-2 Y1214 from protein array and the 
decrased migration of keratinocyte following SOCS-4 knockdown from the wound 
healing assay, it is feasible that SOCS-4 could maintain the activation of VEGFR-2 
to promote keratinocyte migration. Interestingly, a tumour suppressor protein 
BRCA1 was observed to have reduced phosphorylation of S1497. BRCA1 has been 
documented to negatively regulate cell proliferation (Holt et al., 1996, 
Randrianarison et al., 2001). However, in vivo study on epithelial tissue BRCA-1 
conditional knockdown mice demonstrated that decreased activation of BRCA-1 
rendered epidermal hyperprolieferation and also enhanced cell apoptosis in 
epidermis, thus no obvious histological difference was observed (Berton et al., 
2003). This again seems in line with the data obtained in this chapter suggesting 
SOCS-4 does not impact HaCaT cell proliferation. 
In summary, the presence of SOCS-4 potentially has positive effects on 
the adhesion of HECV on matrigel matrix, whereas it has non-significant effects on 
this trait within the HaCaT cell line. Moreover, SOCS-4 may affect the adhesive 
ability of HaCaT and HECV to different matrix surface.  
SOCS-4 also holds the potential to regualte HaCaT and HECV migration. 
Furthermore, SOCS-4 exhibited no significant effect on the growth of HaCaT and 
HECV cells. Therefore, the functional analysis of SOCS- 4 mutant lines indicates a 
role for such molecule in a number of key traits associated with wound healing, 
this chapter also raises a number of interesting downstream signalling 
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mechanisms which may account for some of the functional observations following 
SOCS-4 knockdown. 
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Chapter VI 
Functional significance of SOCS-3exp 
on HaCaT and HECV models
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6.1 Introduction 
SOCS proteins are a family of intracellular proteins containing eight members 
(Alexander, 2002) and were primarily found to exert their function as negative 
regulators of cytokine induced JAK-STAT signalling (Croker et al., 2008a). 
Furthermore, several studies have suggested the involvement of SOCS-3 in 
components of wound healing. SOCS-3 deficient mice expressed a lethal 
inflammatory phenotype, suggesting its regulatory role in the inflammation 
response (Croker et al., 2012) which is an essential stage in wound healing. This is 
in agreement with another study that indicated the exacerbated inflammation 
was related to the overexpression of SOCS-3 (Linke et al., 2010a) further 
supporting a role for SOCS-3 in wound healing. However, the downstream 
mechanism of how SOCS-3 modulates wound healing still remain unclear.  
Based on the q-PCR screening results obtained from the chronic wound 
biopsies in Chapter III, significantly higher gene expression levels of SOCS-3 was 
observed in non-healing chronic wound biopsies compared to that in the 
healing/healed ones, suggesting that the elevated SOCS-3 gene expression on 
wound site correlated with poor healing results. However, whilst this differerntial 
expression of SOCS-3 was not seen in the IHC staining of healing and non-healing 
chronic wounds, this data is in line with a study using SOCS-3 overexpression 
mouse model in a primary epithelial cell line, which demonstrated that the 
upregulation of SOCS-3 attanuted keratinocyte migration, contributing to 
impaired healing (Linke et al., 2010b). Moreover, according to the IHC screening 
on chronic wound biopsies in chpater III, SOCS-3 was found not only extensively 
expressed in all layers of keratinocytes of the epidermis, but in the surrounding 
blood vessels in dermis in all positive stained chronic wounds. Thus, SOCS-3 may 
also play some role in regulating endothelial cell function. 
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Therefore, it is of interest to further investigate the role of SOCS-3 in the 
human keratinocyte (HaCaT) and endothelial (HECV) cell model systems, as they 
represent two key cell types involved in wound healing and to explore the 
functional relevance of this molecule in conjunction with the clinical data. The PCR 
results presented in Chapter IV indicated no SOCS-3 expression in these two cell 
lines. Therefore, SOCS-3 coding sequence was incoporated into a vector and 
transfected into the two cell lines to generate SOCS-3 expression cell model, and 
the expression efficiency was verified by RT-PCR, q-PCR and western blotting (as 
described in Chapter IV). In this Chapter, functional assays were conducted on 
keratinocyte and endothelial SOCS-3 expression cell models. 
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6.2 Methods and materials 
6.2.1 In vitro crystal violet matrigel adhesion assay 
In order to enable the image capture to diversify the data presentation, another 
robust and reproducible methdology, crystal violet stating, was utilised instead of 
MTT for the cell adhesion assay on the SOCS-3exp cell models. The crystal violet 
staining method was originally conducted to evaluate the cytotoxic effects of 
chemicals due to the linear relationship between the ablsorbance of the stained 
cells and cell number (Saotome et al., 1989) and was later verified to be an 
alternative method to MTT assay (Chiba et al., 1998). The preparation of the 
matrigel matrix plate and the cell seeding density was as outlined in section 2.18.3 
in chapter II. 
Cells were seeded on the SFM rehydrated matrigel matrix that were 
prepared in six replicates and the plate was incubated at 37.0°C, 5% CO2 and 95% 
humidity for 45 minutes. Subsequently, the plate wells were washed with 100µl of 
PBS three times to remove nonadherent cells. The adherent cells were then fixed 
in 100µl of 4% formalin for at least 15 minutes before being stained with 100µl of 
1% crystal violet for at maximum of 15 minutes. The crystal violet was removed by 
gentle inversion of the plate, and was gently washed under a slow tap water flow. 
The plate was then placed in a fume cabinet until dried completely. Images were 
then captured for each well at X5 objective magnification using a Leica DMi1 
microscope equipped with a MC120 HD camera and Leica Application Suite 
version 3.0.0 software (Leica Microsystems, Milton Keynes, UK) before the 
addition of the 10% acetic acid. The plate was tapped gently to enable the crystal 
violet to dissolve thoroughly.  
The absorbance of each well was detected at 540nm using ELx800 plate 
reading spectrophotometer (Bio-Tek, Wolf laboratories, York, UK). Initial cell 
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adhesion in each well was determined by the absorbance. Experiments were 
repeated a minimum of three times. 
 
6.2.2 Statistical analysis 
Statistical analysis was undertaken using the SigmaPlot 11 and Graphpad Prism 6 
statistical software packages. Data was analysed using t-test or Mann Whitney 
test, depending on data parameters. Values of p < 0.05 (*), p < 0.01 (**), p < 0.001 
(***) and p < 0.0001 (****) were regarded as statistically significant. 
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6.3 Results 
6.3.1 ECIS based initial attachment & spreading assay and migration assay 
ECIS was performed to evaluate the impact of SOCS-3 expression on the initial 
attachment and spreading as well as migration of HaCaT and HECV. 
As shown in Figure 6-1, the initial attachment and spreading of 
keratinocytes on gold electrode was elevated by SOCS-3 expression starting from 
the 1st hour (p < 0.01) and such effect was consistent until the 4th hour. At the 4th 
hour following inoculation, the average resistance change of HaCaT SOCS-3exp 
was 1854+297 ohm, 103% elevataed compared to that of HaCaT pEF6 which was 
910+203 ohm.(2nd hour: p < 0.01, 3rd hour: p < 0.001, 4th hour: p < 0.0001; Figure 
6-1 A). In addition, increased migration over the open gold electrode was 
observed in the SOCS-3 expression HaCaT cell line in comparison to the control 
line over the 4 hours following the 1st electical wounding, with highly significant 
differernces noted. The average resistance change of HaCaT SOCS-3exp 
(2476+252 ohm) was enhanced 86% compared to HaCaT pEF6 (1328+430 ohm) at 
the 4th (1st and 2nd hour: p < 0.0001, 3rd and 4th hour: p < 0.001; Figure 6-1 B). 
Moreover, similar trends were seen following the 2nd electrical wounding, where 
SOCS-3 expression enhanced the migratory ability of HaCaT over the open gold 
electrode. At the 4th hour, the average resistance change of HaCaT SOCS-3exp 
(1701+228 ohm) was 40% greater than that of HaCaT pEF6 (1218+239 ohm) (1st to 
4th hour: p < 0.05; Figure 6-1 C).  
Interestingly, distinct from the results seen in keratinocyte, SOCS-3 
expression in HECV cells did not affect the initial attachment and spreading on the 
gold electrode (1st to 4th hour: p > 0.05; Figure 6-2 A). However, similar to the 
HaCaT cell line, SOCS-3 expression resulted in an enhanced migration of HECV 
cells across the open gold electrode following both the initial (1st hour: p < 0.001, 
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2nd to 4th hour: p < 0.01)and secondary (1st and 2nd hour: p < 0.0001, 3rd and 4th 
hour: p < 0.001) electrical woundings (Figure 6-2 B, C). Following the 1st electrical 
woudning, the average resistance change of HECV pEF6 and HECV SOCS-3exp 
were 1683+167 ohm and 2662+646 ohm respectively at the 4th hour, 58% 
displaying enhancement following SOCS-3 expression. Furthermore, the 4th hour 
resistance change of HECV pEF6 and HECV SOCS-3exp were 741+165 ohm and 
2583+650ohm respectively following the 2nd electrical wounding, indicating a 248% 
elevation in the SOCS-3 expression line. 
Therefore, SOCS-3 expression only increased the initial attachment and 
spreading of keratinocytes on the gold electrode, whereas the migratory ability of 
both keratinocytes and endothelial cells across the gold electrode were elevated 
by the expression of SOCS-3. 
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Figure 6-1: ECIS based initial adhesion and migration assay on SOCS-3 mutant HaCaT line 
A. The resistance change at 4000Hz over the first four hours following inoculation; B. The resistance change at 4000Hz over the first four hours following the 1st 
electrical wounding; C. The resistance change at 4000Hz over the first four hours following the 2nd electrical wounding. (n=4, representative data is shown, error 
bars represent standard deviation; *: p < 0.05, **: p < 0.01, ***: p < 0.001, ****: p < 0.0001) 
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Figure 6-2: ECIS based initial adhesion and migration assay on SOCS-3 mutant HECV line 
A. The resistance change at 4000Hz over the first four hours following inoculation; B. The resistance change at 4000Hz over the first four hours following the 1st 
electrical wounding; C. The resistance change at 4000Hz over the first four hours following the 2nd electrical wounding. (n=4, representative data is shown, error 
bars represent standard deviation; **: p < 0.01, ***: p < 0.001, ****: p < 0.0001) 
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6.3.2 In vitro crystal violet matrigel adhesion assay 
Crystal violet staining assay was ustilised to test if SOCS-3 expression affects the 
adhesive ability of keratinocyte and endothelial cells to matrigel matrix.  
Analysis of the independent repeats indicated that SOCS-3 expression in 
HaCaT cell lines had little impact on cell matrigel matrix attachment with only a % 
difference noted between control and expression groups, which was not found to 
be statistically significant (p > 0.05; Figure 6-3 A). This is also apparent from the 
representative images, again suggestive that there was very little change in matrix 
attachment between control and SOCS-3 expression HaCaT cellls (Figure 6-3 B, C). 
However, SOCS-3 expression in HECV endothelial cells was found to significantly 
enhance cell matrigel matrix adhesion and resulted in a 48% increase in adherent 
cell numbers (p < 0.05; Figure 6-3 D), a trend which was again apparent from the 
representative images (Figure 6-3 E, F). Hence, the data suggests that SOCS-3 
expression elevated the adhesion of endothelial cell to matrigel matrix but had no 
effect on the adhesive ablity of keratinocyte to the same matrix substratum. 
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Figure 6-3: Crystal violet matrigel adhesion assay on SOCS-3 mutant HaCaT and 
HECV lines 
A, The absorbance, representing adherent HaCaT cell number, was transformed 
into percentage against control group in each repeat. The mean value was 
calculated and plotted in a bar chart; B, C. Representative images captured for  
HaCaT pEF6 and HaCaT SOCS-3exp lines respectively following the crystal violet 
staining; D. The absorbance, representing adherent HECV cell number, was 
transformed into percentage against control group in each repeat. The mean 
value was calculated and plotted in a bar chart. E, F. Representative image 
captured on the HECV pEF6 and HECV SOCS-3exp lines respectively after the 
crystal violet staining. (HaCaT: n=6, HECV: n=5; error bars represent standard 
error of the mean; *: p < 0.05) 
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6.3.3 In vitro MTT cell proliferation assay 
The MTT cell proliferation assay were conducted to investigate the impact of 
SOCS-3 expression on the proliferative ability of HaCaT and HECV cells, 
experiments were repeated for three times and the proliferation rate on day 3 
and day 5 in each repeat was calculated based on the equation shown in chpater 
II section 2.18.2. 
Statistical analysis of the keratinocyte SOCS-3 expression model indicated, 
no statistical difference between SOCS-3 expression and control keratinocytes on 
day 3 (1% decrease following SOCS-3 expression; p > 0.05; Figure 6-4 A). However, 
SOCS-3 expression attenuated the proliferation of keratinocytes on day 5, 
accounting for a 14% decrease compared to control keratinocytes (p < 0.05; 
Figure 6-4 B). Regarding the HECV endothelial cell model, no significant 
differences in proliferative rates between SOCS-3 expression and control HECV 
cells were observed either on day 3 (4% increase following SOCS-3 expression) 
and day 5 (27% increase following SOCS-3 expression) (p > 0.05; Figure 6-4 C, D). 
Taken together, SOCS-3 expression was found to decreased the proliferation of 
keratinocytes 5 days following inoculation but did not have influence the 
proliferative rates of endothelial cells.  
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Figure 6-4: In vitro MTT cell proliferation assay on SOCS-3 mutant HaCaT and 
HECV lines by MTT 
A. The proliferative rate of HaCaT cell on day 3 was transformed into percentage 
against control group in each repeat. The mean value was calculated and plotted 
in a bar chart; B. The proliferative rate of HaCaT cell on day 5 was transformed 
into percentage against control group in each repeat. The mean value was 
calculated and plotted in a bar chart; C. The proliferative rate of HECV cell on day 
3 was transformed into percentage against control group in each repeat. The 
mean value was calculated and plotted in a bar chart; D. The proliferative rate of 
HECV cell on day 5 was transformed into percentage against control group in each 
repeat. The mean value was calculated and plotted in a bar chart. (n=3, error bars 
represent standard error of the mean; *: p < 0.05) 
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6.3.4 In vitro cell migration assay (wound healing assay) 
An in vitro wound healing migration assay was undertaken to further explore the 
impact of SOCS-3 expression in human keratinocytes and endothelial cells. 
Surprisingly, there was no statistical difference observed in the rates of migration 
and wound closure between wounded HaCaT pEF6 and HaCaT SOCS-3exp 
monolayers at each 30-minute interval time point from the initial wounding point 
to the 15th hour when the experiment concluded (p > 0.05; Figure 6-5 A). This 
observation is further apparent in the representative images of the wound at 7.5th 
and 15th hour time points, demonstrating similar wound closure rates between 
HaCaT pEF6 and HaCaT SOCS-3exp (Figure 6-5 B, C). 
Meanwhile, the in vitro wound healing assay was also conducted on SOCS-
3 expression and control HECV cell lines. Similar results were also observed within 
the wounded monolayers of HECV pEF6 and HECV SOCS-3exp lines, showing no 
significant differences between the wound closure and migration rates of these 
two groups each 30-minute interval until the 20th hour (p > 0.05; Figure 6-6 A). 
Moreover, the wound width of the wounded HECV pEF6 and HECV SOCS-3exp, 
which both had a similar initial wound size, was found to display no obvious 
difference either at the 10th and the 20th hour (Figure 6-6 B, C). 
Therefore, SOCS-3 expression seems have no effect on the migratory 
ability of human HaCaT keratinocytes or HECV endothelial cells on plasticware.  
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Figure 6-5: In vitro cell migration assay on SOCS-3 mutant HaCaT line 
A. The distance migrated by the wound edge at each two and half hour interval were normalised to control line in percentage and plotted on a line chart; B. 
Representative pictures of the wounded HaCaT pEF6 monolayer at 0, 7.5th and 15th hour; C. Representative pictures of the wounded HaCaT SOCS3-exp 
monolayer at 0, 7.5th, and 15th hour following wounding. (n=3, representative data is shown; error bars represent standard error of the mean. Image was 
captured at X10 objective magnification; the red line indicates boundary of wound edge) 
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Figure 6-6: In vitro cell migration assay on SOCS-3 mutant HECV line 
A. The distance migrated by the wound edge at each two hour interval were normalised to control line in percentage and plotted on a line chart; B. 
Representative pictures of the wounded HECV pEF6 monolayer at 0, 10thand 20th hour following wounding; C. Representative pictures of the wounded HECV 
SOCS3-exp monolayer at 0, 10th and 20th hour following wounding. (n=3, representative data is shown; error bars represent standard error of the mean. 
Image was captured at X10 objective magnification; the red line indicates boundary of wound edge) 
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6.3.5 Tubule formation assay 
An in vitro Matrigel tubule formation assay was conducted to explore the 
potential of SOCS-3 expression to impact on the microtubule formation capacity 
of HECV cells and to investigate its potential to influence angiogenesis. 
As displayed in Figure 6-7, at the 2nd hour following inoculation, both 
control and SOCS-3 expression cell lines began to form a tubule network, though 
the tube-like structure formed by the SOCS-3 expression line was more intensive 
than the control line. Furthermore, a microtubule network with more sprouts 
were clearly observed in the SOCS-3 expression line at the 4th hour in comparison 
to the control line. This trend was consistent over the next 6 hours until the 
conclusion of the experiment (Figure 6-7 A, B). The tubule formation ability was 
quantified at the 10th hour following cell seeding. Total perimeter of the formed 
tubules, giving an indication of total tubule coverage, was measured and 
compared between control and SOCS-3 expression lines.  The total perimeter of 
the tubules formed by the SOCS-3 expression HECV cell line on matrigel matrix 
was 51% higher than that of by control cells and this trend was found to be 
statistically significant (p < 0.01; Figure 6-7 C). Therefore, SOCS-3 expression 
enhanced the tubule formation ability of endothelial cell on matrigel matrix. 
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Figure 6-7: Tubule formation assay on SOCS-3 mutant HECV line 
A. Representative pictures of the formed tubule of HECV pEF6 at the 2nd, 4th, 6th, 
8th and 10th hour; B. Representative pictures of the formed tubule of HECV SOCS-
3exp at the 2nd, 4th, 6th, 8th and 10th hour; C. The perimeter of the formed tubules 
on each image at the experimental endpoint was manually traced and the total 
perimeter in pixels was quantified. The mean value was then calculated from the 
multiple replicates as the total average perimeter before being normalised to the 
value of the control line. (images were captured at X5 objective magnification; 
n=3; representative data is shown; error bars represent standard deviation; **: p 
< 0.01) 
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6.4 Discussion 
In addition to SOCS-4, explored in the previous chapter, the results obtained from 
Chapter III suggested that gene expression of SOCS-3 was differentially expressed 
between healing and non-healing chronic wounds and though the IHC data did 
not indicate differential expression it did highlight a potential relocalisation of 
SOCS-3 between the two clinical subgroups within the cohort. These observation 
combined with the literature, also suggest interesting links between SOCS-3 and 
wound healing, leading to the endeavor to further characterise the significance of 
SOCS-3 expression in two wound healing in vitro models, HaCaT and HECV. In 
Chapter IV it was suggested that neither HECV nor HaCaT cell lines expressed 
SOCS-3. This observation was suprising given that IHC analysis showed positive 
expression of SOCS-3 in both keratinocyte and endothelial components of the 
tissue, the precise reason for this is unknown but may represent inherent 
differences between immortalised cell lines and human tissue. A similar absence 
of SOCS-3 was also observed in mouse keratinocytes in studies by Linke et al, 
reporting the significance of SOCS-3 expression in transgenic mouse models (Linke 
et al., 2010b), and, in agreement with our observations, in the HaCaT cell line 
(Goren et al., 2006a). 
In order to characterise the functional impact of SOCS-3 expression in 
human keratinocytes and endothelial cells the same functional assays conducted 
on the SOCS-4 mutant lines were also applied to the SOCS-3 expression HaCaT and 
HECV lines. The results from ECIS based initial attachment and spreading assay 
and migration assay showed that SOCS-3 expression elevated the initial 
attachment and spreading as well as migratory ability of HaCaT to the gold 
electrode. Interestingly, instead of observing contradictory results on SOCS-3 
mutant HECV lines, as seen in Chpter V between HaCaT and HECV cells following 
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SOCS-4 knockdown, elevated rates of migration were similarly observed in HECV 
SOCS-3exp compared to HECV pEF6, whereas no statistical significance was 
observed on their initial attachment and spreading to the gold electrode. This 
suggested that SOCS-3 may potentially play a similar role in the migration, but not 
initial attachment and spreading in HaCaT and HECV cells. 
However, the crystal violet matrigel adhesion assay indicated no statistical 
differences in matrigel adhesive ability between SOCS-3 expression HaCaT and 
control HaCaT cell lines, whereas HECV adhesion to the matrigel matrix was 
promoted by the SOCS-3 expression. The discrepancy between ECIS based initial 
adhesion assay and the crystal violet matrigel adhesion assay may suggest the 
alternative adhesive ability of HaCaT and HECV lines to the different matrix 
surface (from gold electrode to matrigel matrix). A previous study has showed 
enhanced expression of 1 integrin in SOCS-3 expression cells, indicating a 
regulatory role fo SOCS-3 in integrin expression (Stevenson et al., 2010). In 
addition, the matrigel utilised in this study consists of laminin and collagen IV 
which are both ligands of 1 integrin (Diamond and Springer, 1994). Therefore, it 
is feasible that SOCS-3 increased cell adhesion to matrigel matrix through the 
enhancement of 1 integrin, potentially accounting for the differential 
attachment to alternate substratum. It is also possible that such a role of SOCS-3 
may be cell specific, depending on the expression profiles and active pathways 
within the cell lines. 
The results from the In vitro cell migration assay (wound healing assay) 
indicated that the cell migration of HaCaT and HECV was not significantly affected 
by SOCS-3 expression, which was again different from that observed in the ECIS 
based migration assay, which showed significantly enhanced migration resulting 
fromby SOCS-3 expression following cell seeding. SOCS-3 has also been proposed 
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to influence keratinocyte migration within the literature, and a wound healing 
assay performed on a murine primary epithelial cell line demonstrated that SOCS-
3 attenuated the migration of keratinocyte on fibronectin (Linke et al., 2010b). 
These contrasting results are likely to attribute to the different integrin expression 
profiles and receptors present in distinct substratum utilised in differernt 
experiment, since it has been documented that extracellular matrix controlled the 
expression of 1 integrin, resulting different cell behaviour (Delcommenne and 
Streuli, 1995). 
The results from the in vitro MTT cell proliferation assay indicated that the 
presence of SOCS-3 impaired the proliferation of HaCaT cells. Additionally, a 
previous study generated a successfully stable SOCS-3 expression HaCaT cell 
model utilising the pcDNA™3.1 Expression Vector and demonstrated that 
keratinocyte proliferation was impaired by the upregulation of SOCS-3 (Goren et 
al., 2006a). This is in line with the finding in the in vitro MTT cell proliferation 
assay in this chapter, suggesting the effectiveness of the SOCS-3 expression model 
established in this study. However, the impaired proliferation of HaCaT cells were 
seen in the 24th hour in the previous publication instead of 5 days observed in this 
chapter. This may due to the differing SOCS-3 expression levels, potentially 
resulting from differing SOCS-3 expression plasmid efficiencies between the two 
studies. Nevertheless, these, taken together, support the role  of SOCS-3 in 
suppressing HaCaT proliferation. Moreover, an in vivo study observed decreased 
mitogenic marker in the epidermis of SOCS-3 overexpression mouse model with 
impaired healing phenotype, which further strengthening the role of SOCS-3 in 
suppressing keratinocyte proliferation (Linke et al., 2010b). However, the data 
presented here, whilst supporting the role of SOCS-3 in HaCaT cells, also suggests 
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a cell specific role of SOCS-3 in regards to proliferation as SOCS-3 expression 
brought about no significant changes in HECV proliferative rates. 
According to the images taken from the tubule formation assay, reduced 
cell aggregation was observed in the SOCS-3 expression endotheilial cells 
compared to the control lines starting from the 4th hour following cell seeding. 
This may be explained by a previous study on murine myeloid cell, which 
demonstrated that SOCS-3 attenuated homotypic cell aggregation through the 
suppression of STAT-3 activation (Wooten et al., 2000). Moreover, the elevated 
tubule formation on matrigel matrix by SOCS-3 expression in endothelial cells 
observed in the tubule formation assay may due to both the enhancement of 
adhesion and the promotion of spreading on such substratum, based on the fact 
that SOCS-3 was found to increase 1 integrin expression (Stevenson et al., 2010) 
and that 11 and 12 was required for VEGF promoted endothelial cell 
spreading (Senger et al., 1997, Senger et al., 2002). Therefore, SOCS-3 expression 
may enhance endothelial cell adhesion to the matrigel matrix by upregulating the 
expression of 1 integrin, and subsequently promotes the migration and 
sprouting through modulation of 11 and 21 integrins, resulting in enhanced 
tubule formation. Interestingly, silencing SOCS-3 in human and mouse retinal 
endothelial cell promoted the IGF-1- and TNF--stimulated cell proliferation (Stahl 
et al., 2012). In addition, SOCS-3 conditional knockdown mice exhibited increased 
pathologic retinal neovascularization but not physiologic vascular development, 
indicating an endogenous negative regulatory role of SOCS-3 in pathologic 
angiogenesis (Stahl et al., 2012). This is in contrast to the results in this current 
study suggesting pro-angiogenic effect of SOCS-3. This may be because the in vitro 
tubule formation assay used in this study is an in vitro approach in comparison to 
the complex microenvironment existing in the in vivo model. Alternatively, the 
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anti-angiogenic role of SOCS-3 observed in the in vivo study may be due to 
pathological stress since such effect was not seen in physiological murine models. 
In summary, SOCS-3 does not influence the migration of HaCaT and HECV 
to the plastic cultureware matrix surface, whereas it appears to increases the 
migratory ability of such cell lines to the gold electrode. Furthermore, the 
presence of SOCS-3 improves the adhesion of HECV on matrigel matrix potentially 
by regulating 1 integrin expression, whereas promote endothelial cell spreading 
the same substratum via modulating 11 and 21, however, this hypothesis 
requires further validation. Moreover, SOCS-3 may affect the migratory and 
adhesive ability of HaCaT and HECV to different matrix surfaces due to the 
regulatory effect of different substratum on integrin expression. In addition, 
SOCS-3 also holds the potential to impair HaCaT proliferation. Therefore, the 
functional analysis of SOCS-3 mutant cell lines indicates a role for this molecule in 
the key cell types involved in wound healing process. 
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Chapter VII  
General discussion
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The aim of the studies in this thesis was to investigate the importance of the SOCS 
family in the wound healing process, exploring their potential to act as prognostic 
factors in clinical cohorts and exploring the potential of SOCS-3 and -4 to influence 
key cellular traits linked to the healing process. 
 
7.1 The clinical significance of SOCS family members in chronic wounds 
Detection of SOCS family members within a clinical venous leg healing/healed and 
non-healing cohort (Cohort 1) using q-PCR highlighted significant elevations in 
SOCS-3 and -4 gene expression in non-healing chronic wounds compared to 
healing/healed chronic wounds. In addition, SOCS-1, SOCS-2, SOCS-5 and SOCS-6 
exhibited a similar trend, though this did not reach statistical significance. 
However, the expression profile of SOCS-7 showed a contrasting trend to the 
other six family members examined, demonstrating enhanced gene expression in 
healing/healed chronic wounds compared to non-healing chronic wounds, though 
again, this did not display any significant differences. Hence, this data suggests 
some association between gene level expression of SOCS-3 and -4 and the healing 
potential of chronic wounds or may represent a predictive marker to identify 
healing potential of such wounds though such applications requires more intense 
investigation in larger gene expression cohorts to fully realise this potential. 
In addition to the gene expression profile, IHC analysis was also 
undertaken to explore protein expression localisation in chronic wound tissues. 
The IHC screening was conducted using a different venous leg cohort (Cohort 2) 
which was defined using the same selection and grouping criteria as the cohort 
(Cohort 1) used for q-PCR analysis. Unfortunately, staining of a subset of this 
cohort showed no clear differences in the expression of SOCS-1 to SOCS-6 
309 
 
between non-healing and healing/healed chronic wounds. The majority of the 
chronic wounds exhibited positive staining for all six proteins predominently in 
epidermis and partially in dermis and SOCS-7 staining appeared to be very weak 
or negative throughout the cohort following staining with two independent 
antibodies. However, IHC staining potentially indicated the relocalisation of SOCS-
3 protein, from wound edge to epidermis distal to the wound edge, in the non-
healing chronic wounds (4 out of 10 positive stained biopsies) in comparison to 
the healing/healed tissues (1 out of 8 positive stained biopsies). This phenomenon, 
whilst only observed in a small number of sections, again indicates that SOCS-3 
may play differing roles within the tissues of healing/healed and non-healing 
chronic wounds and again warrents further establishment in larger cohorts to 
clarify. 
The expression profile of SOCS-3 in normal skin tissues demonstrated that 
SOCS-3 expression was seldomly detected in epithelium (White et al., 2011, Goren 
et al., 2006a, Linke et al., 2010b). This is in line with the PCR screening data 
exploring the expression profile of SOCS-3 in the HaCaT cell line presented in 
chapter VI, which demonstrated no SOCS-3 expression in human HaCaT 
keratinocytes. Additionally, positive expression of SOCS-3 was found in 
inflammatory tissues (White et al., 2011), which is in agreement with the results in 
the IHC screening in the chronic wound biopsies (Cohort 2) in Chapter III, since a 
number of pro-inflammatory SOCS-3-inducible cytokines including IL-6, TNF-, 
IFN- are produced and secreted by the recruited cells in the wound site during 
the healing process (Table 1-8). Together, this may suggest that SOCS-3 is induced 
by cytokine receptor activation through cytokine stimulation following wounding, 
and may have an effect on the regulation of keratinocyte behaviour. Due to the 
fact that a non-healing chronic wound is constitutively trapped in the 
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inflammation stage (Powers et al., 2016), the elevated expression of SOCS-3 
protein may due to the constant stimulation by the continueously produced pro-
inflammatory cytokines.  
SOCS-4 is a poorly characterised member of the SOCS family and its role in 
wound healing remains uncharacterised. Whilst not directly explored in the 
context of wound healing, SOCS-4 has been shown to be induced upon EGF 
stimulation and to inhibit EGFR via competing with STAT-3 and enhancing EGFR 
degradation (Kario et al., 2005, Bullock et al., 2007). A potential role of SOCS-4 has 
also been implicated in the regulation of other STAT family members (Hu et al., 
2010). Given the significance of EGF in wound healing (Barrientos et al., 2008, Yu 
et al., 2010) and the ability of SOCS-4 to impact EGF/STAT signalling it is likely that 
represent a level of control for SOCS-4 in healing. Indeed conditional knockout of 
STAT-3 in the epidermis of mice impaired EGF dependant migration and wound 
healing (Sano et al., 1999). Hence, SOCS-4, acting at this level, may also be able to 
regulate healing. These observations are somewhat supported by the results of 
Chapter III, showing an increase in gene expression of chronic wounds, potentially 
interferes with EGF-STAT signalling to impare healing, though futher work to 
clarify this is needed. However, whilst an interesing theory, this is limited by 
contrasts seen between gene level and protein level expression. In the IHC 
analysis of the clinical cohort, no difference in SOCS-4 expression was observed 
within the subset of tissues stained. This requires further study in larger cohorts 
to clarify the differences seen. Moreover, given the evidence that EGFR distributes 
in keratinocyte in human skin tissue (Nanney et al., 1990), the expression of SOCS-
4 in all layers of the epidermis in the chronic wound biopsies observed in Chapter 
III may attribute to EGF-induced EGFR activation, further suggesting the negative 
regulatory role of SOCS-4 in EGF signalling in chronic wound tissues.  
311 
 
Overall, the clinical data has highlighted some interesting potential links, 
but also raised some interesting points requiring future work.  The differential 
patterns seen between the gene expression and the IHC analysis needs further 
analysis utilising larger cohorts of chronic wounds but also acute wounds and 
normal skin. Certainly, the results give an early indication that gene analysis of 
SOCS-3 and -4 levels may have some prognostic function and may prove useful in 
patient management. The clinical data presented here also suggests that SOCS-1, 
SOCS-2, SOCS-5, SOCS-6 and SOCS-7 do not have great clinical significance in 
terms of chronic wounds and their healing potential. 
 
7.2 The cellular traits of SOCS-4 in essential cell types involved in the wound 
healing and its potential mechanism 
One of the aims of this thesis was to characterise the effect of SOCS-4 on the 
functional characteristics of key keratinocyte and endothelial cell lines and the 
potential of this to impact healing. To achieve this, stable SOCS-4 knockdown lines 
were established as described in Chapter IV. To date there are no clear studies 
focusing directly on the role of SOCS-4 in chronic wound healing or in general 
wound healing. 
The functional characterisation on the established HaCaT and HECV 
knockdown mutant cell lines demonstrated that SOCS-4 did not have any effect 
on the proliferative rate of these cell types at least within 5 days incubation. 
Whilst not in the context of wound healing, SOCS-4 inhibition has also been 
shown not to influence the growth of K1 thyroid cancer cell lines (Mei et al., 2015). 
This evidence partially support the results seen in the in vitro MTT proliferation 
assay conducted in Chapter V, and suggest that SOCS-4 does not have significant 
impact on the proliferation of keratinocyte and endothelial cell. 
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Regarding the ECIS based assays, according to previous literature, the 
initial 10 hours of resistance increase following inoculation in ECIS assay reflects 
the initial attachment and spreading ability of the seeded cells (Wegener et al., 
2000). Interestingly, the ECIS assay in Chapter V demonstrated that SOCS-4 
downregulation reduced the initial attachment and spreading of keratinocyte, 
whereas this ability in endothelial cells was elevated following SOCS-4 knockdown. 
This discrepancy may attributed to the different integrins expression profile of 
keratinocyte and endothelial cell (Longmate and Dipersio, 2014, Hynes, 2007), 
which render them different adherent and migratory abilities influenced by the 
interaction of integrins and stubstratum matrix. This requires further clarification 
from additional scientific study. 
Cell attachment was further studied using a Matrigel matrix assay. 
Matrigel matrix is a protein substrate that resembles the ECM found in many 
tissues and it has been utilised in numerous studies to generate more in vivo-like 
cell culture environments to measure cellular behaviours. Therefore, the results 
observed in the in vitro MTT cell adhesion assay are more likely to represent 
physiological conditions. MTT matrigel matrix adhesion assays conducted in 
Chapter V demonstrated that SOCS-4 did not influence HaCaT keratinocyte 
Matrigel attachment but suppression of SOCS-4 significantly reduced HECV 
endothelial cell matrigel attachment rates. This phenomenon may also be explain 
through a potentially different integrin expression profile present within the two 
cell types, rendering different adhesive ability to matrigel matrix, as the matrigel 
matrix used in this study primarily consists of laminin and collagen IV 
(https://www.corning.com/media/worldwide/cls/documents/CLS-DL-CC-
026%20DL.pdf). SOCS-4 may potentially modulate the expression profile of 
laminin receptors 31, 61, 64 and collagen receptors 11 21 (Hynes, 
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2007) in endothelial cells and maintain its adhesive ability to laminin and collagen 
IV. Though this again requires further scientific clarification. 
Regarding the in vitro migration assays, keratinocyte migratory ability was 
significantly impaired by SOCS-4 downregulation and such a trend was consistent 
between both scratch and ECIS based methodologies, albeit that impariment of 
migration was seen following different time periods. Such a discrepancy may due 
to the variant sensitivity between electrode sensor measurements and manually 
measuring wound edge distances in distinct methodologies. Interestingly, the 
investigation on the migration of SOCS-4 mutant endothelial cells demonstrated 
contradictory results, namely, elevated migration of SOCS-4 knockdown 
endothelial cell on gold electrode and decreased migration following SOCS-4 
downregulation on plastic cultureware in the above mentioned two 
methodologies. This may suggest the diverse effect of SOCS-4 on the migratory 
ability on different matrix surface, since the substratum matrix is capable of 
regulating the integrin expression profile, leading to different cell behaviour 
(Delcommenne and Streuli, 1995). Therefore, the transwell migration assay, 
another method to investigate cell migration, may be required to further clarify 
the hypothesis raised above. Nonetheless, the ECIS based migration assay and the 
wound healing assay, despite presenting some contradicting data, suggested a 
role for SOCS-4 in the regulation of migration within HaCaT keratinocyte and HECV 
endothelial cells. Previous work in a thyroid cancer model has suggested that 
SOCS-4 could inhibt IL-23 mediated migration, suggesting a potentially constrating 
role of SOCS in the regulation of thyroid cancer cells (Mei et al., 2015). Taken 
together with this study, the migrational results presented in Chapter V are novel 
in the context of keratinocyte, endothelial cell and wound based background and 
314 
 
furthermore highlight a potential cell type-specific regulatory role of SOCS-4 in 
migration. 
A tubule formation assay was utilised to investigate the angiogenic ability 
of HECV endothelial cells, following SOCS-4 knockdown and demonstrated a 
decreased formation of tubules, in terms of the number and the total perimeter, 
suggesting loss of SOCS-4 decreases angiogenic potential of this cell line. This is in 
line with observation of the matrigel matrix adhesion assay, and further supports 
the theory that SOCS-4 may play a role in altering the integrin expression profile in 
entothelial cells, not only contributing to its adhesion, but the migration, cell 
membrane assembly and sprouting on laminin and type IV collagen (Senger and 
Davis, 2011). Moreover, the SOCS-4 deficient cells tended to migrate less, an 
observation potentially linked to the results observed in the in vitro wound assay, 
considering migration is one of the prerequiste of sprouting (Ausprunk and 
Folkman, 1977). Therefore, the presence of SOCS-4 may contribute to a positive 
angiogenic response, in another words, SOCS-4 may act as a pro-angiogenic 
regulator in wound healing. 
To explore potential mechanisms account for these function effects, a 
kinexus protein microarray was undertaken to assess changes in protein 
phosphorylation brought about by SOCS-4 konckdown. The screening on the 
potential variation of the protein expression following SOCS-4 knockdown in 
keratinocytes, conduced in Chapter V, highlighted the significant decrease of FAK 
Y397. FAK has been implicated as a critical factor of cell adhesion and migration, 
and Y397 of FAK, an auto phosphorylation site, is able to be activated in response 
to a number of stimuli, including recognition of matrix and initiate a variety of 
downstream signalling cascades contributing to migration (Wozniak et al., 2004, 
Zhao and Guan, 2011). A study showed that FAK mutations on the Y397 site 
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impaired the FAK-mediated cell migration, indicating the indispensable role of 
Y397 in the promotion of cell migration (Cary et al., 1996). This may explain the 
correlation between the decreased FAK Y397 and the downregulation of 
keratinocyte migration following SOCS-4 knockdown in HaCaT observed in 
Chapter V. Therefore, SOCS-4 may potentially affect keratinocyte migration 
though modulating the activation of FAK Y397. Moreover, another study on a FAK 
deficient mouse model and a FAK knockdown endothelial cell model discovered 
endothelial FAK is required for pathological angiogenesis (Tavora et al., 2010). This 
is also in line with the results observed in Chapter V, demonstrating that 
decreased FAK phosporylation correlated with reduced HECV endothelial cell 
tubule formation following SOCS-4 knockdown. Furthermore, Src Y418 
phosphorylation was also decreased following the downregulation of SOCS-4 in 
keratinocyte. It has been demostrated that FAK phosphorylation is the 
prerequisite of Src activation as well as the the formation of FAK/Src complex, and 
cell migration is mediated by the interaction of FAK/Src complex and p130cas 
(Cary et al., 1996, Cary et al., 1998). Taken together, the potential mechanism of 
SOCS-4 modulating the migration of keratinocyte is through the FAK/Src/p130cas 
pathway. Further intense study required to clarify and establish the importance of 
FAK/Src in relation to SOCS-4 and wound healing. 
SOCS-4 has been poorly characterised in terms of wound healing. EGFR 
signalling is relatively well documented within the wound healing pathway and 
evidence has also suggested that SOCS-4 can regulate EGFR signalling, as outlined 
previously (Kario et al., 2005). In the protein array results in Chapter V, EGFR 
phosphorylation on Y1110 was also found reduced in the SOCS-4 knockdown 
keratinocytes. Moreover, SOCS-4 deficiency attenuated the migration of HaCaT 
keratinocytes. EGFR activation by heparin-binding EGF-like growth factor (HBEGF) 
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binding has been proved to facilitate keratinocyte migraion (Shirakata et al., 2005). 
Therefore, it could be theorised that SOCS-4 downregulation may lead to reduced 
HBEGF production by keratinocytes, which in turn decreased the EGFR activation, 
resulting in decreased migration. 
VEGFR-2 is another growth factor involved in wound healing whose 
phosphorylation was found decreased in SOCS-4 deficient keratinocyte in Chapter 
V. The activation of VEGFR-2 has been proved to  promote keratinocyte migration 
(Yang et al., 2006). Thus, the impaired migration of keratinocyte following SOCS-4 
knockdown may attribute to the decreased VEGFR-2 activation, raising another 
potential mechanism of SOCS-4 regulating keratinocyte migration through 
sustaining the activation of VEGFR-2. 
In addition, potein array and wound healing assays conducted in Chapter 
V exhibited reduced phosphorylation of IGF-1R on Y1280 and decreased migration 
of keratinocyte following SOCS-4 knockdown. Since IGF-1-induced IGF-1R 
activation promotes keratinocyte migration via the activation of PI3K (Haase et al., 
2003), SOCS-4 may potentially affect the keratinocyte migration through the 
maintenance of either IGF-1R or PI3K activation.In summary, the study on SOCS-4 
deficient endothelial cells suggested a potential regulatory role for SOCS-4 in 
regulating the interaction of endothelial cells and ECM as well as angiogenesis and 
it could be theorised that this may be through modulation of the integrin profile 
within endothelial cells. Furthermore, the investigation on keratinocyte SOCS-4 
knockdown model demonstrated the importance of SOCS-4 on the human 
keratinocyte migration, and highlighted a number of mechanisms potentially 
responsible for this effect. Therefore, the data suggests that SOCS-4 is an 
important protein that is potentially required for epithelialisation and 
angiogenesis in the wound healing process. 
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7.3 The cellular traits of SOCS-3 in essential cell types involved in the wound 
healing 
Another aim of this thesis was to explore and clarify the impact of SOCS-3 on 
keratinocyte and endothelial cells in an attempt to highlight its importance in key 
healing traits. In vitro cell functional assays were conducted on the SOCS-3 
expression HaCaT and HECV mutant lines. The expression of SOCS-3 did not 
significantly affect the proliferative rate of the endothelial cell during 5-day period, 
whereas, a significantly decreased proliferation was seen in SOCS-3 expression 
HaCaT cells on the 5th day after cell seeding. This is consistent with an in vivo study 
demonstrated overexpression of SOCS-3 attenuated the healing process with 
reduced mitogenic marker (Linke et al., 2010b), strengthening the negative 
regulatory role of SOCS-3 in keratinocyte proliferation. 
The ECIS based initial attachment and spreading assay on SOCS-3 mutant 
HaCaT and HECV models demonstrated elevated initial attachment and spreading 
of keratinocytes following SOCS-3 expression, whereas no difference was shown 
between SOCS-3 expression endothelial cell and its control line. Similar to the 
discrepancy found in the same assay on SOCS-4 mutant keratinocyte and 
endothelial cells, this may due to different integrin expression profile in the two 
cell types which play different roles (keratinocyte for epithelialisation, endothelial 
cell for angiogenesis) in wound healing (Longmate and Dipersio, 2014, Hynes, 
2007).  Moreover, ECIS based migration assays, conducted in Chapter VI, indicated 
that SOCS-3 enhanced the migratory ability of both keratinocyte and endothelial 
cells over the gold electrode, which did not agree with the in vitro wound healing 
migration assay, indicating no difference in migration of either keratinocyte or 
endothelial cell following SOCS-3 expression. Interestingly, an in vitro wound 
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healing assay conducted in a previous study on murine primary keratinocytes 
demonstrated reduced migration of such cells on fibronectin following SOCS-3 
overexpression (Linke et al., 2010b), which is contrast to the results observed 
from the ECIS based migration assay in Chapter VI. Again, this may be explained 
by the different integrin expression caused by different substratum matrix (gold 
electrode on ECIS assay; plastic cultureware in wound healing assay in Chapter VI; 
fibronectin in previous study) (Delcommenne and Streuli, 1995).  
The crystal violet adhesion assay demonstrated that SOCS-3 expression 
enhanced the adhesion of endothelial cell to matrigel matrix, whereas SOCS-3 
upregulation had no effect on such ability of keratinocyte. Previous studies have 
shown that SOCS-3 can enhance the 1 integrins expression, and that 1 interins 
are ligands that bind to laminin and type IV collagen of basement membrane 
(Stevenson et al., 2010, Diamond and Springer, 1994). Given that the primary 
components of matrigel matrix are laminin and type IV collagen, the enhanced 
adhesion of endothelial cells on matrigel matrix could be explained by the 
endothelial cell-dependent elevation of 1 integrin expression following SOCS-3 
upregulation.  
The tubule formation assay conducted on the HECV SOCS-3 expressing 
line demonstrated that the expression of SOCS-3 significantly enhanced tubule 
formation ability of endothelial cells on matrigel matrix. This result is consistent 
with the in vitro crystal violet adhesion assay indicated previously. Previous 
evidence suggestes that 11 and 12 facilitate VEGF-dependent endothelial 
cell sprouting (Senger et al., 1997, Senger et al., 2002). Therefore, the potential 
rationale of increased tubule formation by SOCS-3 expression could be explained 
by the elevation of 1 integrins following SOCS-3 expression, which benefit both 
adhesion and spreading of endothelial cell on the pre-coated laminin and type IV 
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collagen substratum. The tuble formation assay further emphasises that SOCS-3 
may hold the potential to regulate the integrin expression in endothelial cell, and 
subseqently contribute to angiogenesis.. 
 
7.4 Main findings and significance 
The q-PCR screening on chronic wound cohort 1 demonstrated 81% and 93% 
elevated SOCS-3 and SOCS-4 expression in non-healing chronic wounds in 
comparison to healing/healed group respectively suggesting gene expression of 
SOCS-3 and SOCS-4 may be implicated in the healing profile and may present 
useful tools as genetic biomarkers for healing progression. IHC screening on 
chronic wound cohort 2 demonstrated that SOCS-1 to SOCS-6 were expressed 
primarily in all layers of epidermis with higher expression levels in the nucleus of 
the basal layer keratinocytes, whereas much less intensive expression of SOCS-1 
to SOCS-6 were oberved in dermis. However, no different distribution or intensity 
of SOCS-1 to SOCS-6 was observed between the non-healing chronic wounds and 
healing/healed chronic wounds, although there was an intimation of SOCS-3 
relocalisation in non-healing chronic wounds since 75% (3 out of 4) of increased 
SOCS-3 expression in epidermis distal to the wound edge were seen in non-
healing chronic wound tissues. These results suggest that elevated SOCS-3 and 
SOCS-4 gene expression may potentially predict poor healing result of chronic 
wound, although this hypothesis requires further verification on protein level 
based on larger non-healing and healing/healed chronic wound cohort or the 
cohort consisting of normal, acute and chronic wound tissues. 
Characterisation of SOCS-4 knockdown mutants has led to the implication 
that the presence of SOCS-4 in keratinoyctes acts in a pro-migratory fashion, as 
well as promoting cell-matrix adhesion. This further suggests that this is 
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potentially achieved through its regulation of FAK/Src/p130cas pathway, 
HBEGF/EGFR pathway, VEGF/VEGFR-2 pathway and IGF-1/IGF-1R/PI3K pathway. 
Furthermore, the role of SOCS-4 in endothelial cells apprears more relative to the 
particular substratum and environment the cells are located on, though it does 
appear to have a pro-angiogenic function. Such effects may be due to integrin 
profiling of such cells though more work is needed to characterise this in the 
context of SOCS-4. Given the importance of traits such as migration and 
angiogenesis within the wound healing process (Pastar et al., 2014, Tonnesen et 
al., 2000, Senger and Davis, 2011), the functional data suggests that the presence 
of SOCS-4 would promote healing. This again appears to be in contrast to the gene 
expression profile, indicating higher SOCS-4 gene expression in non-healing 
chronic wounds, a trait not confirmed at the protein level. This study has 
suggested a role for SOCS-4 as a potential biomarker and has similarly implicated 
it in regulating key characteristics and pathways relative to wound healing. Hence 
SOCS-4 appears to play some complex role in the wound healing process and this 
requires more intense scientific research to be fully elucidated. 
SOCS-3 expression in HaCaT keratinocytes reduced the proliferation and 
appeared to have substrate specific effects on attachment and migration, 
enhancing these traits in regards to the gold electrode but not plastic cultureware 
or matrigel. The conflict between the different assays and also the negative 
impact on proliferation and in some aspects, pro-migratory impact make it 
difficult to conclude a definative role in promoting or inhibiting wound healing. In 
terms of the endothelial model, even though there is conflict between the 
experimental assays, overall the characterisation suggests a pro-angiogenic 
impact of SOCS-3 expression and this in turn may be significant in the re-
epithelialisation and proliferation stage of wound healing where angiogenesis in a 
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key component. When analysed in conjunction with the clinical data, a pro-
angiogenic phenotype would seem to oppose the observation that SOCS-3 gene 
expression is enhanced in non-healing chronic wounds and displays some 
relocalisation in such wounds compared to healing/healed ones. This may be 
explained by the houskeeping gene (CK-19), an epithelial cell biomarker, used in 
the clinical q-PCR screening. Hence, the results may only represent SOCS-3 
expression profile in keratinocytes but not in endothelial cells. Therefore, SOCS-3 
may potentially exert anti-proliferative role in keratincoytes, whereas play pro-
angiogenic role in endothelial cells in the re-epithelialisation and the proliferation 
stage. 
Taken together, this thesis has furthered the understanding of the role 
played by SOCS-3 and SOCS-4, in chronic wound healing. This study has identified 
differential gene expression between chronic healing and non-healing wounds, 
and also demonstrated a potential shift in localisation of SOCS-3 between these 
chronic wound types.  Furthermore the study has established a role for SOCS-3 
and -4 in several cellular processes of wound healing, such as migration and 
angiogenesis. Whilst highlighting these interesting aspects of SOCS role in wound 
healing, this thesis also raises some questions. Most importantly, there appears to 
be some contrast between clinical observations, where higher gene level 
expression of SOCS-3 and SOCS-4 associated with the non-healing wounds, and 
cellular functions, where SOCS-3 and 4 appear to confer pro-migratory and pro-
angiogenic traits. This may in part be due to the differing nature of basic in vitro 
models and the more complex nature within a multi-cellular tissue environment, 
in this case, a chronic wound environment. This thesis has also implied a potential 
clinical role for SOCS-3 and SOCS-4 gene expression to be used as a potential 
biomarker. Further research to clarify the potential of SOCS family members in 
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chronic wound healing, their implications in much larger clincial cohorts as well as 
in normal wound healing processes would be of benefit and is warranted. 
 
7.5 Future work 
Since the clinical chronic wound biopsies chosen for the IHC screening on SOCS 
members was less than the amount used for transcript expression screening, a 
larger cohort of chronic wounds would be required to further investigate the 
clinical significance of SOCS protein expression pattern in chronic wounds. In 
addition, based on the fact that a possible relocalisation of SOCS-3 was seen in 
chronic wounds distal to the wound edge, the gene expression levels and the 
protein expression pattern between cohorts of acute and chronic wounds is also 
of great interest and this should be investigated fully in future investigations. 
In terms of cellular and molecular study, future work is needed to focus 
on the verification of the potential link between SOCS-4 and FAK and FAK Y397. 
This study looked at the functional impact of SOCS-4, either in a dual SOCS-4/FAK 
knockdown and in combination with small molecule inhibitors targeting FAK and 
Y397 phosphorylation is warranted to expand the knowledge in this area. Given 
the significance of FAK and its downstream signalling and its implications in a wide 
variety of processes, future work is also needed to profile changes in expression of 
FAK and FAK Y397 in the endothelial cells and to apply similar dual 
knockdown/small molecule inhibitor techniques to explore the significance of this 
pathway in the angiogenic response. Furthermore, in addition to the FAK link, the 
Kinexus microarray has provided a number of other very interesting leads to 
follow up, particularly wound relevant pathways such as EGFR, VEGFR and IGF. 
Full verification and follow up of this precious resource will be instrumental in 
fully elucidating the role of SOCS-4 and its significance in wound biology. In 
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addition to these mechanistic studies in relation to SOCS-4, future work should be 
undertaken to explore some of these pathways in SOCS-3 models, particularly the 
FAK link, as previous literature has suggested that SOCS-3 can associate with FAK 
through SH2 and KIR domains in a FAK Y397-dependent manner, subsequently 
enhancing FAK turnover via SOCS box-dependent-proteasomal degradation (Liu et 
al., 2003). 
Moreover, given the significance of the experimental matrix present 
within a number of the assays, the detection of integrin expression profiles 
following SOCS-4 knockdown and SOCS-3 expression in these cell models is also of 
interest to further clarify the mechanisms through which SOCS-3 and -4 may 
mediating the adhesion, migration and spreading of keratinocytes/endothelial 
cells on matrigel matrix. 
Further understanding of these downstream signalling pathways may aid 
in the full realisation of the clinical significance of these molecules, potentially 
allowing multi-target therapeutic design. 
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